Interventions for managing asthma in pregnancy (Review) by Bain, Emily et al.
Cochrane Database of Systematic Reviews
Interventions for managing asthma in pregnancy (Review)
Bain E, Pierides KL, Clifton VL, Hodyl NA, Stark MJ, Crowther CA, Middleton P
Bain E, Pierides KL, Clifton VL, Hodyl NA, Stark MJ, Crowther CA, Middleton P.
Interventions for managing asthma in pregnancy.
Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No.: CD010660.
DOI: 10.1002/14651858.CD010660.pub2.
www.cochranelibrary.com
Interventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
25DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
31ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
31REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
58DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 1 Asthma exacerbations (“frequency of
acute asthma exacerbation till delivery”). . . . . . . . . . . . . . . . . . . . . . . . . 63
Analysis 1.2. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 2 Lung function (FEV1 (%)). . . 64
Analysis 1.3. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 3 Lung function (FVC (%)). . . 64
Analysis 1.4. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 4 Lung function (FEV1/FVC (%)). 65
Analysis 1.5. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 5 Lung function (FEF25%). . . 65
Analysis 1.6. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 6 Lung function (FEF75%). . . 66
Analysis 1.7. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 7 PEF (%). . . . . . . . . 66
Analysis 1.8. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 8 Caesarean birth. . . . . . . 67
Analysis 2.1. Comparison 2 Intravenous theophylline versus control, Outcome 1 Discontinuation of intervention due to
adverse effects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Analysis 2.2. Comparison 2 Intravenous theophylline versus control, Outcome 2 Stillbirth. . . . . . . . . . 68
Analysis 2.3. Comparison 2 Intravenous theophylline versus control, Outcome 3 Neonatal death. . . . . . . . 68
Analysis 2.4. Comparison 2 Intravenous theophylline versus control, Outcome 4 Preterm birth. . . . . . . . . 69
Analysis 3.1. Comparison 3 Inhaled corticosteroid versus control, Outcome 1 Asthma exacerbations. . . . . . . 70
Analysis 3.2. Comparison 3 Inhaled corticosteroid versus control, Outcome 2 Caesarean birth. . . . . . . . . 71
Analysis 3.3. Comparison 3 Inhaled corticosteroid versus control, Outcome 3 Adherence with intervention. . . . 72
Analysis 3.4. Comparison 3 Inhaled corticosteroid versus control, Outcome 4 Induced abortion. . . . . . . . 72
Analysis 3.5. Comparison 3 Inhaled corticosteroid versus control, Outcome 5 Spontaneous abortion. . . . . . . 73
Analysis 3.6. Comparison 3 Inhaled corticosteroid versus control, Outcome 6 Stillbirth. . . . . . . . . . . 73
Analysis 3.7. Comparison 3 Inhaled corticosteroid versus control, Outcome 7 Neonatal death. . . . . . . . . 74
Analysis 3.8. Comparison 3 Inhaled corticosteroid versus control, Outcome 8 Preterm birth. . . . . . . . . . 74
Analysis 3.9. Comparison 3 Inhaled corticosteroid versus control, Outcome 9 Birthweight (g). . . . . . . . . 75
Analysis 3.10. Comparison 3 Inhaled corticosteroid versus control, Outcome 10 Apgar score less than seven. . . . 76
Analysis 3.11. Comparison 3 Inhaled corticosteroid versus control, Outcome 11 Congenital malformation. . . . . 76
Analysis 3.12. Comparison 3 Inhaled corticosteroid versus control, Outcome 12 “Obstetric complications”. . . . 77
Analysis 3.13. Comparison 3 Inhaled corticosteroid versus control, Outcome 13 “Perinatal complications”. . . . . 77
Analysis 3.14. Comparison 3 Inhaled corticosteroid versus control, Outcome 14 “Healthy children delivered”. . . . 78
Analysis 3.15. Comparison 3 Inhaled corticosteroid versus control, Outcome 15 “Other adverse outcomes”. . . . 78
Analysis 4.1. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 1 Asthma exacerbations. . . 79
Analysis 4.2. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 2 Asthmatic symptoms at delivery. 79
Analysis 4.3. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 3 Asthmatic symptoms (nocturnal). 80
Analysis 4.4. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 4 Asthma medication requirements
(rescue oral corticosteroids for exacerbation). . . . . . . . . . . . . . . . . . . . . . . . 80
iInterventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.5. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 5 Asthma medication requirements
(albuterol puffs per day). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Analysis 4.6. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 6 Lung function (proportion of study
visits with FEV1 < 80% predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Analysis 4.7. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 7 Lung function (proportion of study
visits with PEFR < 80% predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Analysis 4.8. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 8 Pre-eclampsia. . . . . . 82
Analysis 4.9. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 9 Caesarean birth. . . . . 83
Analysis 4.10. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 10 Postpartum haemorrhage (blood
loss > 500 mL for vaginal birth and > 1 L for caesarean). . . . . . . . . . . . . . . . . . . . 83
Analysis 4.11. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 11 Chorioamnionitis. . . . 84
Analysis 4.12. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 12 Adverse effects attributed to
intervention. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Analysis 4.13. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 13 Discontinuation of intervention
due to adverse effects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Analysis 4.14. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 14 Adherence with intervention
(self-reported compliance). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
Analysis 4.15. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 15 Adherence with intervention
(measured compliance). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Analysis 4.16. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 16 Perinatal death. . . . . 87
Analysis 4.17. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 17 Gestational age at birth
(weeks). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Analysis 4.18. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 18 Preterm birth. . . . . 88
Analysis 4.19. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 19 Birthweight (g). . . . . 89
Analysis 4.20. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 20 Low birthweight (< 2500 g). 89
Analysis 4.21. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 21 Small-for-gestational age. 90
Analysis 4.22. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 22 Neonatal sepsis (discharge
diagnosis of sepsis). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
Analysis 4.23. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 23 Congenital malformation
(major). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Analysis 4.24. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 24 Antenatal admissions to hospital
for the mother (associated with exacerbation). . . . . . . . . . . . . . . . . . . . . . . . 91
Analysis 4.25. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 25 Emergency department visits for
the mother (associated with exacerbation). . . . . . . . . . . . . . . . . . . . . . . . . 92
Analysis 5.1. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 1
Asthma exacerbations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Analysis 5.2. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 2
Admission to neonatal intensive care unit or special care nursery. . . . . . . . . . . . . . . . . 93
Analysis 5.3. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 3
Asthmatic symptoms (ACQ score). . . . . . . . . . . . . . . . . . . . . . . . . . . 93
Analysis 5.5. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 5
Asthma medication requirements (inhaled corticosteroids). . . . . . . . . . . . . . . . . . . 94
Analysis 5.6. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 6
Asthma medication requirements (long-acting β2-agonists). . . . . . . . . . . . . . . . . . . 95
Analysis 5.10. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 10
Pregnancy-induced hypertension. . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
Analysis 5.11. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 11
Pre-eclampsia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Analysis 5.12. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 12
Gestational diabetes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Analysis 5.13. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 13
Caesarean birth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
iiInterventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.14. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 14
Antepartum haemorrhage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Analysis 5.15. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 15
Postpartum haemorrhage. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Analysis 5.16. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 16
Ruptured membranes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
Analysis 5.17. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 17
Hyperemesis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
Analysis 5.18. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 18
Termination of pregnancy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Analysis 5.19. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 19
Stillbirth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Analysis 5.21. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 21
Preterm birth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Analysis 5.23. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 23
Low birthweight (< 2500 g). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 5.24. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 24
Small-for-gestational age. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 5.25. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 25
Jaundice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Analysis 5.26. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 26
Congenital malformation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Analysis 5.27. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 27
Bronchiolitis (multiple versus one or no episodes). . . . . . . . . . . . . . . . . . . . . . 105
Analysis 5.28. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy, Outcome 28
Croup (multiple versus one or no episodes). . . . . . . . . . . . . . . . . . . . . . . . 105
Analysis 6.1. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 1 Asthma exacerbations. . . . . . . . . . . . . . . . . . . . 106
Analysis 6.2. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 2 Admission to neonatal intensive care unit or special care nursery. . . . . . 106
Analysis 6.3. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 3 Asthmatic symptoms (ACQ score). . . . . . . . . . . . . . . . 107
Analysis 6.4. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 4 Asthmatic symptoms (ACQ score). . . . . . . . . . . . . . . . 108
Analysis 6.5. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 5 Asthma medication requirements (oral corticosteroids). . . . . . . . . 108
Analysis 6.6. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 6 Asthma-related days off work. . . . . . . . . . . . . . . . . . 109
Analysis 6.7. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 7 Hypertension during pregnancy. . . . . . . . . . . . . . . . . 109
Analysis 6.8. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 8 Gestational diabetes. . . . . . . . . . . . . . . . . . . . . 110
Analysis 6.9. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 9 Caesarean birth. . . . . . . . . . . . . . . . . . . . . . 110
Analysis 6.10. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 10 Gestational age at birth (weeks). . . . . . . . . . . . . . . . 111
Analysis 6.11. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 11 Preterm birth. . . . . . . . . . . . . . . . . . . . . . . 111
Analysis 6.12. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 12 Birthweight (g). . . . . . . . . . . . . . . . . . . . . . 112
Analysis 6.13. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 13 Small-for-gestational age. . . . . . . . . . . . . . . . . . . 112
iiiInterventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.14. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 14 Apgar score. . . . . . . . . . . . . . . . . . . . . . . 113
Analysis 6.15. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 15 Congenital malformation. . . . . . . . . . . . . . . . . . 113
Analysis 6.16. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 16 Asthma-related hospital admissions. . . . . . . . . . . . . . . 114
Analysis 6.17. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA)
versus standard care, Outcome 17 Asthma-related emergency visits. . . . . . . . . . . . . . . . 114
Analysis 7.1. Comparison 7 Progressive muscle relaxation (PMR) versus sham training, Outcome 1 Lung function (FEV1
(L)). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Analysis 7.2. Comparison 7 Progressive muscle relaxation (PMR) versus sham training, Outcome 2 Lung function (PEFR
(L/minute)). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Analysis 7.3. Comparison 7 Progressive muscle relaxation (PMR) versus sham training, Outcome 3 Quality of life (STAXI
scores). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Analysis 7.4. Comparison 7 Progressive muscle relaxation (PMR) versus sham training, Outcome 4 Quality of life (SF-36
health survey scores). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
118ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
119APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
120CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
120DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
120SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
121DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
121INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ivInterventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Interventions for managing asthma in pregnancy
Emily Bain1 , Kristen L Pierides1, Vicki L Clifton2,3, Nicolette A Hodyl3, Michael J Stark3,4, Caroline A Crowther1,5, Philippa
Middleton1
1ARCH: Australian Research Centre for Health of Women and Babies, Robinson Research Institute, Discipline of Obstetrics and
Gynaecology, The University of Adelaide, Adelaide, Australia. 2Clinical Research Development, Lyell McEwin Hospital, Adelaide,
Australia. 3Robinson Research Institute, The University of Adelaide, Adelaide, Australia. 4Department of Neonatal Medicine, Women’s
and Children’s Hospital, Adelaide, Australia. 5Liggins Institute, The University of Auckland, Auckland, New Zealand
Contact address: Emily Bain, ARCH: Australian Research Centre for Health of Women and Babies, Robinson Research In-
stitute, Discipline of Obstetrics and Gynaecology, The University of Adelaide, Adelaide, South Australia, 5006, Australia.
emily.bain@adelaide.edu.au.
Editorial group: Cochrane Pregnancy and Childbirth Group.
Publication status and date: New, published in Issue 10, 2014.
Review content assessed as up-to-date: 2 June 2014.
Citation: Bain E, Pierides KL, Clifton VL, Hodyl NA, Stark MJ, Crowther CA, Middleton P. Interventions for managing asthma in
pregnancy. Cochrane Database of Systematic Reviews 2014, Issue 10. Art. No.: CD010660. DOI: 10.1002/14651858.CD010660.pub2.
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Asthma is the most common respiratory disorder complicating pregnancy, and is associated with a range of adverse maternal and
perinatal outcomes. There is strong evidence however, that the adequate control of asthma can improve health outcomes for mothers
and their babies. Despite known risks of poorly controlled asthma during pregnancy, a large proportion of women have sub-optimal
asthma control, due to concerns surrounding risks of pharmacological agents, and uncertainties regarding the effectiveness and safety
of different management strategies.
Objectives
To assess the effects of interventions (pharmacologic and non-pharmacologic) for managing women’s asthma in pregnancy on maternal
and fetal/infant outcomes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (2 June 2014) and the Cochrane Airways Group’s Trials
Register (4 June 2014).
Selection criteria
Randomised and quasi-randomised controlled trials comparing any intervention used tomanage asthma in pregnancy, with placebo, no
intervention, or an alternative intervention. We included pharmacological and non-pharmacological interventions (including combined
interventions). Cluster-randomised trials were eligible for inclusion (but none were identified). Cross-over trials were not eligible for
inclusion.
We included multi-armed trials along with two-armed trials. We also included studies published as abstracts only.
Data collection and analysis
At least two review authors independently assessed trial eligibility and quality and extracted data. Data were checked for accuracy.
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Main results
We included eight trials in this review, involving 1181 women and their babies. Overall we judged two trials to be at low risk of bias,
two to be of unclear risk of bias, and four to be at moderate risk of bias.
Five trials assessed pharmacological agents, including inhaled corticosteroids (beclomethasone or budesonide), inhaled magnesium
sulphate, intravenous theophylline, and inhaled beclomethasone verus oral theophylline. Three trials assessed non-pharmacological
interventions, including a fractional exhaled nitric oxide (FENO)-based algorithm versus a clinical guideline-based algorithm to adjust
inhaled corticosteroid therapy, a pharmacist-led multi-disciplinary approach to management versus standard care, and progressive
muscle relaxation (PMR) versus sham training.
The eight included trials were assessed under seven separate comparisons.
Pharmacological interventions
Primary outcomes: one trial suggested that inhaled magnesium sulphate in addition to usual treatment could reduce exacerbation
frequency in acute asthma (mean difference (MD) -2.80; 95% confidence interval (CI) -3.21 to -2.39; 60 women). One trial assessing
the addition of intravenous theophylline to standard care in acute asthma did not report on exacerbations (65 women). No clear
difference was shown in the risk of exacerbations with the use of inhaled beclomethasone in addition to usual treatment for maintenance
therapy in one trial (risk ratio (RR) 0.36; 95% CI 0.13 to 1.05; 60 women); a second trial also showed no difference, however data
were not clearly reported to allow inclusion in a meta-analysis. No difference was shown when inhaled beclomethasone was compared
with oral theophylline for maintenance therapy (RR 0.88; 95% CI 0.59 to 1.33; one trial, 385 women). None of these trials reported
on neonatal intensive care admissions.
Secondary outcomes: inhaledmagnesium sulphate in acute asthmawas shown to improve lung functionmeasures (one trial, 60 women);
intravenous theophylline in acute asthma was not associated with benefits (one trial, 65 women). No clear differences were seen with
the addition of inhaled corticosteroids to routine treatment in three trials (374 women). While inhaled beclomethasone, compared with
oral theophylline, significantly reduced treatment discontinuation due to adverse effects in one trial (384 women), no other differences
were observed, except for higher treatment adherence with theophylline. Four of the five trials did not report on adverse effects.
Non-pharmacological interventions
Primary outcomes: in one trial, the use of a FENO-based algorithm was shown to significantly reduce asthma exacerbations (RR
0.61; 95% CI 0.41 to 0.90; 220 women); and a trend towards fewer neonatal hospitalisations was observed (RR 0.46; 95% CI 0.21
to 1.02; 214 infants). No exacerbations occurred in one trial assessing pharmacist-led management; this approach did not reduce
neonatal intensive care admissions (RR 1.50; 95% CI 0.27 to 8.32; 58 infants). One trial (64 women) assessing PMR did not report
on exacerbations or neonatal intensive care admissions.
Secondary outcomes: the use of a FENO-based algorithm to adjust therapy led to some improvements in quality of life scores, as well
as more frequent use of inhaled corticosteroids and long-acting β-agonists, and less frequent use of short-acting β-agonists (one trial,
220 women). The FENO-based algorithm was associated with fewer infants with recurrent episodes of bronchiolitis in their first year
of life, and a trend towards fewer episodes of croup for infants. Pharmacist-led management improved asthma control scores at six
months (one trial, 60 women); PMR improved lung function and quality of life measures (one trial, 64 women). No other differences
between comparisons were observed.
Authors’ conclusions
Based on eight included trials, of moderate quality overall, no firm conclusions about optimal interventions for managing asthma
in pregnancy can be made. Five trials assessing pharmacological interventions did not provide clear evidence of benefits or harms to
support or refute current practice. While inhaled magnesium sulphate for acute asthma was shown to reduce exacerbations, this was in
one small trial of unclear quality, and thus this finding should be interpreted with caution. Three trials assessing non-pharmacological
interventions provided some support for the use of such strategies, however were not powered to detect differences in important maternal
and infant outcomes. While a FENO-based algorithm reduced exacerbations, the effects on perinatal outcomes were less certain, and
thus widespread implementation is not yet appropriate. Similarly, though positive effects on asthma control were shown with PMR
and pharmacist-led management, the evidence to date is insufficient to draw definitive conclusions.
In view of the limited evidence base, further randomised trials are required to determine the most effective and safe interventions for
asthma in pregnancy. Future trials must be sufficiently powered, and well-designed, to allow differences in important outcomes for
mothers and babies to be detected. The impact on health services requires evaluation. Any further trials assessing pharmacological
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interventions should assess novel agents or those used in current practice. Encouragingly, at least five trials have been identified as
planned or underway.
P L A I N L A N G U A G E S U M M A R Y
Interventions for managing asthma in pregnancy
Asthma is the most common disorder of the respiratory system (the organs that help you breathe) in pregnancy, affecting up to
one in eight women. During pregnancy asthma can improve, worsen or remain unchanged. Poorly controlled asthma may lead to
complications for mothers including pre-eclampsia (high blood pressure and protein in the urine), gestational diabetes (high blood
glucose) and caesarean birth; complications for babies may include death, preterm birth (before 37 weeks of pregnancy) and being
born low birthweight. Maintaining adequate control of asthma during pregnancy, including effective management and prevention of
exacerbations, is the goal of management. In pregnancy, women may be concerned about risks of taking medications, and their health
professionals may be uncertain about best management strategies.
This review aimed to assess how effective and safe different interventions are for managing asthma during pregnancy. We were able to
include eight randomised controlled trials involving 1181 women and their babies. The trials were of moderate quality overall. Five
trials assessed medications. Inhaled magnesium sulphate helped to reduce further exacerbations for women with acute asthma, and
helped to improve their lung function (one trial of unclear quality, 60 women). For ongoing therapy for pregnant women with stable
asthma, the effect of inhaled corticosteroids on asthma exacerbations was not clear (two trials, 155 women; but data only analysed from
one trial, 60 women); no difference was seen in the chance of exacerbations when inhaled corticosteroids were compared with oral
theophylline, however more women receiving theophylline stopped treatment because of side effects (one trial, 385 women). Three
trials assessed non-drug interventions. Adjusting women’s asthma medications according to how much nitric oxide they exhaled (their
fraction of exhaled nitric oxide (FENO)) was shown to reduce exacerbations and improve their quality of life (one trial, 220 women).
Progressive muscle relaxation improved women’s lung function and quality of life (one trial, 64 women), and asthma management led
by a pharmacist helped to improve asthma control (one trial, 60 women).
Overall, we did not find enough evidence of benefits and harms from the randomised trials to be sure about the best way to manage
asthma in pregnancy, although some interventionswere promising.We need larger, high-quality trials, which should report on important
health outcomes for mothers and babies, including longer-term outcomes for babies into childhood and adulthood. Five trials are
currently being planned or are underway assessing interventions for asthma in pregnancy.
B A C K G R O U N D
Description of the condition
Introduction and definition
Asthma is the most common respiratory disorder complicating
pregnancy. Although a reversible disease, asthma is potentially life
threatening for a mother and her infant (Katz 2008). The preva-
lence of asthma in pregnant women appears to have increased over
recent decades (Katz 2008); estimates vary from approximately
3% to 12% (Kwon 2003; Kwon 2006;McCusker 2011). A review
of studies related to asthma exacerbations during pregnancy sug-
gested that exacerbations requiring medical intervention occur in
approximately 20% of asthmatic women, and approximately 6%
require hospital admission (Murphy 2006).
The effect of pregnancy on asthma
Available data describe a variable course of asthma in pregnancy,
influenced by both the severity of the pre-existing condition, and
physiologic changes during pregnancy (Gluck 2004; Katz 2008).
Asthma may improve, worsen or remain unchanged during preg-
nancy. A meta-analytic review of 14 studies assessing changes in
the course of asthma throughout pregnancy suggested that ap-
proximately one-third of pregnant asthmatic women experience
a symptomatic improvement, one-third experience a worsening,
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and one-third remain the same (Juniper 1993). Later studies have
suggested however, that this concept may underestimate the real
risk of exacerbations during pregnancy (Katz 2008).
While a number of factors that may improve or worsen asthma
have been noted, the mechanisms involved are largely undefined,
and thus a woman’s asthma course during pregnancy is often un-
predictable (Schatz 1999). Consequently, it is essential that a preg-
nant woman with asthma be followed carefully, and managed ap-
propriately.
The effects of asthma on pregnancy
Studies investigating the association between maternal asthma
or exacerbations of asthma and adverse maternal and perinatal
outcomes have revealed inconsistent findings (Katz 2008). Early
retrospective data suggested asthma in pregnancy was associated
particularly with an increased risk of neonatal death, low birth-
weight, preterm birth and pre-eclampsia (Bahna 1972). Subse-
quent retrospective and prospective studies have shown asthma in
pregnancy to be associated with a range of complications - ma-
ternal adverse outcomes including pregnancy-induced hyperten-
sion (Enriquez 2007), pre-eclampsia (Demissie 1998; Enriquez
2007), gestational diabetes (Hodyl 2014), premature rupture
of membranes (Hodyl 2014), caesarean birth (Demissie 1998;
Dombrowski 2004a; Enriquez 2007) (including emergency cae-
sarean birth) (Hodyl 2014), chorioamnionitis (Liu 2001), hyper-
emesis (Bahna 1972), and antepartum and postpartum haemor-
rhage (Enriquez 2007; Hodyl 2014). Adverse perinatal outcomes
that have been linkedwithmaternal asthma include perinatal mor-
tality (Källén 2000), preterm birth (Breton 2009; Demissie 1998;
Dombrowski 2004a; Källén 2000), lowbirthweight (Breton 2009;
Demissie 1998; Enriquez 2007; Källén 2000; Murphy 2006),
small-for-gestational age (Clifton 2009;Hodyl 2014), intrauterine
growth restriction (Bahna 1972; Demissie 1998; Enriquez 2007;
Källén 2000), and congenital malformations (Demissie 1998;
Hodyl 2014). Recently, in a retrospective cohort study of over
220,000 singleton births, designed to assess the effects of maternal
asthma on neonatal morbidity, asthma was shown to be associated
with preterm birth (for each week after 33 completed weeks of ges-
tation), small-for-gestational age, neonatal intensive care unit ad-
mission, hyperbilirubinaemia, respiratory distress syndrome, tran-
sient tachypnoea of the newborn and asphyxia; term infants were
also shown to have an increased risk of intracerebral haemorrhage
and anaemia (Mendola 2014).
A number of studies have failed, however, to demonstrate an associ-
ation between asthma in pregnancy and adverse outcomes includ-
ing low birthweight (Schatz 1995), perinatal mortality (Clifton
2009; Schatz 1995), preterm birth (Clifton 2009; Dombrowski
2004a; Enriquez 2007; Murphy 2006; Schatz 1995), pre-eclamp-
sia (Dombrowski 2004a;Murphy 2006; Schatz 1995) and congen-
ital malformations (Enriquez 2007; Källén 2000; Schatz 1995).
Such discrepant data may be explained in part by the variation be-
tween studies in population characteristics such as asthma severity
and treatment(s) women received, often making comparisons be-
tween studies difficult (Katz 2008). Variation in the proportions of
male and female participants between studies (and failure to anal-
yse by infant sex) may further explain inconsistencies in findings
observed; a number of studies have suggested sex differences in
adverse perinatal outcomes in women with asthma (Clifton 2009;
Murphy 2005b).
Associated with the increased risk of being born preterm, chil-
dren born to mothers with asthma during pregnancy may also be
at an increased risk of long-term health complications associated
with prematurity, including neurodevelopmental sequale (such as
cerebral palsy or other motor impairments, sensory impairments
such as visual and auditory deficits, intellectual/mental impair-
ments; or other developmental ’lags’ not classified as impairments)
and behavioural sequale (such as dysfunction in other cognitive
areas including attention, visual processing, academic progress,
and executive function) (Saigal 2008). Short-term risks for babies
born preterm include severe infections (neonatal sepsis), respira-
tory distress syndrome, jaundice, brain injury (most commonly
intraventricular haemorrhage), necrotising enterocolitis, retinopa-
thy of prematurity, and anaemia of prematurity (Lawn 2013).
A recent meta-analysis including 40 studies and involving over
1,600,000 women assessed the risk of adverse perinatal outcomes
associated with maternal asthma and the size of these effects (
Murphy 2011). This meta-analysis showed maternal asthma to be
associated with an approximate 40% increased risk of both low
birthweight and preterm birth, an approximate 50% increased
risk of pre-eclampsia, and an approximate 20% increased risk of
small-for-gestational age (Murphy 2011). An earlier meta-analysis
showed asthma exacerbations during pregnancy to be associated
with a more than doubled risk of low birthweight (Murphy 2006),
however no increased risk of preterm birth nor pre-eclampsia was
shown.
Investigations
Asthma diagnosis may be made by a history of asthma symptoms
such as breathlessness, chest tightness, cough and sputum produc-
tion, and the use of spirometry (Dombrowski 2006). In the ini-
tial assessment of a pregnant woman with asthma, and at regular
visits, spirometry has been recommended (NAEPP 2005). Due
to the potential for asthma severity to change throughout preg-
nancy, women with persistent asthma have been recommended
to be evaluated monthly, including history, lung auscultation and
assessment of pulmonary function (NAEPP 2005). For women
with very poor asthma control, more frequent review has been
recommended until control is achieved (NAEPP 2005).
Ultrasound is widely regarded as a useful tool for fetal surveillance
in pregnancy. For women with sub-optimal asthma control, or
moderate to severe asthma, more regular fetal ultrasound examina-
tions from 32 weeks’ gestation tomonitor fetal growth, whichmay
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be affected by uncontrolled asthma in pregnancy, has been sug-
gested (NAEPP 2005). During and/or following a severe asthma
exacerbation in pregnancy, fetal monitoring using ultrasound or
cardiotocography has also been recommended (NAEPP 2005).
Description of the intervention
Interventions for managing asthma in pregnancy
Maintaining adequate control of asthmaduringpregnancy, includ-
ing the effective management and prevention of exacerbations, is
the goal of asthma management, shown to be associated with ben-
efits for the mother and her infant (Bracken 2003; Murphy 2006;
Schatz 1995). Asthma control during pregnancy has been defined,
by the United States National Heart, Lung, and Blood Institute in
their expert panel report as: minimal or no chronic symptoms day
or night; minimal or no exacerbations; no limitations of activities;
maintenance of (near) normal pulmonary function; minimal use
of short-acting inhaled β2-agonists; minimal or no adverse effects
from medications (NAEPP 2005).
A critical issue in considering the management of asthma in preg-
nancy, is whether the potential benefit for improving a mother’s
asthma control outweighs potential adverse effects of asthma inter-
ventions on her unborn infant. It must also be considered whether
pregnancy itself alters the effects of asthma interventions, and
thus whether, and how, the management of pregnant women with
asthma should differ from asthma management in those who are
not pregnant.
Interventions for managing asthma during pregnancy have the
potential to not only improve maternal and perinatal health, but
also to reduce associated healthcare costs, for example, through
reducing asthma-related unplanned medical and emergency de-
partment visits for pregnant women, and reducing costs associated
with the adverse maternal and neonatal outcomes linked to poorly
controlled asthma (i.e. preterm birth and neonatal intensive care
unit admissions).
The management of asthma in pregnant and non-pregnant in-
dividuals may involve both non-pharmacological and pharma-
cological interventions; often multiple inter-related strategies are
employed to maintain optimal control. A recent Cochrane re-
view ’Culture-specific programs for children and adults fromminority
groups who have asthma’ suggested some enhanced effectiveness of
culture-specific programs for management for minority groups, as
compared with generic programs, when considering most asthma
outcomes in non-pregnant populations (Bailey 2009).
Pharmacological agents
Pharmacological therapy for asthma aims to control symptoms
and achieve optimal lung function at the lowest effective doses of
medication (NACA 2006).
Pharmacological medications for asthma can be broadly cate-
gorised as rescue agents and maintenance agents, or may alterna-
tively be grouped according to their mechanism of action (anti-
inflammatory agents and bronchodilators). Rescue agents are used
on an ‘as-needed basis’ to treat acute symptoms; the most com-
monly used are short-acting β-agonists. Inhaled anticholinergics,
such as ipratropium, can also be used for severe acute asthma
(NACA 2006). Maintenance agents aim to prevent asthma symp-
toms and exacerbations, and include anti-inflammatory agents
such as inhaled corticosteroids, along with long-acting bron-
chodilators (β-agonists). Less commonly usedmaintenance agents
include mast cell stabilisers, leukotriene-receptor antagonists and
theophylline (a sustained release methylxanthine).
The treatment of asthma during pregnancy with pharmacologi-
cal medications has widely been considered ‘safer’ for a pregnant
woman and her fetus than uncontrolled asthma and the associ-
ated symptoms and exacerbations (NAEPP 2005).While formany
asthma medications there appear to be no, or minimal associated
adverse effects during pregnancy (Bracken 2003; Dombrowski
2006; Liccardi 2003; NAEPP 2005), no Cochrane review has as-
sessed the effects of pharmacological agents on maternal and fe-
tal/infant morbidity, and the optimal pharmacological treatment
strategies for pregnant women are unclear.
For example, while safety data on the use of inhaled short-acting
β-agonists in pregnancy have been regarded as reassuring (NAEPP
2005), a number of epidemiological studies have suggested an
increase in the risk of congenital abnormalities with the use of
maternal bronchodilators, including short-acting β-agonists, anti-
cholinergic agents and theophylline (Källén 2007; Lin 2008). The
use of anti-inflammatory agents (including oral corticosteroids) to
prevent acute exacerbations in pregnancy, has additionally been
associated with an increased risk of cleft lip, cleft palate or both
(Carmichael 2007; Park-Wyllie 2000; Rodríguez-Pinilla 1998).
High doses of inhaled corticosteroids during the first trimester of
pregnancy, as opposed to low tomoderate doses, have also been as-
sociated with an increased risk of congenital malformations (Blais
2009). Other concerns surrounding the use of corticosteroids in
pregnancy persist, with animal studies and observational data sug-
gesting possible adverse effects on growth, risk of neonatal in-
fection, fetal hypothalamo-pituitary-adrenal (HPA) function and
neonatal blood pressure (Mildenhall 2006).There is a recognised
potential that exposure to corticosteroids could program cardio-
vascular settings in the fetus, leading for example, to adult hyper-
tension, dyslipidaemia, and insulin resistance or diabetes mellitus
(Dalziel 2005). A recent study has however demonstrated that the
use of inhaled corticosteroids by pregnant asthmatic women, does
not affect fetal glucocorticoid regulated pathways; and thus the
authors considered that it is unlikely that inhaled corticosteroids
contribute to adverse effects on fetal growth and development
(Hodyl 2011).
Women’s concerns regarding the safety of pharmacological agents,
and health professionals’ lack of certainty (with inconsistent rec-
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ommendations), have been shown to lead to ‘under-dosing,’ lim-
ited adherence to pharmacological treatments by pregnant women
(Lim 2012a; Sawicki 2012), and potentially avoidable morbid-
ity (Murphy 2006). It has been estimated that over one-third of
women may discontinue their asthma medications during preg-
nancy, many without consulting their doctors; and up to one quar-
ter of health professionals may instruct pregnant women to de-
crease or discontinue asthma medication during pregnancy due to
lack of confidence and/or knowledge, despite asthma being well
controlled by current therapy (Lim 2011a). In order to guide the
optimal care of pregnant women, it is therefore essential that the
effects of pharmacological agents used to manage asthma in preg-
nancy be formally evaluated.
Non-pharmacological interventions for asthma
management in pregnancy
A multitude of non-pharmacological measures are often used in
conjunction with pharmacological agents for the management of
asthma. These include: the monitoring of lung function to guide
treatment (e.g. the use of spirometry or serial peak-flow measure-
ments); monitoring of airway inflammation to guide treatment
(e.g. inflammometry - the use of sputum eosinophil counts and
exhaled nitric oxide); lifestyle modification including the avoid-
ance of triggers (such as smoking cessation); dietary interventions;
physical interventions (e.g. breathing exercises; inspiratory mus-
cle training); psychological interventions; educational programs;
written asthma action plans; and combinations of strategies.
While a number of such interventions have been assessed for the
management of asthma in the general population, little is known
regarding their importance for themanagement of asthma in preg-
nancy, and how their effects differ for pregnant women.
Monitoring of lung function and airway inflammation
Monitoring of lung function in pregnancy has been considered a
valuable component of asthmamanagement, used to guide further
treatment and intervention. Impaired pulmonary function during
pregnancy has been associatedwith adverse perinatal outcomes, in-
cluding gestational hypertension and prematurity (Schatz 2006).
After initial assessment, follow-up measures of pulmonary func-
tion are preferably done by the use of spirometry; however peak-
flow measurements have been considered adequate and allow the
patient to monitor serial measurements of lung function at home
(NAEPP2005). It has been recommended that patients withmod-
erate to severe asthma assess their lung function daily by peak-flow
measurements (NAEPP 2005).
An alternative to the monitoring of lung function to guide asthma
management in pregnancy is the monitoring of airway inflamma-
tion - such asmeasuring sputumeosinophil counts and the fraction
of exhaled nitric oxide (FENO) (Petsky 2007; Petsky 2009). These
interventions measure underlying airway inflammation, which is
the target of inhaled corticosteroid therapy. A Cochrane review
’Tailored interventions based on exhaled nitric oxide versus clinical
symptoms for asthma in children and adults’ assessing the use of
FENO compared with clinical symptoms to tailor the dose of in-
haled corticosteroids in the non-pregnant population, found no
clear benefits to recommend the use of FENO-based management
(Petsky 2009). The equivalent review ’Tailored interventions based
on sputum eosinophils versus clinical symptoms for asthma in chil-
dren and adults’ assessing tailored interventions based on sputum
eosinophils did however, support benefits with the use of this tech-
nique for adults with frequent exacerbations and severe asthma
(Petsky 2007).
It is currently unknown whether similar effects are seen for preg-
nant women with the use of such techniques; no Cochrane re-
view has assessed methods for monitoring lung function or air-
way inflammation for improving asthmamanagement in pregnant
women.
Diet, exercise and lifestyle modifications
Avoiding exposure to environmental triggers has been widely con-
sidered an important component in the management of asthma
(Dombrowski 2006). Triggers may include animals, dust mites,
pollens, molds, air pollutants, food additives (e.g. sulphites), cer-
tain drugs and tobacco smoke (Dombrowski 2006). A number
of Cochrane reviews have assessed control measures for asthma
management in the general population (Campbell 2000;Gøtzsche
2008; Kilburn 2001; Singh 2002), however, the importance of
such measures for pregnant women is unclear. Smoking cessation
inparticular has been considered important for both asthmatic and
non-asthmatic pregnant women. During pregnancy, asthma exac-
erbations have been shown to be more common and more severe
in smokers than in non-smokers; such exacerbations may in turn
be associated with maternal and perinatal complications, and thus
the risk of maternal asthma may be greater for smokers (Murphy
2010). A recent retrospective analysis has shown that while ma-
ternal asthma and cigarette smoking during pregnancy are both
independently associated with adverse perinatal outcomes, com-
bined, they compound the risk particularly of preterm birth and
urinary tract infection (Hodyl 2014). The cessation of smoking
in pregnant asthmatic women for improving pregnancy outcomes
has, however, not been formally assessed.
In addition to environmental triggers, it is believed that food ad-
ditives (such as sulphites) may trigger asthma symptoms (Liccardi
2003), and thus their avoidance may improvemanagement. Other
dietary modifications that have been assessed for asthma man-
agement in the general population include dietary supplements
(Allam 2004; Kaur 2009; Thien 2002), sodium (Pogson 2011)
and marine fatty acid manipulation (Thien 2002). A calorie con-
trolled diet for asthma management has also been assessed in the
general population (Cheng 2003).
A number of physical interventions have been evaluated for
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asthma management in the non-pregnant population, including
breathing exercises (Holloway 2004), inspiratory muscle training
(Ram 2003), manual therapies (Hondras 2005), physical train-
ing (Chandratilleke 2012), and yoga (Posadzki 2011). While the
benefits of exercise during pregnancy are now recognised, and
women are thus encouraged to engage in ’light-to-moderate’ exer-
cise in the absence of any known pregnancy or medical complica-
tions (ACOG 2002), the benefits and risks for asthmatic pregnant
women are unclear.
Complementary and alternative medicines
Homoeopathy is a commonly used complementary treatment for
asthma. It is a complementary healing system, based on ’curing
like with like;’ a substance which gives rise to specific symptoms,
when given in pharmacological doses to healthy individuals, can
be used to treat patients presenting with the same symptoms (
McCarney 2004). Other common complementary and alternative
medicinal therapies used in the management of asthma include
herbal remedies (e.g. plants and plant extracts) (Arnold 2008).
Studies have suggested that common reasons pregnantwomenmay
choose to take or turn to herbal remedies and other complemen-
tary and alternative therapies, include their perceived safety and
effectiveness, personal control, accessibility, and the holistic nature
of the treatment (Holst 2009; Westfall 2003). While homoeopa-
thy (McCarney 2004), and other complementary and alternative
therapies, including acupuncture (McCarney 2009), chiropractic
techniques and osteopathy (Hondras 2005), have been assessed in
the general population for the treatment of chronic asthma, their
place in the management of asthma in pregnancy is unclear.
Psychological interventions
The effectiveness of psychological therapies for the management
of asthma in the general population is currently uncertain (Yorke
2006). During pregnancy, it has been suggested that women with
asthma should have access to regular contact with their health-
care provider, for the provision of adequate psychological support,
for reassurance and for the reduction of emotional stress (Liccardi
2003). The effects of specific psychological interventions (such as
cognitive therapy, behavioural therapy, relaxation therapy, biofeed-
back therapy and ’supportive’ counselling) for asthma manage-
ment in pregnancy have however, not been formally reviewed.
Self-management of asthma including asthma action plans
Self-management of asthma may incorporate a range of strategies
- including education, self-monitoring, regular review by a health
professional and the use of written asthma action plans (Gibson
2004), aimed at improving adherence to medication regimens and
encouraging patients to seek prompt attention for exacerbations.
Patient education or educational programs as a component of self-
management plans, have been recognised as an important aspect
in the control of asthma, and may include information regard-
ing the recognition of symptoms, the avoidance of triggers, self-
monitoring and correct peak expiratory flow rate (PEFR) mea-
surement, the appropriate use of medication, and advice regard-
ing when to seek medical attention (Dombrowski 2006; Gibson
2002; Liccardi 2003; Tapp 2007).Written asthma action plans are
individualised plans produced for the purpose of patient self-man-
agement of asthma and its exacerbations. The plans are tailored
to assist individuals in managing their asthma based on symptoms
and/or peak flow measurements, and may include information on
how to recognise worsening asthma, how to act promptly to pre-
vent asthma worsening (including how to modify medications),
and what to do in an emergency (including seeking access to med-
ical care) (Gibson 2004; GINA 2001). While the use of limited
asthma education (information only) was shown in a Cochrane
review to not improve health outcomes in the general population
(Gibson 2002), in the Cochrane review ‘Self-management educa-
tion and regular practitioner review for adults with asthma’, self-
management plans that enabled individuals to adjust their med-
ication using a written action plan were shown to be more effec-
tive than other forms of self-management in the general popula-
tion (Gibson 2002). While asthma action plans have been recog-
nised as a critical component for the management of asthma in
many nations, and comprise part of the recommendations for op-
timum care as devised by the Global Initiative in Asthma (GINA)
(GINA 2001), studies from Australia and the United Kingdom
have suggested declining use despite evidence of clinical benefit
(Jones 2000), and unpopularity with both patients and clinicians
has been noted (Ruffin 2001).
Findings from observational studies have provided support for the
need for self-management skills and the effectiveness of asthma ed-
ucation for women during pregnancy (Murphy 2005a). A prospec-
tive cohort study in Australia assessed asthma self-management
skills and knowledge among a group of 211 pregnant women.
Women received education about asthma control and manage-
ment skills, including trigger avoidance and smoking cessation
where appropriate. Prior to education, approximately 40% of
women reported non-adherence to inhaled corticosteroids, and
inhaler technique was assessed as inadequate for 16%; only 15%
had a written action plan, and 3% performed peak flow monitor-
ing. Following asthma education, significant improvements were
shown in all aspects of asthma self-management; severe asthma,
night symptoms, and reliever medication use were also shown to
be significantly reduced (Murphy 2005a).
While asthma education and management programs have tradi-
tionally been delivered in hospital settings such as antenatal clin-
ics, and by physicians and general practitioners, the role for other
health professionals including community-based pharmacists in
assisting asthma management, is increasingly being assessed. A
number of recent studies have supported the utility of commu-
nity pharmacy-based programs that provide education surround-
ing inhalation technique and medication adherence, in improving
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asthma control and therapeutic outcomes in adult asthmatic pa-
tients (Basheti 2007; Mehuys 2008). The value of such commu-
nity-based self-management programs, and the delivery of educa-
tion by health professionals not traditionally involved in asthma
management for pregnant women, is currently unclear.
While self-management plans including the use of written asthma
action plans, have been associated with improved asthma out-
comes in adults (Abramson 2001; Gibson 2002), their effects are
likely highly dependent upon the population. Studies have sug-
gested that pregnant women may benefit from self-management
education as part of their obstetric care (Murphy 2005a) however,
no systematic review has formally assessed the effectiveness of such
education, nor the use of written asthma action plans.
Why it is important to do this review
Asthma is the most common respiratory disorder complicating
pregnancy, and has been associated with a range of adverse ma-
ternal and perinatal outcomes. There is strong evidence however,
that the adequate control of asthma in pregnancy is associated with
improved health outcomes for both the mother and her infant;
accordingly effective management interventions have the poten-
tial to reduce healthcare costs otherwise associated with poorly
controlled asthma. Despite the known risks of poorly controlled
asthma during pregnancy, it has been shown that a large propor-
tion of pregnant women have sub-optimal asthma control, due
to concerns particularly surrounding the risks of pharmacological
agents, and due to uncertainties regarding the effectiveness and
safety of different management interventions or strategies.
To date, no Cochrane review has evaluated the effectiveness and
safety of any of the known management interventions for asthma
in pregnancy. This systematic review will therefore assess inter-
ventions (both pharmacological and non-pharmacological) used
to manage asthma during pregnancy, to strengthen the link be-
tween the best current evidence and the optimal care of asthmatic
pregnant women.
O B J E C T I V E S
The aim of this review is to systematically assess the effects of
interventions (pharmacologic and non-pharmacologic, including
self-management interventions) for managing women’s asthma in
pregnancy on maternal and fetal/infant outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all published, unpublished and ongoing randomised
controlled trials with reported data. We planned to include quasi-
randomised trials and cluster-randomised trials. We have included
studies published as abstracts only.We includedmulti-armed trials
along with two armed trials. Cross-over trials were not eligible for
inclusion.
Types of participants
We included pregnant women with current asthma (with a health
professional’s diagnosis), regardless of gestational age, parity, plu-
rality, and severity of asthma.
Types of interventions
We included any intervention used to manage asthma in preg-
nancy, compared with a placebo, with no intervention (i.e. stan-
dard care), or with an alternative intervention for managing
asthma.We also included any intervention used tomanage asthma
in a population of reproductive age which included a subset of
pregnant women (where data have been reported separately for
the subset of pregnant women).
We included both pharmacological interventions and non-phar-
macological interventions (along with combined interventions).
Pharmacological interventions, may have included, for example,
the use of rescue agents (e.g. short-acting β-agonists, and inhaled
anticholinergics) and maintenance agents (e.g. inhaled corticos-
teroids, long-acting β-agonists, leukotriene-receptor antagonists,
mast cell stabilisers, sustained release methylxanthines and sys-
temic steroids).
Non-pharmacological interventions may have included any strat-
egy (as described in the Background, such as monitoring of lung
function and airway inflammation; diet, exercise and lifestylemod-
ifications; complementary and alternative medicines; psychologi-
cal interventions; self-management plans) aimed at improving the
management of asthma during pregnancy, and any combination
of strategies.
Types of outcome measures
We considered maternal and fetal/neonatal/infant outcomes relat-
ing to effectiveness and safety of the interventions.
Primary outcomes
For the mother
• Asthma exacerbations (as defined by trialists, e.g. events for
which the woman sought medical attention - an unscheduled
visit to a doctor, presentation to the emergency room, admission
to hospital or where oral corticosteroids were used for treatment)
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For the neonate/infant
• Admission to neonatal intensive care unit or special care
nursery
Secondary outcomes
For the mother
• Asthmatic symptoms (e.g. including episodes of wheeze,
shortness of breath, symptoms scores, i.e. measures of dyspnoea
or breathlessness with Borg score, Visual Analogue Scale, the
Asthma Control Questionnaire score (ACQ), symptom-free
days)
• Asthma medication requirements (e.g. use of rescue
medication, use of preventer medication)
• Lung function (e.g. peak expiratory flow rate (PEFR),
forced expiratory volume in one second (FEV1), forced vital
capacity (FVC))
• Inflammatory markers (e.g. serum and sputum eosinophils,
serum eosinophilic cationic protein (ECP), exhaled nitric oxide)
• Asthma self-management skills (e.g. inhaler technique,
correct knowledge of medication requirements)
• Quality of life (e.g. measured using a validated health-
related generic and/or disease specific quality of life
questionnaire)
• Days/time lost from work or school
• Pregnancy-induced hypertension
• Pre-eclampsia/eclampsia
• Gestational diabetes
• Caesarean birth
• Antepartum haemorrhage
• Postpartum haemorrhage
• Preterm prelabour ruptured membranes
• Preterm labour
• Chorioamnionitis
• Hyperemesis
• Adverse effects (clinical or biochemical) attributed to
intervention and discontinuation of the intervention due to
adverse effect(s)
• Adherence with intervention
Whenever possible, we planned to include change from baseline
data for relevant secondary maternal outcomes (i.e. for asthmatic
symptoms; asthma medical requirements; measures of lung func-
tion; inflammatory markers; and quality of life).
For the fetus/neonate
• Termination of pregnancy
• Stillbirth
• Neonatal death
• Gestational age at birth
• Preterm birth (less than 32 weeks; less than 37 weeks)
• Birthweight
• Low birthweight (less than 2500 g)
• Small-for-gestational age (less than the 10th centile for
gestational age)
• Apgar score of less than seven at five minutes
• Need for active resuscitation (assisted ventilation via an
endotracheal tube) at birth
• Respiratory distress syndrome*
• Intraventricular haemorrhage*
• Periventricular leukomalacia*
• Chronic lung disease*
• Necrotising enterocolitis*
• Retinopathy of prematurity*
• Patent ductus arteriosus*
• Hypothalamo-pituitary-adrenal (HPA) axis function
(however defined by authors)*
• Hyperbilirubinemia*
• Jaundice
• Neonatal sepsis
• Congenital malformation
For the infant, child, and for the child as an adult
• Death*
• Any neurodevelopmental disability (blindness, deafness,
moderate/severe cerebral palsy (however defined by authors), or
development delay/intellectual impairment (defined as
developmental quotient or intelligence quotient more than 2
standard deviations below population mean))*
• Growth assessments (weight, head circumference, length,
skin fold thickness, body mass index)*
• Lung function*
• Respiratory morbidity (including bronchiolitis, croup,
asthma) (however defined by authors)*
• Blood pressure*
• Glucose intolerance/insulin sensitivity (however defined by
authors)*
• Dyslipidaemia (however defined by authors)*
• HPA axis function (however defined by authors)*
• Age at puberty*
• Bone density*
• Visual impairment (however defined by authors)*
• Hearing impairment (however defined by authors)*
• Developmental delay (defined as developmental quotient
more than 2 standard deviations below population mean)*
• Intellectual impairment (defined as intelligence quotient
more than 2 standard deviations below population mean)*
• Cerebral palsy (however defined by authors)*
• Motor delay or impairment (however defined by authors)*
• Educational achievement (completion of high school, or
however defined by authors)*
• Behavioural/learning difficulties (however defined by
authors)*
9Interventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Use of health services
• Antenatal admissions to hospital for the mother and length
of stay
• Emergency department visits for the mother
• Admission to intensive care unit for the mother
• Length of postnatal hospitalisation for the mother
• Length of neonatal hospitalisation for the infant
• Costs of care for the mother or baby or both
* Outcomes not pre-specified at the protocol stage. We have also
reported on composite outcomes not clearly defined in the in-
cluded trials that may have included our pre-specified outcomes:
“obstetric complications”; “perinatal complications”; “healthy children
delivered”;“other adverse outcomes.” We have clearly reported these
as outcomes ’not pre-specified at protocol stage.’
Search methods for identification of studies
Electronic searches
We contacted the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register (2
June 2014).
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. weekly searches of Embase;
4. handsearches of 30 journals and the proceedings of major
conferences;
5. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE and
Embase, the list of handsearched journals and conference pro-
ceedings, and the list of journals reviewed via the current aware-
ness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
In addition, we contacted the Trials Search Co-ordinator of the
Cochrane Airways Group to search their Trials Register (4 June
2014), see: Appendix 1.
We did not apply any language restrictions.
Data collection and analysis
The methods of data collection and analysis are adapted from the
Cochrane Pregnancy and Childbirth Group’s standard methods
text.
Selection of studies
Two review authors (EB and KP) independently assessed for inclu-
sion all the potential studies we identified as a result of the search
strategy. We resolved any disagreement through discussion or, if
required, we consulted a third review author (PM).
We created a study flow diagram tomap out the number of records
identified, included and excluded.
Data extraction and management
We designed a form to extract data. For eligible studies, at least
two review authors (EB and KP) independently extracted the data
using the agreed form. We resolved discrepancies through discus-
sion or, if required, we consulted a third review author (PM). We
entered data into Review Manager software (RevMan 2014) and
checked for accuracy.
When information regarding any of the above was unclear, we
attempted to contact authors of the original reports to provide
further details.
Assessment of risk of bias in included studies
Two review authors (EB and KP) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreement by discussion or by involving a third
assessor (PM).
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should have produced comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
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whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to have affected results.
We assessed blinding separately for different outcomes or classes
of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We have stated whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information was reported, or could
be supplied by the trial authors, we planned to re-include missing
data in the analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review were reported);
• high risk of bias (where not all the study’s pre-specified
outcomes were reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so could not be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
Wemade explicit judgements aboutwhether studies are at high risk
of bias, according to the criteria given in theCochraneHandbook for
Systematic Reviews of Interventions (Higgins 2011). With reference
to (1) to (6) above, we assessed the likely magnitude and direction
of the bias and whether we considered it was likely to impact on
the findings. We planned to explore the impact of the level of bias
through undertaking sensitivity analyses - see Sensitivity analysis.
Measures of treatment effect
Dichotomous data
For dichotomous data, we have presented results as summary risk
ratio (calculated using the Mantel-Haenszel method) with 95%
confidence intervals.
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Continuous data
For continuous data, we have reported the mean difference (with
95% confidence intervals) where outcomes were measured in the
same way between trials. If we had identified trials that measured
the same outcome using different methods, we planned to use and
report the standardised mean difference (with 95% confidence
intervals).
Unit of analysis issues
Cluster-randomised trials
We planned to include cluster-randomised trials in the analyses
alongwith individually-randomised trials. In future updates of this
review, if we include cluster-randomised trials, we plan to adjust
their sample sizes if required using the methods described in the
Cochrane Handbook using an estimate of the intracluster correla-
tion co-efficient (ICC) derived from the trial (if possible), from
a similar trial or from a study of a similar population. If we use
ICCs from other sources, we plan to report this and conduct sen-
sitivity analyses to investigate the effect of variation in the ICC. If
we identify both cluster-randomised trials and individually-ran-
domised trials, we plan to synthesise the relevant information.
We will consider it reasonable to combine the results from both
if there is little heterogeneity between the study designs and the
interaction between the effect of intervention and the choice of
randomisation unit is considered to be unlikely.
We plan to also acknowledge heterogeneity in the randomisation
unit and perform a subgroup analysis to investigate the effects of
the randomisation unit.
Cross-over trials
We considered cross-over trials inappropriate for this research
question, given that women’s asthma courses during pregnancy are
variable and often unpredictable (i.e. asthma in pregnancy is not
a stable chronic condition), and also given the irreversible nature
of many of the chosen review outcomes (for example, stillbirth/
neonatal death and congenital malformations).
Multi-armed trials
We included amulti-armed trial (Wendel 1996).Wehave recorded
and included all outcome data in the review as two-arm compar-
isons. We have included the data for the different arms in inde-
pendent two-arm comparisons in separate meta-analyses.
Had we been unable to include the data in separate comparisons,
we planned to combine them to create a single pair-wise compar-
ison (Higgins 2011). If the control group was shared by two or
more study arms, we planned to divide the control group between
relevant subgroup categories to avoid double-counting the partic-
ipants (for dichotomous data, we planned to divide the events and
the total population, while for continuous data, we planned to
assume the same mean and standard deviation (SD) but planned
to divide the total population). We have described the details in
the ’Characteristics of included studies’ table.
Multiple pregnancies
As infants from multiple pregnancies are not independent, in fu-
ture updates of this review, if trials involving multiple are included,
we plan to use cluster-trial methods in the analyses, where the data
allow, and where multiples make up a substantial proportion of
the trial population, to account for non-independence of variables
(Gates 2004).
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by using sensi-
tivity analysis.
For all outcomes, we have carried out analyses, as far as possible,
on an intention-to-treat basis, i.e. we have attempted to include
all participants randomised to each group in the analyses, and all
participants have been analysed in the group to which they were
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial was
the number randomised minus any participants whose outcomes
were known to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 30% and either a T² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
In future updates of this review, if there are 10 or more studies
in a meta-analysis, we plan to investigate reporting biases (such
as publication bias) using funnel plots. We will assess funnel plot
asymmetry visually. If asymmetry is suggested by a visual assess-
ment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where tri-
als were examining the same intervention, and the trials’ popula-
tions and methods were judged sufficiently similar. Where there
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was clinical heterogeneity sufficient to expect that the underlying
treatment effects differed between trials, or where substantial sta-
tistical heterogeneity was detected, we used random-effects meta-
analysis to produce an overall summary, if an average treatment
effect across trials was considered clinically meaningful. The ran-
dom-effects summary was treated as the average range of possible
treatment effects and we have discussed the clinical implications of
treatment effects differing between trials. If the average treatment
effect was not clinically meaningful, we would not have combined
trials.
Where we have used random-effects analyses, the results have been
presented as the average treatment effect with 95% confidence
intervals, and the estimates of T² and I².
We performed separate comparisons for different types of inter-
ventions. We planned to consider separately, where possible:
• different classes of asthma medications (e.g. we planned to
have separate comparisons for β-agonists (considering short-
acting and long-acting separately); corticosteroids (considering
inhaled and systemic (oral) steroids separately); leukotriene-
receptor antagonists; anticholinergics; mast cell stabilisers,
sustained release methylxanthines);
• dietary interventions;
• physical interventions;
• psychological interventions.
Subgroup analysis and investigation of heterogeneity
Where we identified substantial heterogeneity, we planned to in-
vestigate it using subgroup analyses and sensitivity analyses.Where
we identified substantial heterogeneity we considered whether an
overall summary was meaningful, and if it was, we used random-
effects analysis to produce it.
We planned to carry out the following subgroup analyses.
Maternal characteristics
• Severity of the woman’s asthma (e.g. mild versus moderate;
mild versus severe) (as defined by trialists).
• Smoking history (e.g. current or ex-smoker versus never
smoked).
Characteristics of the intervention
For each pharmacological intervention (i.e. for each asthma medi-
cation class discussed above, and for complementary or alternative
medicines where appropriate):
• specific agent (for example, when considering inhaled
corticosteroids: beclomethasone versus budesonide versus
fluticasone; or when considering short-acting β-agonists:
salbutamol versus terbutaline);
• dose (i.e. low versus high; for example, when considering
dosage of inhaled corticosteroids (HFA-beclomethasone
equivalent): low daily dose (≤ 400 mcg) versus medium daily
dose (> 400 to 600 mcg) versus high daily dose (> 600 mcg).
For non-pharmacological interventions (e.g. dietary, physical, psycho-
logical interventions):
• intensity of the intervention (e.g. provision of information
only versus educational sessions and regular review with a health
professional).
For both:
• duration of the intervention (e.g. short versus long);
• timing of the intervention (e.g. commencement in the first
trimester versus third trimester).
We planned to use only primary outcomes in subgroup analyses.
We planned to assess subgroup differences by interaction tests
available within RevMan (RevMan 2014). We planned to report
the results of subgroup analyses quoting the Chi² statistic and P
value, and the interaction test I² value.
Due to the large number of different comparisons, and paucity
of data, however, we were unable to perform the pre-specified
subgroup analyses.
Sensitivity analysis
We planned to carry out sensitivity analyses to explore the effects
of trial quality assessed by allocation concealment and random
sequence generation, by omitting studies rated as inadequate (’high
risk of bias’) (including quasi-randomised trials) or ’unclear risk
of bias’ for these components. We planned to restrict this to the
primary outcomes. However due to the large number of different
comparisons, paucity of data, and unclear methodological quality
of a number of the included trials, we were unable to perform
sensitivity analyses.
In future updates of this review, we plan to investigate the impact
of including studies with high levels of missing data, and the ef-
fects of any assumptions made such as the value of the ICC used
for cluster-randomised trials, should they be included, using sen-
sitivity analyses.
R E S U L T S
Description of studies
Results of the search
The Pregnancy and Childbirth Group’s Register search retrieved
26 records and the Cochrane Airways Group’s Trials Register
search retrieved 125 records (see Figure 1). Following removal of
duplicates, the titles and/or abstracts of 135 records were screened,
and 99 records were excluded.
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Figure 1. Study flow diagram.
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We assessed 36 full-text records for eligibility, and included
eight trials (Badawy 2012; Caramez 1998; Dombrowski 2004;
Lim 2012; Nickel 2006; Powell 2011; Silverman 2005; Wendel
1996) (28 records), excluded one study (Schonberger 2004)
and five studies (seven records) (ACTRN12613000244707;
ACTRN12613000301763; ACTRN12613000800729;
ACTRN12613000202763; NCT01345396) were classified as
ongoing.
Information for the Caramez 1998 trial has to date been obtained
from a published trial abstract only.
For further details, see Characteristics of included studies;
Characteristics of excluded studies; Characteristics of ongoing
studies.
Included studies
We have included eight trials, involving 1181 women and their
babies in this review (Badawy 2012; Caramez 1998; Dombrowski
2004; Lim 2012; Nickel 2006; Powell 2011; Silverman 2005;
Wendel 1996). The trials were conducted across a number of
different countries, and settings, including in Brazil (Caramez
1998), the United States (Dombrowski 2004; Wendel 1996),
Egypt (Badawy 2012), Germany (Nickel 2006) andAustralia (Lim
2012; Powell 2011). One trial (Silverman 2005) recruited women
from 32 different countries.
The eight trials assessed a variety of different interventions
for the management of asthma during pregnancy, and women
were randomised to a variety of pharmacologic interventions
(Badawy 2012; Caramez 1998; Dombrowski 2004; Silverman
2005; Wendel 1996) and non-pharmacologic interventions (Lim
2012; Nickel 2006; Powell 2011).
Four trials assessed inhaled corticosteroids for asthma manage-
ment in pregnancy (Caramez 1998;Dombrowski 2004; Silverman
2005; Wendel 1996); however they utilised different treatment
regimens and had different comparisons.
InCaramez 1998, 95pregnant asthmaticwomenwere randomised
to receive either “1 mg/day of inhaled beclomethasone” in addition to
an inhaled bronchodilator and a tapered oral corticosteroid (pred-
nisolone) during exacerbations (n = 49), or to the inhaled bron-
chodilator and tapered oral corticosteroid (prednisolone) alone (n
= 46).
Wendel 1996 recruited 65 pregnancy women presenting with
acute asthma exacerbations, and randomised them at two time-
points, thus assessing four differentmanagement strategies. Firstly,
women requiring inpatient management with a FEV1 less than
70% after sequential bronchodilator therapy (isoetharine), were
randomised to receive either intravenous aminophylline (5 mg/kg
loading dose, then 0.5 mg/kg maintenance), intravenous corticos-
teroid (methylprednisolone 1mg/kg every eight hours) (maximum
single dose 80 mg) and an inhaled bronchodilator (albuterol) (n
= 33), or to receive the intravenous corticosteroid (methylpred-
nisolone) and an inhaled bronchodilator (albuterol) only (n = 32).
At discharge, similar to inCaramez 1998,womenwere randomised
to receive inhaled beclomethasone (metered dose, four puffs twice
daily), an inhaled bronchodilator (albuterol metered dose inhaler)
and an oral corticosteroid taper (methylprednisolone) (n = 34), or
to receive the inhaled bronchodilator and an oral corticosteroid
taper (methylprednisolone) alone (n = 31).
In Dombrowski 2004 inhaled beclomethasone was similarly as-
sessed, however it was compared with oral theophylline for women
with moderate asthma; 398 women were randomised to receive
either inhaled beclomethasone (four puffs three times per day) in
combination with a placebo pill (n = 194), or to theophylline pills
(initial dose of 200 mg morning and evening; increased to 300
mg two times per day after three days) and a placebo inhaler (n =
191). All women were also supplied with an inhaled bronchodila-
tor (albuterol) to be used on an ’as needed’ basis.
In Silverman 2005, rather than beclomethasone, the inhaled corti-
costeroid budesonidewas assessed.Once-daily inhaled budesonide
(400 µg) in addition to usual treatment (n = 102) was compared
with once-daily inhaled placebo (n = 117) for the management of
mild-to-moderate asthma. The data included in this review from
the Silverman 2005 trial, relate to the 219 pregnancies that were
reported from 7241 participants included in the START trial (in-
haled Steroid Treatment As Regular Therapy).
Inhaledmagnesium sulphate was assessed in the Badawy 2012 trial
of 60 women with acute asthma during pregnancy. Women were
randomised to receive either routine treatment for acute asthma
exacerbations (that included the inhaled bronchodilator, salbuta-
mol) and inhaled magnesium sulphate (500 mg, 1 mL) (n = 30),
or to routine treatment alone for acute asthma exacerbations (n =
30). In both groups, women received “three sets of nebulization”.
Corticosteroids were also utilised in Powell 2011, however in this
trial, 220 pregnant asthmatic women were randomised to have
their usual asthma therapy (inhaled corticosteroids (budesonide)
and long-acting β-agonist therapy (salbutamol/formoterol)) ad-
justed according to an algorithm based on fractional exhaled nitric
oxide measurements (FENO) (n = 111), or to an algorithm based
on clinical practice guidelines (n = 109) during the second and
third trimesters of pregnancy. In Powell 2011, the FENO-based
algorithm used a sequential process: first, the FENO concentra-
tion was used to adjust the dose of inhaled corticosteroids; and
second, the Asthma Control Questionnaire (ACQ) score was used
to adjust the dose of long-acting β-agonist therapy (for further
details of the intervention and control algorithms see Additional
Table 1; Table 2; Table 3; Table 4).
In Lim 2012, similar to Powell 2011, pregnant women were ran-
domised to different asthma management strategies. Sixty women
were randomised to either a pharmacist-led ’Multi-disciplinary
Approach to Management of Maternal Asthma (MAMMA) (n =
30), or to usual care (which did not include any additional mon-
itoring or education sessions) (n = 30). Women in the interven-
tion group experienced a collaborative approach to their asthma
management (involving family, physicians and asthma educators),
in which asthma education, monitoring, feedback and follow-up
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were components of the monthly intervention. Women received
pharmacist-led management reviews (which included administra-
tion of the ACQ, and questions about oral corticosteroid use,
asthma related admissions, days off work and preventer/reliever
use); if during review the ACQ scores increased by 0.5 or there
had been a documented exacerbation, pharmacists and physicians
collaborated on ’step-up’ therapy. Women were also given a hand-
held device (and instructions) to use for home monitoring of lung
function.
Finally, in the Nickel 2006 trial, progressive muscle relaxation
(PMR) for the management of asthma was assessed in 64 preg-
nant women with bronchial asthma. Women were randomised to
receive PMR sessions (30-minute group sessions, three times per
week for eight weeks) (n = 32) or to receive sham training sessions
(also 30-minute sessions, three times per week) (n = 32). In the
PMR sessions, women were instructed to deliberately apply ten-
sion to certain muscle groups then release the tension and focus on
how the muscles relaxed during the process; women also received
precise instructions for daily practice at home (15 minutes, two
times a day using a shortened form of the procedure).
Excluded studies
We excluded one trial from this review (Schonberger 2004), as the
unit of randomisation was ‘the family’ and this trial included both
pregnant and non-pregnant women; data for pregnant women
alone could not be extracted.
Risk of bias in included studies
Summaries for the risk of bias of the included studies are given in
Figure 2 and Figure 3. Overall we judged two trials to be at a low
risk of bias, two trials to be at an unclear risk of bias, and the other
four trials to be at a moderate risk of bias.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Five of the included trials were judged to have used adequate
methods to generate their random sequence (Dombrowski 2004;
Lim 2012; Nickel 2006; Powell 2011; Silverman 2005). In
Dombrowski 2004, the sequence was generated by the co-ordi-
nating centre using the simple urn model; while in Lim 2012,
Nickel 2006, Powell 2011 and Silverman 2005, random number
sequences were computer-generated. In the remaining three trials
(Badawy 2012; Caramez 1998; Wendel 1996), the methods used
to generate the random sequence were not described, and thus the
risk of selection bias was judged as unclear.
In four of the trials, methods to conceal allocation were judged
to be adequate (Dombrowski 2004; Lim 2012; Powell 2011;
Silverman 2005). Dombrowski 2004 used sequentially numbered
medication kits; Lim 2012 used sequentially numbered, sealed,
opaque envelopes; in Powell 2011, an algorithm keeper, not di-
rectly involved in assessment or care of women, concealed the
treatment algorithm group fromwomen and study personnel; and
Silverman 2005 used central randomisation (at the sponsor’s site
by a person not involved in the analysis of data). In the other four
trials (Badawy 2012; Caramez 1998; Nickel 2006; Wendel 1996),
the methods to conceal allocation were not described in sufficient
detail, and thus the risk of selection bias was judged as unclear.
Blinding
In three trials the risk of performance and detection bias were both
judged to be low (Dombrowski 2004; Powell 2011; Silverman
2005). In Dombrowski 2004 and Silverman 2005, a placebo was
used to blind women, study personnel and outcome assessors
(Dombrowski 2004: women received inhaled beclomethasone and
placebo pills or inhaled placebo and theophylline pills; Silverman
2005: women received inhaled budesonide or inhaled placebo).
In Dombrowski 2004, while serum theophylline concentrations
were obtained for treatment regulation, samples were taken from
women in both groups. These samples were assessed by the Bio-
statistics Co-ordinating Centre who provided study investigators
with instructions to increase or decrease the dose of theophylline
pills; to maintain blinding, they also ’adjusted’ the dose of placebo
pills. In Powell 2011, women and study personnel were blinded,
with the research assistant who collected data at monthly appoint-
ments sending data to an ’algorithm keeper’, who applied the rel-
evant algorithm and sent treatment recommendations to the re-
search assistant; outcome assessors were also blind to group allo-
cation.
Two trials were judged to be at a high risk of performance bias; the
use of a placebo was not detailed in Wendel 1996, and it was not
possible due to the nature of the intervention, to blind women/
study personnel in Lim 2012. The remaining three trials were
judged to be at an unclear risk of performance bias (Badawy 2012;
Caramez 1998;Nickel 2006). InBadawy 2012 andCaramez 1998,
insufficient informationwas available to determine risk of bias, and
in Nickel 2006, while sham training was used, it was unclear as to
whether this would have been successful in blinding women (with
instructions in sham sessions and PMR session differing), and
study personnel administering the training could not be blinded.
While the risk of performance bias was judged as high and unclear
in Lim 2012 and Nickel 2006 respectively, both trials were judged
to be at a low risk of detection bias with outcome assessors reported
to be blind to group allocation. In Badawy 2012, Caramez 1998
andWendel 1996 therewas insufficient information to confidently
determine risk of detection bias.
Incomplete outcome data
Four trials (Badawy 2012; Lim 2012; Powell 2011; Wendel 1996)
were judged to have a low risk of attrition bias. In Powell 2011,
while 11/111 women withdrew from the FENO group after ran-
domisation and 6/109 withdrew from the control group, with-
drawals were for similar reasons, and all women were included in
the final analyses (with the final visit before withdrawing counted
as the ’end of study’ visit); in Wendel 1996, no women were lost
to follow-up or excluded during the inpatient phase of the trial,
and in the outpatient phase, one woman out of 34 women in the
intervention group was lost to follow-up and 4/31 women from
the control group were lost to follow-up; no other exclusions were
detailed. In Lim 2012, one woman in each group (2/60) was lost
to follow-up.
For the other four trials, the risk of attrition bias was judged to
be unclear (Caramez 1998; Dombrowski 2004; Nickel 2006;
Silverman 2005).
Selective reporting
Two trials, Lim 2012 and Powell 2011, were judged to be at a low
risk of reporting bias, with data reported for all expected outcomes
(as per the trial protocol and registration respectively). For one
trial (Wendel 1996), the risk of reporting bias was judged to be
high, with perinatal and obstetric outcome data reported overall
only (including some women who were not randomised and were
managed as outpatients).
For the remaining five trials (Badawy 2012; Caramez 1998;
Dombrowski 2004; Nickel 2006; Silverman 2005), there was in-
sufficient information available to confidently assess selective re-
porting and thus the risk of reporting bias was judged to be un-
clear.
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Other potential sources of bias
In Nickel 2006, Lim 2012 and Powell 2011, groups were well
balanced at baseline, and no other obvious sources of bias were
identified. The other five trials (Badawy 2012; Caramez 1998;
Dombrowski 2004; Silverman 2005; Wendel 1996) were judged
to be at an unclear risk of other potential sources of bias. In Badawy
2012 and Caramez 1998, there was insufficient information avail-
able to determine risk of other bias; the Caramez 1998 trial has
been published in abstract form only; and while in the Badawy
2012 trial it was reported that“both groups were comparable”, data
were only reported on age, education, parity and duration of preg-
nancy, and no information was available for example, on baseline
level of asthma control. In Silverman2005 andWendel 1996, base-
line characteristics by group were not reported. In Dombrowski
2004, the frequency of self-reported smoking was significantly
higher in the theophylline group. The authors of Dombrowski
2004 also reported that after an interim data review, it became
apparent that the frequency of the primary outcome was below
that projected; thus to increase the primary outcome, the eligibil-
ity requirements for the trial were changed after enrolment of 311
women to increase the frequency of the primary outcome (by only
including women who required regular asthma treatment).
Effects of interventions
Eight trials, involving 1181women and their babieswere included.
Due to the variety of different interventions assessed and compar-
ison groups used in the included trials, the results are presented
under seven different comparisons.
1. Inhaled magnesium sulphate versus control (for acute
asthma)
2. Intravenous theophylline versus control (for acute asthma)
3. Inhaled corticosteroid versus control
4. Inhaled corticosteroid versus oral theophylline
5. FENO algorithm versus clinical guideline algorithm to
adjust asthma therapy
6. Pharmacist-led multi-disciplinary approach to management
of maternal asthma (MAMMA) versus standard care
7. Progressive muscle relaxation (PMR) versus sham training
1. Inhaled magnesium sulphate versus control (for
acute asthma)
One trial involving 60 women was included in this comparison
(Badawy 2012).
Primary outcomes
Maternal
In Badawy 2012, the addition of magnesium sulphate (500 mg (1
mL)) to routine treatment for acute asthma exacerbations (which
included inhaled salbutamol (1 mL salbutamol solution dissolved
in 8 mL normal saline)) (women in both groups received “three sets
of nebulization”) was shown to significantly reduce the frequency
of acute asthma exacerbations until birth (mean difference (MD)
-2.80; 95% confidence interval (CI) -3.21 to -2.39; 60 women)
(Analysis 1.1). Themean frequency of acute exacerbations was 0.4
(standard deviation (SD): 0.57) in themagnesium sulphate group,
compared with 3.2 (SD: 0.98) in the control group.
Neonatal/infant
Badawy 2012 did not report on admission to neonatal intensive
care unit or special care nursery for the infant.
Secondary outcomes
Maternal
The addition of magnesium sulphate to routine treatment, com-
pared with routine treatment alone, was shown to significantly
improve lung function, as measured by FEV1 (%) (MD 23.63%;
95% CI 19.72 to 27.54; 60 women) (Analysis 1.2); FVC (%)
(MD 16.63%; 95% CI 10.44 to 22.82; 60 women) (Analysis
1.3); FEV1/FVC (%) (MD 19.42%; 95% CI 14.52 to 24.32; 60
women) (Analysis 1.4); FEV25% (MD 11.65%; 95% CI 8.06 to
15.24; 60 women) (Analysis 1.5); FEV75% (MD 12.92%; 95%
CI 8.91 to 16.93; 60 women) (Analysis 1.6); and PEF (%) (MD
18.03%; 95% CI 12.49 to 23.57; 60 women) (Analysis 1.7).
There was no difference observed between groups in Badawy 2012
in the numbers of caesarean births (risk ratio (RR) 0.83; 95% CI
0.43 to 1.63; 60 women) (Analysis 1.8).
Badawy 2012 did not report on: asthmatic symptoms, asthma
medication requirements, inflammatory markers, asthma self-
management skills, quality of life, days/time lost from work/
school, pregnancy-induced hypertension, pre-eclampsia/eclamp-
sia, gestational diabetes, antepartum haemorrhage, postpartum
haemorrhage, preterm prelabour ruptured membranes, preterm
labour, chorioamnionitis, hyperemesis, adverse effects and discon-
tinuation of the intervention due to adverse effects, or adherence
with the intervention.
Fetal/neonatal
Badawy 2012 did not report on any of the secondary review out-
comes for the fetus/neonate, however reported that both groups
had a “smooth neonatal period”.
Fetal/neonatal (outcomes not pre-specified at protocol stage)
Badawy 2012 did not report on any of the outcomes for the fetus/
neonate that were not pre-specified at protocol stage.
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Infant/child/adult (outcomes not pre-specified at protocol
stage)
Badawy 2012 did not report on longer-term outcomes for the
infant as a child or adult.
Use of health services
Badawy 2012 did not report on any of the secondary review out-
comes related to the use of health services.
2. Intravenous theophylline versus control (for acute
asthma)
One trial involving 65 women was included in this comparison
(Wendel 1996).
Primary outcomes
Maternal
Wendel 1996 did not report on asthma exacerbations.
Neonatal/infant
Wendel 1996 did not report on admission to neonatal intensive
care unit or special care nursery for the infant.
Secondary outcomes
Maternal
In Wendel 1996, three of the 33 women admitted to hospital for
an acute asthma exacerbation who received intravenous amino-
phylline (5 mg/kg loading dose, then 0.5 mg/kg maintenance)
in addition to intravenous methylprednisolone 1 mg/kg every
eight hours (maximum single dose 80 mg) discontinued the inter-
vention due to adverse effects (nervousness, vomiting, or insom-
nia with therapeutic serum concentrations), compared with none
of the 32 women who received intravenous methylprednisolone
alone. This difference between groups was not statistically signif-
icant (RR 6.79; 95% CI 0.36 to 126.50; 65 women) (Analysis
2.1).
Wendel 1996 did not report on: asthmatic symptoms, asthma
medication requirements, inflammatory markers, asthma self-
management skills, quality of life, days/time lost from work/
school, pregnancy-induced hypertension, pre-eclampsia/eclamp-
sia, gestational diabetes, caesarean birth, antepartum haemor-
rhage, postpartum haemorrhage, preterm prelabour ruptured
membranes, preterm labour, chorioamnionitis, hyperemesis, or
adherence with the intervention.
Fetal/neonatal
There were no stillbirths or neonatal deaths reported in either
group in the Wendel 1996 trial (Analysis 2.2; Analysis 2.3). Sim-
ilary, no cases of preterm birth were reported (Analysis 2.4).
Wendel 1996 did not report on termination of pregnancy, gesta-
tional age at birth, birthweight, low birthweight and small-for-ges-
tational age, Agpar score less than seven at five minutes, need for
active resuscitation, jaundice, neonatal sepsis or congenital mal-
formations.
Fetal/neonatal (outcomes not pre-specified at protocol stage)
Wendel 1996 did not report on any of the outcomes for the fetus/
neonate that were not pre-specified at protocol stage.
Infant/child/adult (outcomes not pre-specified at protocol
stage)
Wendel 1996 did not report on longer-term outcomes for the
infant as a child or adult.
Use of health services
Wendel 1996 reported that there was no difference in the mean
length of hospitalisation following an acute exacerbation between
the aminophylline and usual treatment groups (theophylline
group: 3.2 days; control group: 2.7 days) (standard deviationswere
not reported) (Analysis 2.5).
Wendel 1996 did not report on emergency department visits for
themother, admission to intensive care unit for themother, length
of postnatal hospitalisation for the mother, length of neonatal
hospitalisation for the infant, or costs of care for the mother, baby
or both.
3. Inhaled corticosteroid versus control
Three trials involving 374 women were included in this compari-
son (Caramez 1998; Silverman 2005; Wendel 1996), however for
each outcome, only one or two of the trials contributed outcome
data. We were able to perform meta-analyses for only two out-
comes.
Primary outcomes
Maternal
There was no clear difference in the risk of asthma exacerbations
for women who received inhaled beclomethasone in addition to
usual treatment (an inhaled bronchodilator and oral corticosteroid
taper), compared with those receiving usual treatment alone in the
Wendel 1996 trial (RR 0.36; 95% confidence interval (CI) 0.13
to 1.05; 60 women) (P = 0.06) (Analysis 3.1).
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The Caramez 1998 trial also reported on asthma exacerbations,
comparing women who received inhaled beclomethasone in addi-
tion to routine asthma therapy with those receiving routine treat-
ment only. The abstract reported that “There was no statistic sig-
nificant difference between the two asthmatic patients groups con-
cerning number of asthma exacerbations (23/49 x 28/46 p=ns) and
exacerbations during delivery (10/49 x 7/46, p=ns).” As it could
not be confidently determined from the information contained in
the published abstract whether these results pertained to the total
number of exacerbations, or numbers of women who experienced
exacerbations, these data were not combined with data from the
Wendel 1996 trial in a meta-analysis.
Neonatal/infant
The three trials included in this comparison did not report on
admission to neonatal intensive care unit or special care nursery
for the infant.
Secondary outcomes
Maternal
No difference was shown overall for the outcome caesarean birth
when an inhaled corticosteroid (Caramez 1998: beclomethasone;
Silverman 2005: budesonide) in addition to usual treatment was
compared with usual treatment alone (average RR 1.65; 95% CI
0.57 to 4.79; two trials, 314 women) (Analysis 3.2). Substantial
statistical heterogeneity was identified for this outcome (T² = 0.44;
I² = 71%), which is likely to be in part explained by the use of
different corticosteroids, according to different regimens, and thus
a random-effects model was used; the subgroup interaction test
(comparing the two trials) was not significant (Chi² = 3.06, P =
0.08, I² = 67.4%).
In theWendel 1996 trial, full adherence with the intervention was
reported (RR 1.00; 95% CI 0.94 to 1.07; 60 women) (Analysis
3.3); adherence was considered appropriate if the returned inhalers
weighed 75% of the normative values.
The three trials did not report on: asthmatic symptoms, asthma
medication requirements, lung function, inflammatory markers,
asthma self-management skills, quality of life, days/time lost from
work/school, pregnancy-induced hypertension, pre-eclampsia/
eclampsia, gestational diabetes, antepartum haemorrhage, post-
partum haemorrhage, preterm prelabour ruptured membranes,
preterm labour, chorioamnionitis, hyperemesis, adverse effects and
discontinuation of the intervention due to adverse effects.
Maternal (outcomes not pre-specified at protocol stage)
The Caramez 1998 trial reported on “obstetric complications”, and
found no difference between the inhaled beclomethasone and
usual treatment groups (RR 0.79; 95% CI 0.40 to 1.59; 95
women) (Analysis 3.12); and similarly, found no difference be-
tween groups for the outcome“perinatal complications” (RR 1.41;
95% CI 0.71 to 2.81; 95 infants) (Analysis 3.13).
Fetal/neonatal
There were no differences observed in the Silverman 2005 trial in
the numbers of induced abortions (reasons not given) (RR 0.57;
95%CI 0.15 to 2.24; 219women) (Analysis 3.4) and spontaneous
abortions (RR 1.56; 95% CI 0.75 to 3.25; 219 women) (Analysis
3.5), between the inhaled budesonide and usual treatment groups.
There were no perinatal deaths (stillbirths or neonatal deaths) in
the Wendel 1996 trial (Analysis 3.6; Analysis 3.7).
Similarly, there were no differences observed between the in-
haled corticosteroid and usual treatment groups for the outcomes
preterm birth (RR 0.84; 95% CI 0.43 to 1.63; two trials, 314
women) (Analysis 3.8), birthweight (MD -34.00 g; 95% CI -
290.17 to 222.17; one trial, 95 infants) (Analysis 3.9), Apgar score
less than seven (timing not reported) (RR 0.94; 95% CI 0.06 to
14.57; one trial, 95 infants) (Analysis 3.10), or congenital mal-
formations (not described) (RR 0.29; 95% CI 0.03 to 2.52; one
trial, 219 infants) (Analysis 3.11).
The three trials did not report on: gestational age at birth, low
birthweight, small-for-gestational age, need for active resuscita-
tion, jaundice or neonatal sepsis.
Fetal/neonatal (outcomes not pre-specified at protocol stage)
The three trials did not report on the fetal/neonatal outcomes
that were not pre-specified at protocol stage, though Silverman
2005 reported on “healthy children delivered” and did not detect
a difference between the inhaled budesonide and usual treatment
groups (RR 0.99; 95% CI 0.86 to 1.15; 219 infants) (Analysis
3.14); and similarly reported no difference between groups for the
outcome “other adverse outcomes” (RR 0.76; 95% CI 0.13 to 4.49;
219 infants) (Analysis 3.15).
Infant/child/adult (outcomes not pre-specified at protocol
stage)
The three trials included in this comparison did not report on
longer-term outcomes for the infant as a child or adult.
Use of health services
The three trials did not report on any of the secondary review
outcomes related to the use of health services.
4. Inhaled corticosteroid versus oral theophylline
One trial involving 398 women was included in this comparison
(Dombrowski 2004).
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Primary outcomes
Maternal
There was no difference observed between women receiving in-
haled beclomethasone and women receiving oral theophylline in
the occurrence of asthma exacerbations (RR 0.88; 95% CI 0.59
to 1.33; 385 women) (Analysis 4.1).
Neonatal/infant
Dombrowski 2004 did not report on admission to neonatal in-
tensive care unit or special care nursery for the infant.
Secondary outcomes
Maternal
There were no differences seen in the occurrence of asthma symp-
toms at delivery (RR 1.09; 95% CI 0.71 to 1.68; 378 women)
(Analysis 4.2), or the frequency of nocturnal asthma symptoms
(MD -0.02; 95% CI -0.07 to 0.02; 385 women) (Analysis 4.3),
between women receiving inhaled beclomethasone and women
receiving oral theophylline.
Considering asthma medication requirements, there were no dif-
ferences observed between the inhaled beclomethasone and oral
theophylline groups in the use of rescue oral corticosteroids for ex-
acerbations (RR0.75; 95%CI 0.40 to 1.39; 385women) (Analysis
4.4), or in the mean number of albuterol puffs per day (MD -
0.10; 95% CI -0.54 to 0.34; 385 women) (Analysis 4.5). Sim-
ilarly, considering lung function measures, there were no differ-
ences observed between groups in the proportion of study visits
with FEV1 less than 80% predicted (MD -0.05; 95% CI -0.12 to
0.01; 385 women) (Analysis 4.6), or the proportion of study visits
with PEFR less than 80% predicted (MD -0.04; 95% CI -0.09 to
0.02; 385 women) (Analysis 4.7).
No differences were detected between the inhaled beclomethasone
and oral theophylline groups for the outcomes, pre-eclampsia (RR
1.04; 95% CI 0.53 to 2.05; 384 women) (Analysis 4.8), caesarean
birth (RR 1.01; 95%CI 0.63 to 1.62; 384 women) (Analysis 4.9),
postpartum haemorrhage (defined as blood loss of greater than
500mL for vaginal births and greater than 1 L for caesarean births)
(RR 1.17; 95% CI 0.52 to 2.65; 358 women) (Analysis 4.10),
chorioamnionitis (RR 0.98; 95% CI 0.42 to 2.30; 384 women)
(Analysis 4.11), adverse effects attributed to the intervention (in-
cluding nausea (RR 0.33; 95%CI 0.11 to 1.00; 385 women), ner-
vousness (RR 0.33; 95% CI 0.07 to 1.61; 385 women), insomnia
(RR 0.09; 95% CI 0.00 to 1.61; 385 women), tremor (RR 0.25;
95% CI 0.03 to 2.18; 385 women), palpitations (RR 0.66; 95%
CI 0.11 to 3.88; 385 women) and heartburn (RR 2.95; 95% CI
0.12 to 72.06; 385 women)) (Analysis 4.12). Women receiving
inhaled beclomethasone were however significantly less likely to
discontinue the intervention because of adverse effects, compared
with women receiving oral theophylline (RR0.35; 95%CI 0.14 to
0.86; 384women) (Analysis 4.13); six women (3.1%) receiving in-
haled beclomethasone ceased treatment because of adverse effects,
compared with 17 women (8.9%) receiving oral theophylline.
No difference was observed between groups for self-reported ad-
herence (MD 0.01; 95% CI -0.06 to 0.08; 385 women) (Analysis
4.14), however, women in the theophylline group had signifi-
cantly highermeasured adherence (assessed by serum theophylline
concentrations, pill counts and weighing the used beclometha-
sone canisters) (MD -0.08; 95% CI -0.16 to -0.01; 322 women)
(Analysis 4.15)).
Dombrowski 2004 did not report on inflammatory markers,
asthma self-management skills, quality of life, days/time lost from
work or school, pregnancy-induced hypertension, gestational di-
abetes, antepartum haemorrhage, preterm prelabour ruptured
membranes, preterm labour or hyperemesis.
Fetal/neonatal
Nodifferences were detected between the inhaled beclomethasone
and oral theophylline groups for the outcomes perinatal death (re-
ported as ’perinatal demise’; stillbirth and neonatal death were not
reported separately) (RR 0.77; 95% CI 0.18 to 3.41; 374 infants)
(Analysis 4.16), gestational age at birth (MD -0.10 weeks, 95%
CI -0.83 to 0.63; 384 infants) (Analysis 4.17), preterm birth (RR
1.26; 95% CI 0.83 to 1.93; 384 infants) (Analysis 4.18), birth-
weight (MD 16.00 g; 95% CI -128.25 to 160.25; 384 infants)
(Analysis 4.19), low birthweight (less than 2500 g) (RR 1.03; 95%
CI 0.51 to 2.08; 310 infants) (Analysis 4.20), small-for-gestational
age (RR 1.03; 95% CI 0.44 to 2.40; 310 infants) (Analysis 4.21),
discharge diagnosis of sepsis (RR 0.70; 95% CI 0.22 to 2.15; 377
infants) (Analysis 4.22), or major congenital malformations (RR
1.18; 95% CI 0.36 to 3.79; 382 infants) (Analysis 4.23).
Dombrowski 2004 did not report on termination of pregnancy,
Apgar score of less than seven at five minutes, need for active
resuscitation, or jaundice.
Fetal/neonatal (outcomes not pre-specified at protocol stage)
Dombrowski 2004 did not report on any of the outcomes for the
fetus/neonate that were not pre-specified at protocol stage.
Infant/child/adult (outcomes not pre-specified at protocol
stage)
Dombrowski 2004 did not report on longer-term outcomes for
the infant as a child or adult.
Use of health services
Considering the use of health services, no differences were ob-
served between the inhaled beclomethasone and oral theophylline
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groups for antenatal hospital admissions for the mother associ-
ated with an exacerbation (RR 0.66; 95% CI 0.30 to 1.42; 385
women) (Analysis 4.24) or emergency department visits for the
mother associated with an exacerbation (RR 0.82; 95% CI 0.53
to 1.28; 385 women) (Analysis 4.25).
Dombrowski 2004 did not report on admission to the intensive
care unit for the mother, postnatal hospitalisation for the mother,
length of neonatal hospitalisation for the infant, or costs of care
for the mother, baby or both.
5. FENO algorithm versus clinical guideline algorithm
to adjust asthma therapy
Primary outcomes
One trial involving 220 women was included in this comparison
(Powell 2011).
Maternal
The group of women who had their treatment (inhaled corticos-
teroid therapy) adjusted using a validated FENO-based treatment
algorithm experienced significantly fewer asthma exacerbations
compared with the group who had their treatment adjusted ac-
cording to a clinical guideline-based algorithm (RR 0.61; 95% CI
0.41 to 0.90; 220 women) (Analysis 5.1); 28/111 (25.2%) women
in the FENO group had an exacerbation, compared with 45/109
(41.3%) in the clinical guideline group.
Neonatal/infant
There was a trend towards fewer admissions to the neonatal inten-
sive care unit or special care nursery for infants born to mothers
who had their treatment adjusted using a validated FENO-based
treatment algorithm, with eight admissions for the 105 infants
in the FENO group, compared with 18 admissions for the 109
infants in the clinical guideline group (RR 0.46; 95% CI 0.21 to
1.02; 214 infants) (P = 0.05) (Analysis 5.2).
Secondary outcomes
Maternal
No clear significant differences were shown between the group
of women who had their treatment adjusted using a validated
FENO-based treatment algorithm compared with the group of
women who had their treatment adjusted according to a clinical
guideline-based algorithm for the outcomes: asthmatic symptoms
(as assessed by ACQ score: MD -0.16; 95% CI -0.36 to 0.04;
220 women (Analysis 5.3); and symptom-free days per week (me-
dian (IQR) FENO algorithm group: 7 (4 to 7); clinical algorithm
group: 6 (2 to 7); P = 0.058) (Analysis 5.4)); and lung function
at the end of the study (as measured by FENO (ppb), FEV1 (L)
and FEV1 (%) (Analysis 5.8)). Considering asthmamedication re-
quirements, the FENO-based treatment algorithm resulted in sig-
nificantly more women being treated with inhaled corticosteroids
at the end of the study, compared with the clinical guideline-based
algorithm group (RR 1.62; 95% CI 1.26 to 2.09; 220 women)
(Analysis 5.5). Similarly, more women received long-acting β-ag-
onists in the FENOgroup than in the clinical guideline group (RR
2.33; 95%CI 1.46 to 3.71; 220 women) (Analysis 5.6), and short-
acting β-agonist use was significantly less in the FENO group
than in the clinical guideline group (Analysis 5.7). Though lower
in the FENO group, the beclomethasone dipropionate equivalent
inhaled corticosteroid dose did significantly differ between groups
(Analysis 5.7).
Considering quality of life, women in the FENO group scored
higher on the SF-12 mental summary (low = 0; high = 100) (me-
dian (IQR) FENO group: 56.9 (50.2 to 59.3); clinical guideline
group: 54.2 (46.1 to 57.6); P = 0.037); however no difference
between groups was shown for the SF12 physical summary score,
or the Asthma Quality of Life Questionnaire - Marks (AQLQ-M)
total score (Analysis 5.9).
No differences between groups were shown for the maternal out-
comes, pregnancy-induced hypertension (RR 0.65; 95% CI 0.26
to 1.61; 210 women) (Analysis 5.10); pre-eclampsia (RR 0.61;
95% CI 0.15 to 2.49; 210 women) (Analysis 5.11); gestational
diabetes (RR 0.74; 95% CI 0.31 to 1.77; 210 women) (Analysis
5.12); caesarean birth (elective: RR 0.83; 95% CI 0.42 to 1.63;
210 women; non-elective: RR 0.75; 95% CI 0.36 to 1.55; 210
women) (Analysis 5.13); antepartumhaemorrhage (RR1.02; 95%
CI 0.06 to 16.08; 210 women) (Analysis 5.14); postpartum haem-
orrhage (RR 1.27; 95% CI 0.35 to 4.61; 210 women) (Analysis
5.15); ruptured membranes (RR 1.36; 95% CI 0.60 to 3.09; 210
women) (Analysis 5.16); or hyperemesis (no events in either group)
(Analysis 5.17).
Powell 2011 did not report on inflammatory markers, asthma self-
management skills, days/time lost from work or school, preterm
labour, chorioamnionitis, adverse effects and discontinuation of
the intervention due to adverse effects, and adherence with the
intervention.
Fetal/neonatal
There was one termination in the FENO group (Analysis 5.18),
and there was one stillbirth in each group (Analysis 5.19).
There was no significant difference between groups for gestational
age at birth (weeks) (median (IQR) FENO group: 39.9 (38.7 to
40.7); clinical guideline group: 39.6 (38.4 to 40.6); P = 0.224)
(Analysis 5.20); pretermbirth (RR0.69; 95%CI 0.26 to 1.88; 214
infants) (Analysis 5.21); birthweight (g) (median (IQR) FENO
group: 3520 (3060 to 3920); clinical guideline group: 3460 (3040
to 3730); P = 0.233) (Analysis 5.22); low birthweight (< 2500
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g) (RR 1.04; 95% CI 0.31 to 3.48; 214 infants) (Analysis 5.23);
small-for-gestational age (RR 0.91; 95% CI 0.47 to 1.77; 214
infants) (Analysis 5.24); and jaundice (RR 1.04; 95% CI 0.21
to 5.03; 214 infants) (Analysis 5.25). There was one congenital
malformation in the FENO group (Analysis 5.26).
Powell 2011 did not report on neonatal death, Apgar score of less
than seven at five minutes, need for active resuscitation at birth,
or neonatal sepsis.
Fetal/neonatal (outcomes not pre-specified at protocol stage)
Powell 2011 did not report on any of the outcomes for the fetus/
neonate that were not pre-specified at protocol stage.
Infant/child/adult (outcomes not pre-specified at protocol
stage)
Infants born to mothers in the FENO group were less likely to
have recurrent episodes of bronchiolitis in their first 12 months of
life (Analysis 5.27) (RR 0.09; 95% CI 0.01 to 0.69; 128 infants);
a trend towards fewer infants with recurrent episodes of croup in
their first 12 months of life for infants born to mothers in the
FENO group was also observed (RR 0.13; 95% CI 0.02 to 1.04;
129 infants) (P = 0.05) (Analysis 5.28).
Powell 2011 did not report on any other longer-term outcomes
for the infant as a child or adult.
Use of health services
Powell 2011 did not report on any of the secondary review out-
comes related to the use of health services.
6. Pharmacist-led multi-disciplinary approach to
management of maternal asthma (MAMMA) versus
standard care
One trial involving 60 women was included in this comparison
(Lim 2012).
Primary outcomes
Maternal
Lim 2012 reported that there were no exacerbations in either the
MAMMA or standard care groups (Analysis 6.1).
Neonatal/infant
There were three neonatal intensive care or special care admissions
among the 29 infants born to mothers in the MAMMA group,
and two admissions among the 29 infants born to mothers in the
standard care group (RR 1.50; 95% CI 0.27 to 8.32; 58 infants)
(Analysis 6.2)
Secondary outcomes
Maternal
In Lim 2012, ACQ scores were not significantly different between
groups at three-month assessment (MD -0.17; 95% CI -0.54 to
0.20; 58 women); however at six-month assessment, the mean
ACQ score of the intervention group (mean: 0.54, SD: 0.32) was
significantly lower (better) than that of the control group (mean:
1.1, SD: 0.67) (MD -0.56; 95% CI -0.83 to -0.29; 58 women)
(Analysis 6.3); this difference was considered ’clinically significant’
by the trial authors. The ACQ score in the intervention group
decreased by a mean of 0.46 (SD: 1.05) at three months and
0.89 (SD: 0.98) at six months. The control group had a mean
decrease of 0.15 (SD: 0.63) at three months and 0.18 (SD: 0.73)
at six months. The MD in ACQ scores between groups was -0.31
(95% CI -0.76 to 0.14; 58 women) at three months and -0.71
(95% CI -1.15 to -0.27; 58 women) at six months; the difference
at six months was significant (Analysis 6.3). All women in the
intervention group had an ACQ score less than 1.5 indicating
adequately controlled asthma, compared with 20/29 (69%) in the
standard care group (RR 1.44; 95% CI 1.12 to 1.84; 58 women)
(Analysis 6.4); this difference between groups was significant.
No women in either group of the Lim 2012 trial required oral
corticosteroid use (Analysis 6.5), nor required any asthma-related
days off work (Analysis 6.6). There was no difference between
the MAMMA and standard care groups for the outcomes: hyper-
tension during pregnancy (RR 5.00; 95% CI 0.25 to 99.82; 58
women) (Analysis 6.7), gestational diabetes (RR 5.00; 95% CI
0.25 to 99.82; 58 women) (Analysis 6.8) and caesarean birth (RR
0.89; 95% CI 0.40 to 1.98; 58 women) (Analysis 6.9).
Lim 2012 did not report on: lung function, inflammatory mark-
ers, asthma self-management skills, quality of life, pre-eclamp-
sia/eclampsia, antepartum haemorrhage, postpartum haemor-
rhage, preterm prelabour ruptured membranes, preterm labour,
chorioamnionitis, hyperemesis, adverse effects and discontinua-
tion of the intervention due to adverse effects, or adherence with
the intervention.
Fetal/neonatal
There was no difference between the MAMMA and standard care
groups for the outcomes: gestational age at birth (MD 0.00 weeks;
95% CI -1.21 to 1.21; 58 infants) (Analysis 6.10), preterm birth
(RR 1.50; 95%CI 0.27 to 8.32; 58 infants) (Analysis 6.11), birth-
weight (MD7.80 g -324.94 to 340.54; 58 infants) (Analysis 6.12),
small-for-gestational age (RR 1.00; 95% CI 0.07 to 15.24; 58 in-
fants) (Analysis 6.13), Apgar scores at one and five minutes (MD
0.70; 95% CI -0.04 to 1.44; 58 infants) (MD 0.30; 95% CI -
0.07 to 0.67; 58 infants) (Analysis 6.14). There were no congeni-
tal malformations reported in the Lim 2012 trial (Analysis 6.15).
Lim 2012 did not report on termination of pregnancy, stillbirth,
neonatal death, low birthweight, need for active resuscitation (as-
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sisted ventilation via an endotracheal tube) at birth, jaundice, and
neonatal sepsis.
Fetal/neonatal (outcomes not pre-specified at protocol stage)
Lim 2012 did not report on any of the outcomes for the fetus/
neonate that were not pre-specified at protocol stage.
Infant/child/adult (outcomes not pre-specified at protocol
stage)
Lim 2012 did not report on longer-term outcomes for the infant
as a child or adult.
Use of health services
In Lim 2012, there were no asthma-related hospital admissions or
emergency visits for women in either group after trial commence-
ment (Analysis 6.16; Analysis 6.17).
Lim 2012 did not report on length of postnatal hospitalisation for
the mother, length of neonatal hospitalisation for the infant, or
costs of care for the mother, baby or both.
7. Progressive muscle relaxation (PMR) versus sham
training
One trial involving 64 women was included in this comparison
(Nickel 2006).
Primary outcomes
Maternal
Nickel 2006 did not report on asthma exacerbations.
Neonatal/infant
Nickel 2006 did not report on admission to neonatal intensive
care unit or special care nursery for the infant.
Secondary outcomes
Maternal
PMR sessions compared with sham training sessions, significantly
improved lung function measurements for pregnant women with
bronchial asthma; final FEV1 (L) (MD0.47; 95%CI 0.23 to 0.71;
64 women) (Analysis 7.1); final PEFR (L/minute) (MD 50.60;
95% CI 44.80 to 56.40; 64 women) (Analysis 7.2).
Women who received PMR sessions, compared with women who
received sham training sessions, were more likely to score lower on
two of five scales of the State-Trait Anger Expression Inventory;
State-Anger (MD -3.90; 95% CI -5.64 to -2.16; 64 women) and
Trait-Anger (MD -5.60; 95% CI -7.42 to -3.78; 64 women). No
differences were observed between groups for Anger-In (MD -
1.10; 95% CI -2.82 to 0.62; 64 women); Anger-Out (MD -2.00;
95% CI -4.55 to 0.55; 64 women); or Anger-Control (MD 0.50;
95% CI -1.75 to 2.75; 64 women) (Analysis 7.3).
Women who received PMR sessions were more likely to score
higher on five of the eight domains of the SF-36; role physical
(MD 7.00; 95% CI 3.88 to 10.12); vitality (MD 7.70; 95% CI
3.67 to 11.73); social functioning (MD 12.80; 95% CI 8.50 to
17.10); role emotional (MD12.20; 95%CI8.09 to 16.31);mental
health (MD 6.10; 95% CI 1.84 to 10.36). Differences were not
observed for: physical functioning (MD 1.50; 95% CI -1.23 to
4.23); bodily pain (MD 3.10; 95% CI -1.46 to 7.66); or general
health perceptions (MD 4.30; 95% CI -0.24 to 8.84) (Analysis
7.4).
Nickel 2006 did not report on: asthmatic symptoms, asthmamed-
ication requirements, inflammatory markers, asthma self-man-
agement skills, quality of life, days/time lost from work/school,
pregnancy-induced hypertension, pre-eclampsia/eclampsia, gesta-
tional diabetes, caesarean birth, antepartum haemorrhage, post-
partum haemorrhage, preterm prelabour ruptured membranes,
preterm labour, chorioamnionitis, hyperemesis, adverse effects and
discontinuation of the intervention due to adverse effects, or ad-
herence with the intervention.
Fetal/neonatal
Nickel 2006 did not report on any of the secondary review out-
comes for the fetus/neonate.
Fetal/neonatal (outcomes not pre-specified at protocol stage)
Nickel 2006 did not report on any of the secondary review out-
comes for the fetus/neonate not pre-specified at protocol stage.
Infant/child/adult (outcomes not pre-specified at protocol
stage)
Nickel 2006 did not report on longer-term outcomes for the infant
as a child or adult.
Use of health services
Nickel 2006 did not report on any of the secondary review out-
comes related to the use of health services.
D I S C U S S I O N
Summary of main results
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This systematic review aimed to assess the effects of interventions
(pharmacologic and non-pharmacologic, including self-manage-
ment interventions) for managing women’s asthma in pregnancy
on maternal and fetal/infant outcomes. Eight trials (randomising
1181 women and their babies), at a moderate risk of bias overall,
were eligible for inclusion, and were assessed under seven different
comparisons in the review. Five of the trials assessed pharmacolog-
ical agents, including inhaledmagnesium sulphate (Badawy 2012)
and intravenous theophylline (Wendel 1996) for women follow-
ing acute asthma exacerbations; and inhaled corticosteroids (be-
clomethasone and budesonide) (Caramez 1998; Silverman 2005;
Wendel 1996), including verus oral theophylline (Dombrowski
2004) for maintenance therapy. The other three trials assessed
non-pharmacological interventions for asthma management dur-
ing pregnancy, including a validated fractional exhaled nitric oxide
(FENO)-based algorithm versus a clinical guideline-based algo-
rithm to adjust asthma therapy (Powell 2011), a pharmacist-led
multi-disciplinary approach to asthma management versus stan-
dard care (Lim 2012), and progressive muscle relaxation (PMR)
versus sham training (Nickel 2006).
Considering primary review outcomes, relatively few differences
were seen across the seven comparisons for the trials that reported
on these outcomes. For women following acute asthma exacerba-
tions, inhaled magnesium sulphate in addition to standard treat-
ment in Badawy 2012 (60 women) was shown to significantly
reduce the frequency of acute exacerbations before birth. The
Badawy 2012 trial was however judged to be at an unclear risk of
bias overall; thus this result must be interpreted with caution. In
theWendel 1996 trial (65 women), which assessed the addition of
intravenous theophylline to standard treatment in acute asthma,
asthma exacerbations were not reported. An inhaled corticosteroid
(beclomethasone) in addition to usual treatment for maintenance
therapy, did not have a clear effect on asthma exacerbations in two
trials (of largely unclear methodological quality) (Caramez 1998;
Wendel 1996) (155 women); and when inhaled beclomethasone
was compared to oral theophylline in the Dombrowski 2004 trial
for maintenance therapy (385 women), no clear difference was
shown in the rate of exacerbations. None of the five trials assessing
pharmacological interventions reported on the neonatal primary
outcome of neonatal intensive care unit admissions.
In regards to non-pharmacological interventions, the use of a val-
idated FENO-based treatment algorithm (compared with a clin-
ical guideline-based algorithm) to adjust asthma therapy (FENO
used to adjust dose of inhaled corticosteroids; andAsthmaControl
Questionnaire score used to adjust dose of long-acting β2 agonist)
was shown to reduce exacerbations in Powell 2011 (220 women),
and a trend towards reduced neonatal intensive care unit admis-
sions was also shown. No women in Lim 2012 (60 women) (as-
sessing a pharmacist-led multi-disciplinary approach to maternal
asthma management) had exacerbations, and no difference was
shown in the risk of admission to the neonatal intensive care unit
in this trial. In Nickel 2006 (64 women), comparing PMR with
sham training, asthma exacerbations and neonatal intensive care
unit admissions were not reported.
Similarly, across the seven comparisons, there were few differences
observed for secondary review outcomes. In theWendel 1996 trial,
intravenous theophylline in addition to usual treatment following
acute exacerbations was not associated with differences in mater-
nal or infant outcomes (discontinuation due to adverse effects,
stillbirth, neonatal death, pretermbirth, length of hospitalisation).
The addition of inhaled magnesium sulphate compared to rou-
tine treatment following acute exacerbations in Badawy 2012, was
however shown to improve lung function (as measured by FEV1,
FVC, FEV1/FVC, FEF25-75 and PEF) compared to routine treat-
ment alone. No difference was seen for caesarean birth (the only
other outcome reported in the Badawy 2012 trial).
When inhaled corticosteroids in addition to usual treatment were
compared with no additional treatment for maintenance therapy
(Caramez 1998; Silverman 2005; Wendel 1996), no differences
were seen for the secondary outcomes reported (including: cae-
sarean birth, compliance with the intervention, abortion, still-
birth, neonatal death, preterm birth, birthweight, Agpar score
less than seven, congenital malformations). When inhaled be-
clomethasone was compared with oral theophylline for mainte-
nance therapy in one trial (Dombrowski 2004), no differences
were seen for a range of maternal and infant outcomes (ma-
ternal: asthma symptoms, medication requirements, measures of
lung function, pre-eclampsia, caesarean birth, postpartum haem-
orrhage, chorioamnionitis, self-reported compliancies) (infant:
perinatal mortality, gestational age at birth, preterm birth, birth-
weight, low birthweight, small-for-gestational age, sepsis, major
congenital malformations) (health services: antenatal hospital ad-
missions, emergency department visits). While women receiv-
ing beclomethasone did not experience significantly fewer adverse
effects overall (nausea, nervousness, insomnia, tremor, palpita-
tions, heartburn), they were shown to have a significantly lower
risk of discontinuing the intervention because of adverse effects,
compared with women receiving oral theophylline (Dombrowski
2004).
In addition to significantly reducing asthma exacerbations, the
FENO-based treatment algorithm in Powell 2011, was shown to
improve some measures of quality of life (mental summary scores
on the SF-12). The use of the FENO-based algorithm was also
shown to influence treatment profile, with more women in this
group receiving inhaled corticosteroids (though at a non-signif-
icantly lower equivalent dose) and long-acting β-agonists, and
fewer women in this group receiving short-acting β-agonists. No
differenceswere seenwith the use of FENO-basedmanagement for
the other maternal and infant outcomes reported by the trial (ma-
ternal: symptoms, lung function, pregnancy-induced hyperten-
sion, pre-eclampsia, gestational diabetes, caesarean birth, antepar-
tum or postpartum haemorrhage, ruptured membranes, hyper-
emesis) (infant: stillbirth, gestational age at birth, preterm birth,
birthweight, low birthweight, small-for-gestational age, jaundice,
26Interventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
congenital malformations) (Powell 2011). At 12-month follow-
up in Powell 2011, infants born to mothers in the FENO group
were shown to have a significantly reduced risk of recurrent bron-
chiolitis, and a trend towards a reduced risk of recurrent croup.
When a pharmacist-led multi-disciplinary approach to manage-
ment of maternal asthma was compared with standard care in Lim
2012, significant improvements in asthma control at six months
were observed (which were not observed at three months). No
other differences were seen in this trial for the maternal or infant
secondary review outcomes that were reported (maternal: hyper-
tension in pregnancy, gestational diabetes) (infant: gestational age
at birth, preterm birth, birthweight, small-for-gestational age, Ap-
gar scores, congenital malformations).
Finally, in Nickel 2006, when PMR was compared with sham
training, improvements were seen in measures of lung function
(FEV1 and PEFR) and in some measures of quality of life (five
of eight domains on the SF-36 (role physical, vitality, social func-
tioning, role emotional, mental health), and two of five scales on
the State-Trait Anger Expression Inventory (State-Anger, Trait-
Anger)).
The five trials in this review assessing pharmacological interven-
tions did not provide clear evidence of benefits or harms to sup-
port or refute current practice (Badawy 2012; Caramez 1998;
Dombrowski 2004; Silverman 2005;Wendel 1996), which varies,
but commonly follows a ’step-wise approach’, guided by ran-
domised evidence from non-pregnant populations and observa-
tional data from pregnancy studies (Dombrowski 2008; NAEPP
2005; Schatz 2009). Short-acting bronchodilators (particularly
short-acting inhaledβ-agonists such as albuterol (salbutamol) have
been recommended for symptom relief in women with mild, in-
termittent asthma; in mild persistent asthma, a daily low-dose
inhaled corticosteroid has been recommended (with budesonide,
with the greatest amount of safety data in pregnancy, preferred
to beclomethasone, which was the inhaled corticosteroid assessed
in three trials in this review (Caramez 1998; Dombrowski 2004;
Wendel 1996)). Low-dose inhaled corticosteroids are favoured
over methylxanthines, such as theophylline (which was the focus
of two trials in this review (Dombrowski 2004; Wendel 1996)),
mast cell stabilisers (such as cromolyn) and leukotriene-receptor
antagonists. For moderate and severe persistent asthma, the com-
bination of a low-dose inhaled corticosteroid with a long-acting β-
agonist (such as salmeterol or formoterol) or an increased dose of
the inhaled corticosteroid has been recommended. For the man-
agement of exacerbations during pregnancy, the use of a combi-
nation of pharmacological agents including short-acting inhaled
β-agonists, inhaled anticholinergic agents (ipratropium bromide),
and oral/intravenous systemic corticosteroids, has been supported
(Dombrowski 2008; NAEPP 2005; Schatz 2009); the addition of
inhaledmagnesium sulphate for exacerbationmanagement, which
showed some benefits in one trial in this review (Badawy 2012),
is not currently recommended in practice.
Three trials included in this review provide promise for the optimi-
sation of asthma management in pregnancy with the use of non-
pharmacological interventions (Lim 2012; Nickel 2006; Powell
2011). Though positive effects on asthma control were observed
in this review with PMR (one trial: Nickel 2006), and a phar-
macist-led, multi-disciplinary approach to management (with the
provision of education and regular review) (one trial: Lim 2012),
this evidence is unlikely to be sufficient to support clinical practice
recommendations. Similarly, while the use of an algorithm incor-
porating FENO to adjust inhaled corticosteroid dose and asthma
symptoms to adjust β-agonist dose showed reductions in exacer-
bations during pregnancy, and changes in maintenance pharma-
cologic therapy (with more frequent use of inhaled corticosteroids
at lower daily doses), this evidence is unlikely to be sufficient to
recommend universal implementation into the antenatal care set-
ting (Powell 2011). The benefits and/or harms for perinatal out-
comes are as yet, uncertain; further, there is a need to consider and
evaluate the resource implications of such a management strategy,
given that FENO measurement devices are not routinely avail-
able in many clinical settings. Though the randomised evidence
for non-pharmacological interventions for asthma management
in pregnancy accumulated to date is unlikely to be sufficient for
widespread practice change, the need for such strategies to be in-
corporated into themanagement of awoman’s asthmaduringpreg-
nancy is increasingly being recognised. Clinical practice guidelines
have highlighted the need to ensure that pregnant women have
access to education about asthma and its relationship with preg-
nancy, and have the opportunity to develop the skills necessary
for asthma management (such as correct inhaler technique, abil-
ity to self-monitor and follow a long-term management plan, and
knowledge of how to promptly handle signs of worsening asthma)
(Dombrowski 2008; NAEPP 2005).
Overall completeness and applicability of
evidence
There is currently a lack of randomised evidence in this area,
with only eight trials completed to date. The largest trial in-
cluded almost 400 women (Dombrowski 2004), however, in
five of the included trials, the sample sizes were of less than
100 women (Badawy 2012; Caramez 1998; Lim 2012; Nickel
2006; Wendel 1996)). Encouragingly, at least five further trials
are currently planned or underway (ACTRN12613000202763;
ACTRN12613000244707; ACTRN12613000301763;
ACTRN12613000800729; NCT01345396).
The scarcity of data for the management of asthma during preg-
nancy was evident, not only in the limited number of completed
trials, but also in the small number of outcomes evaluated in
some of the included trials. Considering primary outcomes, only
five of the eight included trials reported on asthma exacerbations
(Badawy 2012; Caramez 1998; Dombrowski 2004; Lim 2012;
Powell 2011), and only two trials reported on neonatal intensive
care unit or special care nursery admissions (Lim 2012; Powell
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2011). For the majority of outcomes, data were reported by less
than half of the included trials; the most commonly reported
secondary review outcomes were lung function, stillbirth, birth-
weight, congenital malformations (each reported by four trials),
preterm birth and caesarean birth (both reported by five trials).
Only one (Powell 2011) of the eight included trials completed to
date has reported on follow-up outcomes of the infants (Powell
2011 has reported on the outcomes of bronchiolitis and croup).
Clinical heterogeneity of the data and also of the study designs
(with a variety of different interventions and comparisons assessed
across the eight trials), meant that very little data could be pooled
in meta-analysis, making interpretation difficult. Different meth-
ods of measuring outcomes, such as lung function, and different
outcome definitions across trials, such as for asthma exacerbations,
also made comparisons between trials difficult. At present there
is no commonly accepted definition for asthma exacerbations. A
further drawback of definitions for exacerbations is that they are
currently based on retrospective criteria; prospective criteria for
the definition of asthma exacerbations, including in pregnancy,
would be desirable.
Two of the eight included trials assessed xanthines for asthmaman-
agement in pregnancy; intravenous aminophylline was assessed
for acute asthma (Wendel 1996), and oral theophylline for main-
tenance treatment of asthma (Dombrowski 2004). These agents
are, however, now infrequently used in clinical practice, partic-
ularly outside of the United States and developing world (Giles
2013), with the risk-benefit balance shown to be unfavourable
(Nair 2012; Seddon 2006; Tee 2007). If oral theophylline is to be
used in pregnancy, careful titration of the dose and regular moni-
toring to maintain the recommended serum theophylline concen-
tration are required, due to the potential for serious toxicity from
excessive dosing (NAEPP 2005).
Three included trials evaluating inhaled corticosteroids for main-
tenance treatment utilised beclomethasone (Caramez 1998;
Dombrowski 2004; Wendel 1996). While inhaled corticosteroids
are currently recognised as the preferred preventative medication
for managing asthma in pregnancy, it is important to note that
agents such as fluticasone and budesonide (as utilised in the later
Silverman 2005 and Powell 2011 trials), rather than beclometha-
sone, have been regarded as ’preferred’ inhaled corticosteroids for
use in pregnancy, with the most gestational safety data for budes-
onide (George 2012; NAEPP 2005).
The Powell 2011 trial, which revealed benefits of a FENO-based
algorithm to adjust asthma therapy, included only non-smoking
pregnant women. As a proportion of pregnant women (including
pregnant asthmatic women) continue to smoke during pregnancy,
it is important that the effects of this intervention in the smoking
pregnant population are assessed.
Quality of the evidence
Overall, the methodological quality of the studies included in this
reviewwasmoderate, with two trials judged to be of low risk of bias
(Lim 2012; Powell 2011), four trials judged to be at a moderate
risk of bias (Dombrowski 2004; Nickel 2006; Silverman 2005;
Wendel 1996), and two trials judged to be at an unclear risk of
bias (Badawy 2012; Caramez 1998).
Considering trials assessing pharmacological interventions, both
the Badawy 2012 and Caramez 1998 trials were judged to be of
an unclear methodological quality overall; similarly, the method-
ological quality of Wendel 1996 was largely unclear, however the
trial was judged to be at high risk of both performance bias and re-
porting bias. Dombrowski 2004 and Silverman 2005 were judged
to be at a comparatively higher quality (based on the available
information) than the other pharmacological trials, with low risk
of selection, performance, and detection bias; however the risks of
attrition and reporting bias in these trials were unclear.
In regards to trials of non-pharmacological interventions, both
Lim 2012 and Powell 2011 were judged to be of high method-
ological quality overall, with both trials judged to be at a low risk
of selection, detection, attrition and reporting bias. Lim 2012 was
however at an high risk of performance bias, due to the nature of
the intervention, and the inability to blind participants and study
personnel. The methodological quality of Nickel 2006 was less
certain, as while methods for random sequence generation and
blinding of outcome assessors were judged as adequate, the risks
of selection bias (due to inadequate allocation concealment), and
of performance, attrition and reporting bias, were unclear.
Potential biases in the review process
The search for studies in this area was performed using the
Cochrane Pregnancy and Childbirth Group’s Trials Register
(which is updated weekly to monthly with information from
the Cochrane Central Register of Controlled Trials (CENTRAL),
MEDLINE, Embase, handsearches from 30 journals and confer-
ence proceeding of major conferences and alerts for a further 44
journals) and using the Cochrane Airways Group’s Trials Register
(also updated weekly to monthly with information from CEN-
TRAL, MEDLINE, Embase, PsycINFO, CINAHL, AMED, and
handsearches from the proceedings of eight major conferences). It
is unlikely that studies that have been conducted have beenmissed,
however unpublished studies, or ongoing studies not registered in
clinical trial registries could be missing. Should such studies be
identified, we will include them in future updates of the review.
We aimed to reduce bias wherever possible by having at least two
review authors independently working on study selection, data
extraction and ’Risk of bias’ assessment.
Agreements and disagreements with other
studies or reviews
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This systematic review is the first Cochrane review to assess the
randomised controlled trial evidence of both pharmacological and
non-pharmacological interventions for managing asthma during
pregnancy.
In relation to non-pharmacological interventions, our findings are
consistent with a recently published review of randomised tri-
als of healthcare interventions for improving asthma in pregnant
women (Zairina 2014). This review similarly concluded that while
non-pharmacological interventions were associated some signifi-
cant improvements in maternal asthma control and neonatal out-
comes, that firm conclusions could not be drawn, due to the lim-
ited number of reported studies, the clinical heterogeneity of the
interventions, variations in outcome measures and limitations in
study designs (Zairina 2014).
While a Cochrane review of tailoring asthma interventions based
on FENO (in comparison to clinical symptoms) in children and
adults did not show clear benefits to recommend the use of FENO
for clinical practice (Petsky 2009), the findings of the Powell 2011
trial, provide some promise for the use of a FENO-based algorithm
to adjust asthma therapy in pregnant women. In contrast to the
findings of the Petsky 2009 review, which showed that FENO did
not significantly reduce exacerbations, and may be associated with
higher doses of inhaled corticosteroids in children and adolescents,
in Powell 2011, exacerbations for pregnant women were reduced
with the use of FENO to adjust inhaled corticosteroid dose, and
while more women in the FENO group were treated with inhaled
corticosteroids, their mean daily dose was in fact lower (though
not significant).
In Lim 2012 and Powell 2011, women were also provided with
education on asthma self-management skills (inhaler technique,
knowledge and action plans) and adherence was assessed and op-
timised. For Lim 2012, asthma education, monitoring, feedback
and follow-up were integral components of the monthly inter-
vention, and asthma action plans were recommended by the trial
pharmacist, drafted alongside a respiratory physician and signed
off by a family physician. Asthma education programs and self-
management plans that enable individuals to adjust therapy based
on written action plans have been proven to be effective in im-
proving health outcomes in the general asthmatic population in
randomised trials and systematic reviews (Gibson 2002); observa-
tional studies have also suggested benefits of asthma eduction and
self-management skill development for pregnant women (Murphy
2005a). Previous studies have supported the utility of pharmacist-
led or community pharmacy-based programs in asthmatic patients
(Basheti 2007; Mehuys 2008), as was shown to be of potential
benefit for pregnant women in Lim 2012; this topic will be the
focus of an upcoming Cochrane review of pharmacy programs for
all patients (Ryan 2013).
The use of relaxation therapies in the general asthmatic popula-
tions was the focus of a systematic review byHuntley 2002. In this
review, five of the 15 included trials assessed PMR (as was the focus
of the Nickel 2006 trial included in this review), and the authors
concluded that while there is currently a lack of evidence for the
efficacy of relaxation therapies in asthma management, largely due
to the poor methodology of the studies, and inherent problems of
conducting such trials, there is some evidence that muscular relax-
ation can improve lung function of patients with asthma (Huntley
2002); similar to the findings of the Nickel 2006 trial.
While many reviews in non-pregnant populations have strongly
supported the use of inhaled corticosteroids such as inhaled be-
clomethasone (Adams 2005) and budesonide (Adams 1999), the
benefits and potential harms for pregnant women have been less
certain. Our review findings are in line with those of a recent,
comprehensive systematic review of the safety of regular preven-
tive asthma medications during pregnancy (Lim 2011b). This re-
view similarly highlighted the lack of randomised evidence in this
area, however concluded that while some negative outcomes of
preventive asthma medications have been reported, that no clear,
direct association with medication use in most of these cases has
been shown. In this review, the use of inhaled corticosteroids was
not shown to be associated with any particular adverse event (Lim
2011b).
When inhaled corticosteroids have been compared with oral xan-
thines (such as theophylline) in previous reviews, such as in chil-
dren, it has been shown that while xanthines are an effective pre-
ventative treatment, they may be less effective than inhaled corti-
costeroids, with a less favourable side-effect profile (Seddon 2006).
In this review, while the Dombrowski 2004 trial did not show
oral theophylline to be less effective than inhaled beclomethasone,
a higher rate of discontinuation due to adverse effects with oral
theophylline was seen.
In regards to the use of inhaled magnesium sulphate in addition
to routine treatment in the management of acute asthma, a recent
Cochrane review (Powell 2011) did not show a significant im-
provement in lung function overall, as was suggested for pregnant
women in the Badawy 2012 trial. This review, however acknowl-
edged the considerable between-study heterogeneity, and noted
that individual results from three of the included trials showed
possible improvements in lung function with inhaled magnesium
sulphate in those with severe asthma exacerbations (Powell 2012).
The Badawy 2012 trial, however, was judged to be at an unclear
risk of bias overall, with a lack of methodological information pro-
vided to confidently assess trial quality; thus the results of this trial
should be interpreted with caution.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently a limited and incomplete body of evidence from
randomised trials assessing the effects of interventions for manag-
ing asthma during pregnancy, which is insufficient to make firm
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conclusions about optimal interventions. The ability to draw con-
clusions is limited particularly by variability in the quality of the
trials conducted to date, by the small sample sizes of many of these
trials, and by variation in characteristics of the interventions as-
sessed in the trials.
The results from five trials in this review assessing pharmacological
interventions did not provide clear evidence of benefits or harms to
support or refute current practice (Badawy 2012; Caramez 1998;
Dombrowski 2004; Silverman 2005; Wendel 1996). While in-
haled magnesium sulphate was shown to reduce asthma exacerba-
tions for pregnant women with acute asthma, this was in one small
trial, of unclear quality (Badawy 2012), and thus this evidence is
insufficient to guide practice. While no clear effect on asthma ex-
acerbations was seen with the addition of inhaled beclomethasone
to routine asthma therapy in two trials (Caramez 1998; Wendel
1996), these trials were also both of unclear methodological qual-
ity, and had small sample sizes.
Similarly, the randomised evidence for non-pharmacological in-
terventions for asthma management in pregnancy accumulated to
date is not sufficient to support widespread implementation or
practice change. The three included trials provided some support
for the use of such strategies, however were not powered to de-
tect differences in important maternal and infant outcomes (Lim
2012; Nickel 2006; Powell 2011). While a FENO-based algo-
rithm to adjust asthma therapy reduced exacerbations for preg-
nant women, the effects on perinatal outcomes were less certain,
and thus widespread implementation into the clinical practice set-
ting is not yet likely to be appropriate (Powell 2011). Similarly,
though positive effects on asthma control were shown with PMR
(Nickel 2006) and a pharmacist-led, multi-disciplinary approach
to asthma management for pregnant women (Lim 2012), the ev-
idence to date is insufficient to guide practice change.
Implications for research
In light of the limited current evidence, further randomised con-
trolled trials are required to determine the most effective and safe
management interventions for women with asthma during preg-
nancy. Future trials must be sufficiently powered, and well-de-
signed, to allow important differences in relevant clinical outcomes
for the mother and her baby to be detected, and to allow longer-
term infant, child and/or adult outcomes to be assessed. The im-
pact on health services of management interventions requires eval-
uation prior to implementation into clinical practice.
A number of important questions remain surrounding the optimal
care of asthmatic pregnant women. If further trials are conducted
focused on the effectiveness and safety of pharmacological agents,
it is important that the agents assessed are either those commonly
utilised or recommended in current clinical practice (for example,
considering inhaled corticosteroids, budesonide, rather than be-
clomethasone, should be utilised in any planned trials), or novel
agents, not yet assessed in pregnancy. In addition to evaluating
effectiveness and safety, such trials may address specific consider-
ations such as dosage.
Though future trials of pharmacological agents for asthma man-
agement in pregnancy are warranted, it is likely that research ef-
forts will be primarily directed towards trials aimed at optimising
asthmamanagement through non-pharmacological interventions;
there are a multitude of possible non-pharmacological strategies
and combinations of strategies that may be assessed (as detailed
in the Background of this review, non-pharmacologic strategies
may include: monitoring lung function to guide treatment (such
as the use of spirometry); monitoring of airway inflammation to
guide treatment (such as the use of FENO); lifestyle modification
and the avoidance of triggers (such as smoking cessation); dietary
interventions; physical interventions; psychological interventions;
educational programs and asthma action plans).
Given the benefits of a FENO-based algorithm to adjust asthma
therapy observed in the Powell 2011 trial, further trials utilising an
algorithm incorporating FENO to adjust inhaled corticosteroid
therapy are a priority. At least one such trial (The Breathing for Life
Trial: ACTRN12613000202763) is planned/underway in Aus-
tralia, with a target size of over 1100 women; thus powered to
detect a difference in a primary composite adverse outcome for
the infant (preterm birth, intrauterine growth restriction, perina-
tal mortality or neonatal hospitalisation at birth). Importantly, the
trial aims to assess this management strategy in both smoking and
non-smoking pregnant women (non-smoking women alone were
the focus of the Powell 2011 trial). Further trials of interventions
that have shown promise, such as the use of PMR (Nickel 2006),
and a pharmacist-led,multi-disciplinary approach tomanagement
(Lim 2012), powered to detect differences in asthma exacerbations
and perinatal outcomes are needed; the cost-effectiveness of these
interventions should also be evaluated.
Four additional randomised trials have been identified as being
planned or underway (see:
Ongoing studies), three in Australia (ACTRN12613000244707;
ACTRN12613000301763; ACTRN12613000800729) and one
in Belgium (NCT01345396). One trial (target sample size: 378
women) aims to assess a respiratory nurse-led ’Antenatal Asthma
Management Service’ (AAMS) based in the antenatal outpatient
clinic compared with standard care (ACTRN12613000244707);
one trial (target sample size: 104 women) aims to assess dietary
modification for asthma control (increased consumption of an-
tioxidant rich foods) (ACTRN12613000301763); one trial (tar-
get sample size: 70 women), ’Management of Asthma with Sup-
portive Telehealth of Respiratory function in Pregnancy’ (MAS-
TERY) aims to assess the effects of a ’Breathe-easy’ mobile phone
application (ACTRN12613000800729); and the final trial (tar-
get sample size: 80 women) aims to assess the effects of an asthma
education program on asthma control (NCT01345396).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Badawy 2012
Methods Randomised controlled trial.
Participants 60 women were randomised.
Setting: Sohag University Hospital, Eqypt from October 2010 to June 2011
Inclusion criteria: pregnant women who were not completely or partially controlled on
routine acute asthma therapy; with a history of bronchial asthma under routine therapy;
with clinical evaluation of bronchial asthma according to GINA guidelines
Exclusion criteria: women with the following complications: congestive heart failure,
angina history, renal problems, history suggestive of pulmonary embolism; women with
very severe asthma presenting with manifestations requiring endotracheal intubation;
associated medical illness from history/medical examination (diabetes, hypertension);
fever of more than 38 degrees; inability to perform pulmonary function test
Interventions Intervention group (inhaled magnesium sulphate) (n = 30)
Women received routine treatment for acute asthma exacerbations, which include oxy-
gen, intravenous corticosteroids (solucortif 100 mg vial), intravenous aminophylline
(500 mg/5 mL), and nebulised salbutamol and magnesium sulphate (mixture of: 1 mL
salbutamol, 1 mL (500 mg) magnesium sulphate, and 8 mL normal saline)
Control group (n = 30)
Women received routine treatment for acute asthma exacerbations, as above (including
nebulised salbutamol (1 mL salbutamol solution dissolved in 9 mL normal saline, with
no magnesium sulphate)
Women received a maximum of 3 sets of nebulisation, 20 minutes apart; 2 hours later,
pulmonary function tests and blood gas analysis were done
All women were allowed to be discharged from the emergency unit when their signs of
distress and dyspnoea were improved; their oxygen saturation was more than 94%; and
their FEV1 was more than 60%. If women did not meet these signs of improvement
they were admitted to the intensive care unit for monitoring and management; women
were then followed up in the outpatient clinic with routine antenatal care
Outcomes Pulse rate; pH; arterial oxygen tension; arterial carbon dioxide tension; oxygen satura-
tion; potassium; FEV1; FVC; FEV1/FVC; FEF25%; FEF75%; PEFR; acute asthma ex-
acerbations (until birth);mode of birth (normal vaginal birth; caesarean section); “smooth
neonatal period”.
Notes Review authors have contacted trial authors for further information with no response as
at 28/08/2014
Risk of bias
Bias Authors’ judgement Support for judgement
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Badawy 2012 (Continued)
Random sequence generation (selection
bias)
Unclear risk Quote from abstract “Patients were divided into two
groups in a double blind randomization.” Quote from
manuscript: “The studied patients were randomized into
two groups through separate envelopes”.
Allocation concealment (selection bias) Unclear risk As above.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote:“The medications were given by doctor who was
not a part of the study...”. Group A (control group) re-
ceived routine treatment for acute exacerbations which
included nebulised salbutamol (1 mL in 9 mL saline).
Group B (intervention group) received the same treat-
ment, however received nebulised salbutamol and mag-
nesium sulphate (1 mL salbutamol, 1 mL magnesium
sulphate, and 8 mL saline)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk As above.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No loss to follow-up reported for the 60 women.
Selective reporting (reporting bias) Unclear risk Insufficient information to determine reporting bias.
Other bias Unclear risk Groups were comparable at baseline for reported char-
acteristics (age, education, parity and duration of preg-
nancy). Insufficient information to determine other
sources of bias
Caramez 1998
Methods Randomised controlled trial.
Participants 95 women were randomised.
Setting: Brazil.
Inclusion criteria: pregnant asthmatic women.
Exclusion criteria: none detailed.
Interventions Intervention group (inhaled beclomethasone) (n = 49)
Inhaled beclomethasone (1 mg/day); inhaled bronchodilators and tapered oral pred-
nisolone during exacerbations
Comparison group (n = 46)
Inhaled bronchodilators and tapered oral prednisolone during exacerbations
Outcomes Asthma exacerbations in pregnancy and during delivery; type of birth; obstetric compli-
cations; perinatal outcomes
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Caramez 1998 (Continued)
Notes Information taken from abstract only. Review authors have contacted trial authors for
further information with no response as at 28/08/2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotes: “prospective, randomised, controlled study”…
“randomly assigned”;with no further details (only abstract
available).
Allocation concealment (selection bias) Unclear risk As above.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described in abstract.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described in abstract.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient information to determine attrition bias.
Selective reporting (reporting bias) Unclear risk Insufficient information to determine reporting bias.
Other bias Unclear risk Insufficient information to determine other risk of bias.
Dombrowski 2004
Methods Randomised controlled trial.
Participants 398 women randomised (385 included in analyses).
Setting: 13 centres of the Maternal-Fetal Medicine Units Network of the National
Institute of Child Health and Human Development, USA, from December 1995 to
February 2000
Inclusion criteria: moderate asthma (see notes below for definition); singleton viable
pregnancy and no major anomalies; < 26 weeks’ gestation
Exclusion criteria: prenatal care or birth planned elsewhere; imminent birth; gestational
hypertension or pre-eclampsia; current (or history of ) epilepsy treated with medications;
allergy/sensitivity to theophylline; inhaled steroid or albuterol; treatment with oral cor-
ticosteroids for another medical condition; participation in another asthma study; active
pulmonary disease other than asthma; cardiac disease; pre-gestational diabetes; endocrine
disorders requiring medication; sickle cell disease; acute/chronic liver disease; inability
to schedule an ultrasound; inability to give informed consent; women with unstable/
severe asthma
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Dombrowski 2004 (Continued)
Interventions Intervention group - inhaled beclomethasone (n = 199 randomised, 194 included
in analyses)
Women received inhaled beclomethasone 4 puffs 3 times per day (504 mcg/d approxi-
mately), and placebo pills (assumed at the same regimen as the theophylline pills)
Comparison group - oral theophylline (n = 199 randomised, 191 included in anal-
yses)
Women received inhaled placebo 4 puffs 3 times per day and theophylline pills - the
initial dose was 200 mg morning and evening; this was increased to 300 mg 2 times per
day after 3 days. The total dose was adjusted between 400-800 mg per day with a serum,
target level of 8 to 12 mcg/mL
All women: on randomisation all women were instructed to discontinue all other asthma
medications and were supplied with open-label albuterol inhalers to be used on an ‘as
needed’ basis. Women received spacers with the inhalers to reduce oral deposition and
systemic absorption of the active drug. Dosage of placebo and theophylline tablets was
halved during use of a macrolide antibiotic
National Asthma Education and Prevention Program guidelines for asthmamanagement
constituted standard care (objective measures of pulmonary function, mitigating asthma
triggers, patient education).Womenwere suppliedwith peak flowmeters, asthma diaries,
and plastic pillow and mattress covers. They were instructed in home environmental
control measures, and in home rescue algorithms
Outcomes Primary outcome: proportion of women with at least 1 validated asthma exacerbation
(defined as asthma symptoms (cough, dyspnoea or wheezing) that resulted in a medical
intervention, including an emergency visit, need for oral corticosteroids or hospitalisa-
tion)
Secondary
Treatment failure (see notes below for definition); withdrawal; other asthma outcomes
(proportion study visits with FEV1 < 80%, or PEFR < 80% predicted; albuterol (mean
daily puffs); nocturnal symptoms; symptoms at delivery); delivery and perinatal out-
comes (chorioamnionitis; pre-eclampsia; preterm birth; haemorrhage; caesarean birth;
oligohydramnios; gestational age at birth; birthweight; birth length; major malforma-
tion; perinatal demise; jitteriness; hyaline membrane disease; discharge diagnosis of sep-
sis)
Notes Moderate asthma: women were considered to have moderate asthma if they had symp-
toms 8 or more days over the past 4 weeks not attributable to upper respiratory infections
and/or a FEV1 60% to 80% predicted more than 4 hours after bronchodilator. Women
with mild asthma by symptoms and FEV1, but who required regular medications for
asthma control were also considered to have moderate asthma (with regular medication
defined as at least 4 weeks of daily theophylline (≥ 1 dose/day), ipratropium (≥ 4 puffs/
day), or 2 or more puffs per day of inhaled β2-agonists, cromolyn, nedocromil, or in-
haled corticosteroids
Treatment failure: defined as more than 2 asthma exacerbations resulting in an emer-
gency visit/course of systemic corticosteroids, or 1 or more asthma hospitalisation ≥
48 hours, or unacceptable symptoms. All treatment failures were considered to have
achieved the primary outcome of the trial
Risk of bias
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Dombrowski 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation sequence, stratified by centre, was
generated by the Biostatistics Coordinating Centre of
George Washington University by using the simple urn
model
Allocation concealment (selection bias) Low risk Study medications were packaged and labelled with a
drug code by a central pharmacy that was responsible for
distribution of study drugs to the centre. Each woman
was randomly assigned by clinical centre staff by assign-
ing the next sequentially numbered drug code and the
corresponding study medication kit
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The trial was described as ‘double masked’, with the
use of placebos (inhaler/tablets). All investigators were
blinded to the 3 interim analyses of data until completion
of the study. Serum theophylline concentrations were
obtained (samples taken from women in both groups),
and the Biostatistics Co-ordinating Centre provided in-
vestigators with instructions to increase/decrease dose of
theophylline pills; to maintain blinding, they also ‘ad-
justed’ the dose of placebo pills
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk As above.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 398 women were randomised (199 to each group); only
13 (3.3%) women were lost to follow-up before primary
outcome determination (these were excluded from all
analyses). It is unclear for some outcomes how many
women are lost, as the tables describe“some data based
on fewer than 385 participants” but it is not clear for
which outcomes, and for which groups. 1 woman in
the theophylline group had primary outcome data, but
delivery data could not be obtained. In regards to study
completion and compliance data: “Some data were lost by
the service contracted to ascertain measured compliance; the
remaining data are based on 132women in the theophylline
and 190 in the beclomethasone” groups.
Selective reporting (reporting bias) Unclear risk With no access to a trial protocol, it is difficult to as-
sess selective reporting (and secondary outcomes were
roughly defined in themanuscript methods; quote: “Sec-
ondary outcomes included treatment failures, participant
withdrawal, and delivery and perinatal outcomes”).
42Interventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dombrowski 2004 (Continued)
Other bias Unclear risk The frequency of self-reported smokingwas significantly
higher in the theophylline group. After an interim data
review, it became evident that the aggregate frequency
of the primary outcome would be below the projected
35%. To increase the primary outcome rate, the data
safety and monitoring committee changed eligibility re-
quirements after enrolment of 311 women to include
only women who required regular asthma medications
as they had a greater frequency of the primary outcome.
58 women in the beclomethasone group discontinued
intervention, and 68 in the theophylline group discon-
tinued the intervention (treatment failure, side effects,
self-withdrawal)
Lim 2012
Methods Randomised controlled trial.
Participants 60 women were randomised.
Setting: antenatal clinics at 2 major Victorian women’s hospitals, Australia
Inclusion criteria: pregnant women with asthma attending antenatal outpatient clinics,
up to 20 weeks’ gestation, who could communicate in English
Exclusion criteria: women under the age of 18 years; women who have not had asthma
symptoms (wheeze, chest tightness, and/or use of reliever medication) in the last year;
women unable to meet the demands of the trial; women included in a previous ex-
ploratory study ’Asthma during pregnancy; the experiences, concerns and views of preg-
nant women;’ women who have a miscarriage or termination
Interventions Intervention group - Multi-disciplinary Approach to Management of Maternal
Asthma (MAMMA©) (n = 30)
Women experienced a collaborative approach to asthma management - involving family,
physicians, pharmacists and asthma educators. Asthma education, monitoring, feedback
and follow-up were integral components of the monthly intervention. Women received
pharmacist-led medication management review at the beginning of the trial, periodic re-
view of inhaler device technique by asthma educator, trigger avoidance and smoking ces-
sation support (if relevant). Each participant was given a hand-held, portable, electronic
spirometer to encourage home-monitoring, and trained in how to use it. Women were
instructed to contact the pharmacist if their lung function deteriorated (FEV1/FEV6
< 0.75). Each month participants were contacted by the trial pharmacist by phone/in
person to assess their asthma control using a short data collection form which included
the ACQ; assessments were approximately 30 minutes.The pharmacist provided feed-
back to the family physicians where the ACQ scores increased by 0.5 or more or if there
had been documented exacerbations. The pharmacist and physician then collaborated
on appropriate ’step-up’ therapy for the women. Asthma action plans were also recom-
mended by the trial pharmacist, and were drafted alongside a respiratory physician at
the discretion of the woman’s family physician who signed off on the final plan
Control group - standard care (n = 30)
Women received usual medical care (including regular antenatal visits) and did not
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Lim 2012 (Continued)
receive the intervention, any additional monitoring or education sessions. If at follow-
up (at 3 and 6 months) their asthma control was of concern (2 or more documented
exacerbations without resolution since prior assessment, or their ACQ score was greater
than 2, women were advised to notify their family physician)
Both groups of women were given a summarised version of the ’Asthma and Healthy
Pregnancy’ brochure from the Asthma Foundation of New South Wales, Australia to
minimise the risks of poorly controlled asthma
Outcomes Primary outcome: ACQ score (change from baseline at 3 and 6 months).
Secondary outcomes: asthma exacerbations (defined as having asthma-related hospital
visits, emergency visits, days off work or oral corticosteroid use); development of an-
tenatal complications (hypertensive disorders or pregnancy; antepartum haemorrhage;
gestational diabetes; gestational age at birth); neonatal outcomes (gestational age at birth;
birthweight percentile; Apgar scores; admission to neonatal intensive care or special care
nursery; mode of birth; postnatal complications)
Notes Pilot study.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random sequence of numbers generated during the
’Random allocation’ software program by an external re-
searcher, not part of the research team
Allocation concealment (selection bias) Low risk Block randomisation (with stratification: mild intermit-
tent asthma vs. moderate-severe persistent asthma) us-
ing random blocks of 4 and 6, using numbered, sealed
opaque envelopes. The leading investigator allocated
women to the usual care group or the intervention group
at the time of recruitment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind women and study personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A research assistant, blinded to group allocation per-
formed assessment at 3 and 6 months
Incomplete outcome data (attrition bias)
All outcomes
Low risk One woman from each group (2/60) withdrew from the
trial. Intention-to-treat analysis performed
Selective reporting (reporting bias) Low risk No selective reporting identified; data reporting for all
outcomes specified in the trial protocol
Other bias Low risk No other obvious risk of bias identified.
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Nickel 2006
Methods Randomised controlled trial.
Participants 64 women were randomised.
Setting: Germany.
Inclusion criteria:pregnantwomen suffering frombronchial asthma,whowere regularly
seen by a gynaecologist
Exclusion criteria: women were excluded who had current use of medication, anything
other than the usual types of asthma medication during the previous 4 weeks; psychosis;
severe anxiety and/or depression; substance abuse; use of psychotropic medication or
psychotherapy; or if they smoked or had hypertension
Interventions Intervention group - progressive muscle relaxation (PMR) (n = 32)
Women were treated in 30 minute group PMR sessions, 3 times per week over 8 weeks.
Women deliberately applied tension to certain muscle groups then released the tension
and focused on how the muscles relaxed during the process (right foot, right lower leg
and foot, entire right leg, left foot, left lower leg and foot, entire left leg, right hand, right
forearm and hand, entire right arm, left hand, left forearm and hand, entire left arm,
abdomen, chest, neck and shoulders, face). The women received precise instructions for
daily practice at home (15 minutes 2 times a day using shortened form of the procedure)
Control group - sham training (n = 32)
Women were prescribed movement with their extremities as a placebo intervention, also
in 30-minute sessions 3 times a week. The women also received instruction for daily
practice at home, using shortened exercises
Both groupswere testedweekly. All womenwere tested in themorning, under controlled
room temperature and light conditions. Women were asked to not eat or drink and to
abstain from sport, alcohol and caffeine during the 24 hours prior
Outcomes Systolic blood pressure; FEV1; PEFR; heart frequency; coefficient of variation; high
frequency; low frequency; middle frequency; State-Trait Anger Expression Inventory
(STAXI) and Health Survey (SF-36) measures
Notes All women participated in the PMR or sham training and were tested in the morning (8/
9 am) under controlled room temperature and light conditions. Women were instructed
not to eat or drink (only water allowed) and to abstain from sport, alcohol and caffeine
during the 24 hours preceding the experiment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomized numbers generate by an Excel table”.
Allocation concealment (selection bias) Unclear risk Method of concealment not described in sufficient de-
tail; quote: “The clinic administration conducted the ran-
domization procedure confidentially”.
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Nickel 2006 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Sham training was used, although it is unclear whether
this was effective in blinding women (i.e. the exercises/
instructions would have differed), and study personnel
administering the training would have been aware of
group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All measurements (blood pressure and lung parame-
ter measurement, and ECG recordings) were arranged
by blinded medical/technical personnel. Blinded profes-
sional staff checked the data for completeness (question-
naires). The data were twice fed independently to the
computer and automatically checked for deviations
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6 women (2 in PMR group and 4 in control group) did
not attend more than 2 examination days and “dropped
out of the study”; however they were included in analyses
(intention to treat), although it is unclear where the data
from the lost women has come from
Selective reporting (reporting bias) Unclear risk With no access to a trial protocol it is not possible to con-
fidently assess selective reporting. No clinical outcomes
related to pregnancy/birth were included
Other bias Low risk No other obvious risk of bias identified. Baseline char-
acteristics were similar between groups
Powell 2011
Methods Randomised controlled trial.
Participants 220 women randomised.
Setting: 2 antenatal clinics (John Hunter Hospital and Maitland Hospital, New South
Wales, Australia) from June 2007 to December 2010
Inclusion criteria: non-smoking pregnant women (> 18 years) with asthma attending
the antenatal clinics; between 12 to 20 weeks’ gestation; doctor’s diagnosis of asthma;
using inhaled therapy for asthma within the past year. Asthma diagnosis confirmed by
respiratory physician’s diagnostic interview
Exclusion criteria: inability to attend antenatal clinic visits during pregnancy; inability
to performmanoeuvres required for spirometry and FENO; requirement for > 3 courses
of oral corticosteroid in the previous 12 months; admission to hospital for asthma exac-
erbation in the previous 3 months; maintenance oral corticosteroids; maintenance oral
theophylline; current smoking; concomitant chronic medical illness; chronic lung dis-
ease; drug/alcohol dependence
Interventions All women: FENO and spirometry were measured at visit 1 and ACQ administered.
Asthma self-medication skills (inhaler technique, knowledge, action plan) and adherence
were assessed and optimised. Eligible women commenced a 2 week ’run-in’ period.
Women using inhaled corticosteroids continued with their current dose (administered as
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budesonide with dose equivalence from guidelines); women with uncontrolled asthma,
not using maintenance inhaled corticosteroids were started on budesonide. Following
randomisation, women were reviewed monthly at the antenatal clinical until birth; a
research assistant collected data for clinical symptoms, ACQ score, present treatment
FENO and FEV1. ACQ score, treatment and FENO were sent to the algorithm keeper,
who applied the relevant algorithm and sent the treatment recommendation to the
research assistant in the clinic who informed the woman. Women were seen by the
investigator in the clinic if their asthma was uncontrolled and they were at the maximum
treatment level of the algorithm
Intervention group - FENO algorithm to adjust therapy (n = 111)
Asthma therapy (inhaled corticosteroid (budesonide) and long-acting β-agonist therapy
(salbutamol/formoterol)) adjusted according to FENO during the 2nd and 3rd trimester
of pregnancy (approximately 6months). The FENOalgorithm used a sequential process:
first, the FENO concentration was used to adjust the dose of inhaled corticosteroids;
and second, the ACQ score was used to adjust the dose of long-acting β2 agonist (see
Additional Table 1 and Table 2). The cut-off points for the algorithm were derived from
a prospective cohort study of asthma in pregnancy
Control group - clinical guideline algorithm to adjust therapy (n = 109)
Asthma therapy (inhaled corticosteroid and long-acting β-agonist therapy) adjusted
according to clinical guidelines (GINA) during the 2nd and 3rd trimester of pregnancy
(approximately 6 months). The clinical algorithm was based on asthma control (ACQ)
with cut-off points defined as: well controlled asthma (< .75), partially controlled asthma
(0.75 - 1.50), and uncontrolled asthma (> 1.5) (see Additional Table 3). A woman with
uncontrolled asthma had her dose increased by 1 treatment step; those with well asthma
had their inhaled corticosteroid dose reduced by 1 treatment step; the intermediate
group had no definite treatment change undertaken (See Additional Table 4). Women
who remained uncontrolled, taking the maximum allowed dose, were assessed and their
treatment decision decided by a respiratory physician
Outcomes Primary outcome: total number of asthma exacerbations (moderate and severe), defined
as events for which the woman sought medical attention (unscheduled visit to doctor,
presentation to the emergency roomor admission tohospital, orwhenoral corticosteroids
were used). (All exacerbations occurring after randomisation were included; and those
separated by 7 days or more were counted as a second event - data was collected at
monthly visits, follow-up phone calls, and review of medical records)
Secondary outcomes: exacerbation types (unscheduled visit to doctor; presentation to
the emergency room; admission to hospital; oral corticosteroids use); quality of life (as-
sessed using generic (short form 12, version 1) and disease specific (asthma quality of life
questionnaire - Marks) questionnaires; asthma treatment (oral corticosteroid use; β2-
agonist use; inhaled corticosteroid use; beclomethasone dipropionate equivalent inhaled
corticosteroid dose; long-acting β2-agonist use; symptom-free days); lung function mea-
sures (FENO (ppb); FEV1 (L) and (%)); asthma symptoms (ACQ score (at exacerba-
tion, at end of study); perinatal outcomes (gestational age; birthweight; birth length;
birth head circumference; labour (spontaneous/induced/no labour/augmented); mode
of birth (vaginal/forceps/vacuum/caesarean (elective or emergency); maternal complica-
tions (pre-eclampsia; gestational diabetes; pregnancy-induced hypertension; antepartum
haemorrhage; postpartum haemorrhage; ruptured membranes; hyperemesis; protein-
uria); fetal complications (stillbirth; termination of pregnancy; preterm birth; intrauter-
ine growth restriction; jaundice; neonatal hospitalisation; congenital malformation)
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Powell 2011 (Continued)
Follow-up outcomes: wheeze, bronchiolitis, croup (selected outcomes from ’A parent
completed questionnaire to describe the patterns of wheezing and other respiratory symptoms
in infants and preschool children’.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A statistician used a computer-generated random
number list”.
Allocation concealment (selection bias) Low risk Quote: “Allocation to treatment algorithm group was con-
cealed from the participant, research assistant and investi-
gators through the use of an algorithm keeper who was not
directly involved in assessment or care of women”.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “The research assistant collected data at monthly
antenatal clinic appointments, and sent this to the algo-
rithm keeper, who applied the relevant algorithm and sent
the treatment recommendation to the research assistant”.
Blinding of women was assessed as successful, with most
women not aware of the group to which they were as-
signed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blind to group allocation. For
follow-up, the examination of the infant and interview
of the primary carer was conducted by an investigator
who was blinded with respect to management group and
pregnancy outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk 11/111 women withdrew from the FENO group after
randomisation (3: personal reasons; 4: lost to follow-up;
1: inadequate time; 1: travel too far; 1: termination -
spina bifida; 1: antenatal care elsewhere). 6/109 women
withdrew from control group (3: personal reasons; 1: lost
to follow-up; 1: did not like treatment adjustment; 1:
asthma not seen as a problem). All women were included
in final analyses, with final visit before dropping out
counted as ’end of study’ visit
Of the 220 women in the trial, 174 (79%) consented to
12-month follow-up 146 infants attended the 12-month
follow-up visit. 146/174 (82%) of the infants completed
the follow-up at 12 months
Selective reporting (reporting bias) Low risk No obvious risk of reporting bias, with data reported
for the expected outcomes (as per trial registration). For
the follow-up outcomes, it is reported that 146 infants
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completed follow-up, however the table reports outcome
data for only amaximumof 129 infants (67 in the FENO
group and 62 in the clinical guideline group)
Other bias Low risk Groups well-balanced at baseline. No other obvious risk
of bias identified
Silverman 2005
Methods Randomised control trial.
Participants 219 women who were pregnant in the STARTTrial. The STARTTrial randomised 3642
women to budesonide and 3599 to placebo
Setting: 32 countries, from October 1996 to January 1998.
Inclusion criteria: women with symptoms at least weekly, but not as often as daily
during the 3 months prior; women with reversible airway obstruction, defined as an
increase in FEV1 of more than 12% after receiving a short-acting bronchodilator or as
a decline in FEV1 of more than 15% on exercise testing, or as a variation of more than
15% between the 2 highest and 2 lowest PEFR recordings in a 14-day period
Exclusion criteria: asthma symptoms; treatment formore than2 years before entry;more
than 30 days of corticosteroid treatment or more than 1 depot corticosteroid injection
per year; where delaying ICS treatment was judged as inappropriate; pre-bronchodilator
FEV1 < 60% of predicted; post-bronchodilator FEV1 < 80% predicted; other clinically
significant disease
Interventions 3 year ’double-blind phase’ (A )
Intervention group - inhaled budesonide (n = 102)
Once-daily 400 µg budesonide via dry powder inhaler in addition to usual asthma
treatment
Control group (n = 117)
Once-daily placebo via dry powder inhaler in addition to usual asthma treatment. The
placebo consisted of lactose
2 year ’open-label phase’ (B)
All women received 400 µg budesonide in addition to usual therapy
Outcomes Healthy children; adverse outcomes: spontaneous abortion, induced abortion, congenital
abnormality, extrauterine pregnancy, other; preterm labour; caesarean delivery
Notes In total 223 participants in the START Trial reported that pregnancy began during part
A of the study (the 3-year double-blind phase); 4 of these women (3 taking budesonide
and 1 taking placebo) were lost to follow-up. The data set thus includes 219 pregnancies
(102 in the budesonide group and 117 in the placebo group)
Risk of bias
Bias Authors’ judgement Support for judgement
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Silverman 2005 (Continued)
Random sequence generation (selection
bias)
Low risk Within each stratum, patients were randomised in blocks of
10 - 5 in each treatment group, with the use of a computer
program
Allocation concealment (selection bias) Low risk Randomisation was done at the sponsor’s site by a person
not involved in the analysis of data (central randomisation)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All study inhalers were identical in appearance. Only the
person responsible for the packaging knew the randomisa-
tion code
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Only the person responsible for the packaging knew the
randomisation code
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The trial included 2473 females (1250 in the budesonide
group and 1223 in the placebo group) aged 15 to 50 years
(there were no pregnancies in patients aged less than 15
years). In total, 223 participants reported that pregnancy
began during part A of the study; 4 of these patients (3
takingbudesonide and1 taking placebo)were lost to follow-
up. The data set thus includes 219 pregnancies
Selective reporting (reporting bias) Unclear risk Unclear from trial protocol (START trial) as to whether this
analysis, and these particular outcomes were pre-specified.
As per themanuscript: ”birth weight and gestational age were
not recorded.
Other bias Unclear risk Baseline characteristics of participants in the START study
were similar between groups, however this is an analysis of
a subset of individuals from the START study
Wendel 1996
Methods Randomised controlled trial.
Participants 65 women were randomised.
Setting: Parkland Hospital, Dallas, Texas, USA, from January 1993 to May 1994
Inclusion criteria: pregnant women with an acute asthma exacerbation (defined as
respiratory symptoms that prompted a visit to the emergency department or prenatal
clinic and that necessitated inhaled bronchodilator therapy)
Exclusion criteria: steroid dependent asthma.
Interventions All women prior to randomisation: all women received intravenous hydration with
5% dextrose in Ringer’s solution. A certified respiratory therapist performed baseline
pulmonary function therapy, and women received inhaled β2-agonists (maximum 3
doses of isoetharine). Women with a FEV1 of ≥ 70% of predicted volume on the basis
of height, weight and age received outpatient management
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Wendel 1996 (Continued)
Women with a FEV1 < 70% of predicted volume on the basis of height, weight and age
were admitted and were treated with IV hydration for at least 24 hours, and received
an inhaled β2-adrenergic receptor agonist (albuterol by metered dose inhaler) every 4
hours
They were then randomised to:
Inpatient intervention group - aminophylline group (n = 33)
Women received intravenous methylprednisolone 1 mg/kg every 8 hours (maximum
single dose 80 mg),along with intravenous aminophylline (5 mg/kg loading dose,
then 0.5mg/kgmaintenance). Serum theophylline concentrationsweremeasured every
12 hours until at a therapeutic level (10-20 µg/dL). Intravenous aminophylline was
continued until discharge or troublesome side effects
Inpatient control group (n = 32)
Women were given IV methylprednisolone only (as above).
When FEV1 stabilised at ≥ 70% and there was obvious clinical improvement, intensive
therapy was discontinued. Women were then discharged from hospital, and further
randomised to either:
Outpatient intervention group - inhaled beclomethasone (n = 34)
Albuterol metered dose inhaler, 2 puffs every 4 hours as needed; beclomethasone me-
tered dose inhaler, 4 puffs twice daily; and oral methylprednisolone taper.
Outpatient control group (n = 31)
Albuterol metered dose inhaler 2 puffs every 4 hours as needed, and oral methylpred-
nisolone taper
Outcomes Discontinuation of aminophylline due to adverse effects; mean hospital stay (as inpatient
initially), subsequent exacerbations (failure of outpatient management with readmission
for inpatient therapy); obstetric complications (including spontaneous abortion; preg-
nancy-induced hypertension; diabetes; asthma exacerbations in labour; caesarean deliv-
ery; induction/augmentation; chorioamnionitis; haemorrhage; meconium; postpartum
infection); perinatal outcomes (Apgar score < 1 at 1 minute; at 5 minutes; cord arterial
blood pH; gestational age at birth; birthweight; preterm birth; small-for-gestational age;
stillbirth; neonatal death); adherence
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described in detail; quote: “They were randomly as-
signed to one of two regimens as follows;” and “further ran-
domized”. Randomisation for outpatient trial was strat-
ified according to inpatient groups
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo use and no detail of blinding - thus consid-
ered unlikely
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Wendel 1996 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No placebo use and no detail of blinding.
Incomplete outcome data (attrition bias)
All outcomes
Low risk For the inpatient randomisation, it appears no women
were lost to follow-up or excluded from analyses. Re-
garding the outpatient randomisation, 1/34 woman in
the intervention group was lost to follow-up, and 4/31
women in the control group were lost. No other exclu-
sions detailed
Selective reporting (reporting bias) High risk Perinatal and obstetric outcomes reported only overall
(including some women who were not randomised and
were managed as outpatients)
Other bias Unclear risk No detail of differences between group at baseline (in-
patient randomisation or outpatient randomisation)
ACQ: asthma control questionnaire
ECG: electrocardiogram
FEF: forced expiratory flow
FENO: fraction of exhaled nitric oxide
FEV1: forced expired volume in one second
FVC: forced vital capacity
GINA: Global Initiative in Asthma
ICS: inhaled corticosteroid
IV: intravenous
PEFR: peak expiratory flow rate
vs: versus
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Schonberger 2004 The unit of randomisation was ‘the family’ and not all pregnant women included in the trial had asthma
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Characteristics of ongoing studies [ordered by study ID]
ACTRN12613000202763
Trial name or title The Breathing for Life Trial.
Methods Randomised controlled trial.
Participants Inclusion criteria: pregnant women at 12 to 20 weeks’ gestation; physician diagnosed asthma and asthma
symptoms or treatment in prior 12 months
Exclusion criteria: inability to attend monthly study visits; inability to perform manoeuvres required for
spirometry or FENO; drug or alcohol dependence; unknown dates/gestational age not confirmed by ultra-
sound; chronic oral steroid use or use of immunosuppressant therapy
Interventions Intervention group (FENO algorithm)
FENO will be measured at monthly visits during the second and third trimesters of pregnancy and the level
used to adjust maintenance therapy. When FENO is high, inhaled corticosteroid therapy will be increased,
when FENO is in a mid-range no change will be made, and when FENO is low, inhaled corticosteroids will
be decreased. If symptoms are present, long-acting β-agonists will be added
Control group (standardised usual care)
Women will receive an initial asthma assessment, and asthma therapy will be adjusted by their usual care
providers. FENO measurements will not be made
Outcomes Primary outcome: adverse perinatal outcome (either preterm birth, intrauterine growth restriction, perinatal
mortality or neonatal hospitalisation at birth)
Secondary outcomes:maternal asthma exacerbations requiring medical intervention during pregnancy; ma-
ternal hospitalisations or emergency department presentations for asthma during pregnancy; maternal hospi-
talisations for asthma during pregnancy; preterm birth; intrauterine growth restriction; perinatal mortality;
neonatal hospitalisation at birth; mean birthweight; multiple episodes of bronchiolitis in the first year of
life; hospitalisation or emergency department presentation for severe respiratory illness (bronchiolitis, croup
or wheezing) in the first year of life; multiple episodes of croup in the first year of life; hospitalisation for
bronchiolitis in first year of life; atopy at age 3; physician diagnosed asthma at age 6
Starting date 5/03/2013.
Contact information Professor Peter Gibson: Centre for Asthma and Respiratory Diseases Level 2, West Wing Hunter Medical
Research Institute, Locked Bag 1, HRMC Newcastle, New South Wales 2310, Australia
+61 02 40420143
peter.gibson@hnehealth.nsw.gov.au
Notes Target sample size: 1180.
ACTRN12613000244707
Trial name or title Antenatal Asthma Management Service (AAMS).
Methods Randomised controlled trial.
Participants Inclusion criteria: women at less than 20 weeks’ gestation, who have asthma which has been previously
diagnosed by a doctor and is not currently in remission; aged 18 to 45 years; expected to give birth to a
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ACTRN12613000244707 (Continued)
singleton and able to speak English
Exclusion criteria: previous participation in an asthma study run at the hospital or a pre-existing chronic
medical condition (i.e. diabetes, hypertension, cardiac disease, HIV/hepatitis, renal disease, haematology dis-
order (i.e. thalassaemia, thrombophilia), thyroid disorder, psychiatric disease requiring therapy with antide-
pressant or antipsychotic, epilepsy)
Interventions Intervention group
Women will receive care through the nurse-led Antenatal AsthmaManagement Service, based in the antenatal
outpatient clinic. The Antenatal Asthma Management Service will be led by a respiratory nurse with qualifi-
cations in asthma management and education and spirometry. All women will receive asthma education with
a full assessment of their asthma at 18, 24, 30 and 36 weeks’ gestation conducted by a respiratory nurse. Each
antenatal visit will include a 60-minute session where asthma management skills will be assessed. In addition,
women will receive education about asthma control and management skills including trigger avoidance and
smoking cessation counselling when appropriate. During the first visit at 18 weeks, all women will be provided
with a written asthma action plan. Current asthma management therapies will be evaluated and recommenda-
tions regarding optimal therapy made if required. A detailed asthma management report will be forwarded to
the woman’s preferred family physician who will review and assess appropriateness of recommended changes
in therapy. This preferred provided will be the lead clinician responsible for the woman’s asthma in pregnancy
Control group
Standard care will be as outlined in the South Australian Perinatal Practice Guidelines, which involves women
self-managing their disease and seeking guidance formanagement when required from amidwife, obstetrician,
respiratory physician or GP
Outcomes Primary outcome: asthma exacerbations (moderate and severe) defined as events for which the woman sought
medical attention (i.e. an unscheduled visit to a doctor, presentation to the emergency department room or
admission to hospital, or when oral corticosteroids were used for treatment of asthma)
Secondary outcomes: for the mother: ACQ score and FEV1 throughout gestation for the mother; asthma-
related quality of life; perceived control of asthma; medication adherence; asthma knowledge; hypertensive
disorders of pregnancy; antepartum haemorrhage; gestational diabetes; preterm labour; need for antenatal
hospitalisation; weight gain during pregnancy; chorioamnionitis requiring antibiotics during labour; length
of postnatal stay; use of postnatal antibiotics; postpartum haemorrhage (of greater than 500 mL); emergency
caesarean; for the infant/child: gestational age at birth; preterm birth; birthweight; birth length; head cir-
cumference; intrauterine growth restriction; birthweight percentile; Agpar scores, congenital malformations;
admission to neonatal intensive care unit or special care nursery; stillbirth
Starting date Trial registered 28/02/2013.
Contact information Associate ProfessorVickiClifton:TheRobinson Institute, TheUniversity of Adelaide, LyellMcEwinHospital,
Haydown Road, Elizabeth Vale, South Australia 5112, Australia
+61 8 8133 2133
vicki.clifton@adelaide.edu.au
Notes Target sample size: 378.
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ACTRN12613000301763
Trial name or title Dietary modification for asthma control in pregnancy.
Methods Randomised controlled trial.
Participants Inclusion criteria: pregnant women with mild or moderate/severe asthma currently using inhaled corticos-
teroids; older than 18 years; poor diet quality (less than 1 serving/day fruit and less than 2 servings/day
vegetable, determined from Food Frequency Questionnaire)
Exclusion criteria: recent (past month) respiratory tract infection; intermittent asthma; current smoker;
use of antioxidant supplements; previous pregnancy complications including growth restriction, stillbirth or
preterm delivery
Interventions At approximately 14 weeks’ gestation, the 4-week run-in period (prior to the 12 week intervention) will
commence in which all women will be provided with individual asthma management, education and advice
(by a respiratory nurse), and will complete a food frequency questionnaire. At 18 weeks, women will be
randomised to the intervention or control
Intervention group
Womenwill receive a copy of the same booklet received in standard care (see below).Womenwill be counselled
on types of antioxidant-rich foods to purchase and consume, including fruits, vegetables, and lean meat;
women will also be provided with a list of foods high in antioxidants, and asked to identify which of the foods
they are most likely to purchase and consume over the 12 weeks.Women will be given meal/snack suggestions
to assist compliance. A shopping voucher of $30 per week per woman will also be provided to contribute to
the cost of fruits, vegetables, whole grains and lean meats
Control group
The control group will receive standard care which includes a booklet on “Healthy Eating During Pregnancy”,
which contains the recommended number of servings of each food group to be consumed during pregnancy
(according to the 2013 Australian Dietary Guidelines), as well as further information on key nutrients during
pregnancy, supplements, weight gain and guidance on, for example, alcohol, caffeine and water. No other
dietary education will be provided to this group
Outcomes Primary outcome: asthma control score, using the validated ACQ.
Secondary outcomes: plasma circulating concentrations of antioxidants; markers of oxidative stress (plasma
8-F2 isoprostanes); exhaled FENO; time to, and number of, exacerbations: asthma exacerbations during
pregnancy (moderate and severe exacerbations) defined as events for which the participant sought medical
attention (i.e. an unscheduled visit to a doctor, presentation to the emergency department room or admission
to hospital, or when oral corticosteroids were used for treatment of asthma)
Starting date Trial registered: 19/03/2013.
Contact information Associate ProfessorVickiClifton:TheRobinson Institute, TheUniversity of Adelaide, LyellMcEwinHospital,
Haydown Road, Elizabeth Vale, South Australia 5112, Australia
+61 8 8133 2133
vicki.clifton@adelaide.edu.au
Notes Target sample size: 104.
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ACTRN12613000800729
Trial name or title Management of Asthma with Supportive Telehealth of Respiratory function in Pregnancy (MASTERY)
Methods Randomised controlled trial.
Participants Inclusion criteria: pregnant women aged 18 years and older who can communicate in English. Women will
be included if they have asthma and used any asthma medications in 12 months before pregnancy and/or
during their current pregnancy
Exclusion criteria: women with asthma who are unable to communicate in English or cannot use a smart
mobile phone (iPhone or Android)
Interventions Intervention group
Women will be provided with a COPD-6 and a specifically designed Breathe-easy application installed on
their mobile phone. They will be asked to measure their lung function using the COPD-6 device twice daily
and to record their asthma symptoms and medication usage in Breathe-easy. The lung function data will be
transmitted to a central server and reviewed by the researcher daily. The data will also be sent to participants’
general practitioners. Women and the research team will have secure access to the online portal. Any clinically
significant reduction in lung function will be brought to the attention of the participants’ general practitioners
in order for them to determine if any medication changes or unscheduled visit related to asthma are needed.
The total duration of the intervention will be 7 to 9 months depending on when the participants had their
first antenatal visit
Control group
The control group will receive usual medical care provided by the antenatal clinics and/or their health
professionals
Outcomes Primary outcome: asthma control as measured by Juniper’s ACQ.
Secondary outcomes: quality of life on Juniper’s Mini Asthma Quality of Life Scale; asthma-related health
visits; preventer to reliever use ratio; asthma-related days off work/study; gestational age at birth; develop-
ment of antenatal complications, such as hypertensive disorders of pregnancy, antepartum haemorrhage and
gestational diabetes; birthweight; Apgar scores
Starting date 12/08/2013.
Contact information Dr Johnson George: Centre for Medicine Use and Safety Faculty of Pharmacy and Pharmaceutical Sciencesm
Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
+61 3 9903 9178
Johnson.George@monash.edu
Notes Target sample size: 70.
NCT01345396
Trial name or title Influence of an Asthma Education Programme on Asthma Control During Pregnancy
Methods Randomised controlled trial.
Participants Inclusion criteria: pregnant woman; less than 20 weeks of gestation; diagnosis of asthma before the pregnancy
(clinical history and specific medications used); agreement to enter into the study
Exclusion criteria: pregnant woman (more than 20 weeks of gestation at the inclusion time); history of major
respiratory problems during previous pregnancy; refusal to enter into the study
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NCT01345396 (Continued)
Interventions Intervention group (health education about asthma)
Women will receive 3 face-to-face appointments (at less than 20, 36 weeks’ gestation, and 12 weeks after
birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
Control group
Women will receive no education.
Outcomes Primary outcome: level of asthma control (ACQ).
Secondary outcomes: number of unscheduled visits to the doctor for asthma; quality of life; knowledge
about asthma
Starting date 02/2010.
Contact information Professor Vincent Ninane: Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium
Notes Target sample size: 80.
ACQ: Asthma Control Questionnaire
FENO: fraction of exhaled nitric oxide
FEV1: forced expired volume in one second
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D A T A A N D A N A L Y S E S
Comparison 1. Inhaled magnesium sulphate versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Asthma exacerbations
(”frequency of acute asthma
exacerbation till delivery”)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 Lung function (FEV1 (%)) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3 Lung function (FVC (%)) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Lung function (FEV1/FVC (%)) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5 Lung function (FEF25%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6 Lung function (FEF75%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7 PEF (%) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8 Caesarean birth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. Intravenous theophylline versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Discontinuation of intervention
due to adverse effects
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Stillbirth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Neonatal death 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4 Preterm birth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5 Length of hospitalisation for the
mother (days)
Other data No numeric data
Comparison 3. Inhaled corticosteroid versus control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Asthma exacerbations 1 60 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.13, 1.05]
1.1 Beclomethasone (four
puffs, twice daily)
1 60 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.13, 1.05]
2 Caesarean birth 2 314 Risk Ratio (M-H, Random, 95% CI) 1.65 [0.57, 4.79]
2.1 Beclomethasone (1 mg
daily)
1 95 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.75, 1.62]
2.2 Budesonide (400 µg daily) 1 219 Risk Ratio (M-H, Random, 95% CI) 3.15 [1.04, 9.60]
3 Adherence with intervention 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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3.1 Beclomethasone (four
puffs, twice daily)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.94, 1.07]
4 Induced abortion 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Budesonide (400 µg daily) 1 219 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.15, 2.24]
5 Spontaneous abortion 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Budesonide (400 µg daily) 1 219 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.75, 3.25]
6 Stillbirth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Beclomethasone (four
puffs, twice daily)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Neonatal death 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Beclomethasone (four
puffs, twice daily)
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Preterm birth 2 314 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.43, 1.63]
8.1 Beclomethasone (1 mg
daily)
1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.41, 2.16]
8.2 Budesonide (400 µg daily) 1 219 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.24, 2.12]
9 Birthweight (g) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Beclomethasone (1 mg
daily)
1 95 Mean Difference (IV, Fixed, 95% CI) -34.0 [-290.17, 222.
17]
10 Apgar score less than seven 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Beclomethasone (1
mg/day)
1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.06, 14.57]
11 Congenital malformation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Budesonide (400 µg/day) 1 219 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.03, 2.52]
12 ”Obstetric complications” 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Beclomethasone (1 mg
daily)
1 95 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.40, 1.59]
13 ”Perinatal complications” 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Beclomethasone (1 mg
daily)
1 95 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.71, 2.81]
14 ”Healthy children delivered” 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Budesonide (400 µg
daily)
1 219 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.86, 1.15]
15 ”Other adverse outcomes” 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 Budesonide (400 µg
daily)
1 219 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.13, 4.49]
Comparison 4. Inhaled corticosteroid versus oral theophylline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Asthma exacerbations 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Asthmatic symptoms at delivery 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Asthmatic symptoms (nocturnal) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Asthmamedication requirements
(rescue oral corticosteroids for
exacerbation)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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5 Asthmamedication requirements
(albuterol puffs per day)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6 Lung function (proportion of
study visits with FEV1 < 80%
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7 Lung function (proportion of
study visits with PEFR < 80%
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8 Pre-eclampsia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9 Caesarean birth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10 Postpartum haemorrhage
(blood loss > 500 mL for
vaginal birth and > 1 L for
caesarean)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11 Chorioamnionitis 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12 Adverse effects attributed to
intervention
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Nausea 1 385 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.11, 1.00]
12.2 Nervousness 1 385 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.07, 1.61]
12.3 Insomnia 1 385 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.00, 1.61]
12.4 Tremor 1 385 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.03, 2.18]
12.5 Palpitations 1 385 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.11, 3.88]
12.6 Heartburn 1 385 Risk Ratio (M-H, Fixed, 95% CI) 2.95 [0.12, 72.06]
13Discontinuation of intervention
due to adverse effects
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14 Adherence with intervention
(self-reported compliance)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
15 Adherence with intervention
(measured compliance)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
16 Perinatal death 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17 Gestational age at birth (weeks) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18 Preterm birth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19 Birthweight (g) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
20 Low birthweight (< 2500 g) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
21 Small-for-gestational age 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
22 Neonatal sepsis (discharge
diagnosis of sepsis)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
23 Congenital malformation
(major)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
24 Antenatal admissions to
hospital for the mother
(associated with exacerbation)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
25 Emergency department visits
for the mother (associated with
exacerbation)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Comparison 5. FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Asthma exacerbations 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Admission to neonatal intensive
care unit or special care nursery
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Asthmatic symptoms (ACQ
score)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Asthmatic symptoms
(symptom-free days)
Other data No numeric data
5 Asthmamedication requirements
(inhaled corticosteroids)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6 Asthmamedication requirements
(long-acting β2-agonists)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7 Asthmamedication requirements Other data No numeric data
8 Lung function Other data No numeric data
9 Quality of life Other data No numeric data
10 Pregnancy-induced
hypertension
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11 Pre-eclampsia 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12 Gestational diabetes 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13 Caesarean birth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Elective 1 210 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.42, 1.63]
13.2 Non-elective 1 210 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.36, 1.55]
14 Antepartum haemorrhage 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15 Postpartum haemorrhage 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16 Ruptured membranes 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17 Hyperemesis 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18 Termination of pregnancy 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19 Stillbirth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20 Gestational age at birth (weeks) Other data No numeric data
21 Preterm birth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
22 Birthweight (g) Other data No numeric data
23 Low birthweight (< 2500 g) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
24 Small-for-gestational age 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
25 Jaundice 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
26 Congenital malformation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
27 Bronchiolitis (multiple versus
one or no episodes)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
28 Croup (multiple versus one or
no episodes)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Comparison 6. Pharmacist-ledmulti-disciplinary approach tomanagement of maternal asthma (MAMMA) versus
standard care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Asthma exacerbations 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Admission to neonatal intensive
care unit or special care nursery
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Asthmatic symptoms (ACQ
score)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 3 months 1 58 Mean Difference (IV, Fixed, 95% CI) -0.17 [-0.54, 0.20]
3.2 6 months 1 58 Mean Difference (IV, Fixed, 95% CI) -0.56 [-0.83, -0.29]
3.3 3 months - baseline 1 58 Mean Difference (IV, Fixed, 95% CI) -0.31 [-0.76, 0.14]
3.4 6 months - baseline 1 58 Mean Difference (IV, Fixed, 95% CI) -0.71 [-1.15, -0.27]
4 Asthmatic symptoms (ACQ
score)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 ACQ score < 1.5
(adequately controlled asthma)
1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.44 [1.12, 1.84]
5 Asthmamedication requirements
(oral corticosteroids)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6 Asthma-related days off work 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7 Hypertension during pregnancy 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8 Gestational diabetes 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9 Caesarean birth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10 Gestational age at birth (weeks) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11 Preterm birth 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12 Birthweight (g) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13 Small-for-gestational age 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14 Apgar score 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 1 minute 1 58 Mean Difference (IV, Fixed, 95% CI) 0.70 [-0.04, 1.44]
14.2 5 minute 1 58 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.07, 0.67]
15 Congenital malformation 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16 Asthma-related hospital
admissions
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17 Asthma-related emergency
visits
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 7. Progressive muscle relaxation (PMR) versus sham training
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Lung function (FEV1 (L)) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 Lung function (PEFR
(L/minute))
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3 Quality of life (STAXI scores) 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 State-Anger 1 64 Mean Difference (IV, Fixed, 95% CI) -3.90 [-5.64, -2.16]
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3.2 Trait-Anger 1 64 Mean Difference (IV, Fixed, 95% CI) -5.60 [-7.42, -3.78]
3.3 Anger-In 1 64 Mean Difference (IV, Fixed, 95% CI) -1.10 [-2.82, 0.62]
3.4 Anger-Out 1 64 Mean Difference (IV, Fixed, 95% CI) -2.0 [-4.55, 0.55]
3.5 Anger-Control 1 64 Mean Difference (IV, Fixed, 95% CI) 0.5 [-1.75, 2.75]
4 Quality of life (SF-36 health
survey scores)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Physical functioning 1 64 Mean Difference (IV, Fixed, 95% CI) 1.5 [-1.23, 4.23]
4.2 Role physical 1 64 Mean Difference (IV, Fixed, 95% CI) 7.0 [3.88, 10.12]
4.3 Bodily pain 1 64 Mean Difference (IV, Fixed, 95% CI) 3.10 [-1.46, 7.66]
4.4 General health perceptions 1 64 Mean Difference (IV, Fixed, 95% CI) 4.30 [-0.24, 8.84]
4.5 Vitality 1 64 Mean Difference (IV, Fixed, 95% CI) 7.70 [3.67, 11.73]
4.6 Social functioning 1 64 Mean Difference (IV, Fixed, 95% CI) 12.80 [8.50, 17.10]
4.7 Role emotional 1 64 Mean Difference (IV, Fixed, 95% CI) 12.20 [8.09, 16.31]
4.8 Mental health 1 64 Mean Difference (IV, Fixed, 95% CI) 6.10 [1.84, 10.36]
Analysis 1.1. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 1 Asthma exacerbations
(“frequency of acute asthma exacerbation till delivery”).
Review: Interventions for managing asthma in pregnancy
Comparison: 1 Inhaled magnesium sulphate versus control
Outcome: 1 Asthma exacerbations (”frequency of acute asthma exacerbation till delivery”)
Study or subgroup Magnesium sulphate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Badawy 2012 30 0.4 (0.57) 30 3.2 (0.98) -2.80 [ -3.21, -2.39 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours magnesium Favours no magnesium
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Analysis 1.2. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 2 Lung function (FEV1
(%)).
Review: Interventions for managing asthma in pregnancy
Comparison: 1 Inhaled magnesium sulphate versus control
Outcome: 2 Lung function (FEV1 (%))
Study or subgroup Magnesium sulphate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Badawy 2012 30 56.31 (8.25) 30 32.68 (7.15) 23.63 [ 19.72, 27.54 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-50 -25 0 25 50
Favours no magnesium Favours magnesium
Analysis 1.3. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 3 Lung function (FVC
(%)).
Review: Interventions for managing asthma in pregnancy
Comparison: 1 Inhaled magnesium sulphate versus control
Outcome: 3 Lung function (FVC (%))
Study or subgroup Magnesium sulphate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Badawy 2012 30 84.2 (12.75) 30 67.57 (11.67) 16.63 [ 10.44, 22.82 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-100 -50 0 50 100
Favours no magnesium Favours magnesium
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Analysis 1.4. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 4 Lung function
(FEV1/FVC (%)).
Review: Interventions for managing asthma in pregnancy
Comparison: 1 Inhaled magnesium sulphate versus control
Outcome: 4 Lung function (FEV1/FVC (%))
Study or subgroup Magnesium sulphate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Badawy 2012 30 67.74 (10.67) 30 48.32 (8.6) 19.42 [ 14.52, 24.32 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-100 -50 0 50 100
Favours no magnesium Favours magnesium
Analysis 1.5. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 5 Lung function
(FEF25%).
Review: Interventions for managing asthma in pregnancy
Comparison: 1 Inhaled magnesium sulphate versus control
Outcome: 5 Lung function (FEF25%)
Study or subgroup Magnesium sulphate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Badawy 2012 30 41.22 (6.99) 30 29.57 (7.19) 11.65 [ 8.06, 15.24 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-100 -50 0 50 100
Favours no magnesium Favours magnesium
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Analysis 1.6. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 6 Lung function
(FEF75%).
Review: Interventions for managing asthma in pregnancy
Comparison: 1 Inhaled magnesium sulphate versus control
Outcome: 6 Lung function (FEF75%)
Study or subgroup Magnesium sulphate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Badawy 2012 30 46.41 (6.78) 30 33.49 (8.91) 12.92 [ 8.91, 16.93 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-100 -50 0 50 100
Favours no magnesium Favours magnesium
Analysis 1.7. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 7 PEF (%).
Review: Interventions for managing asthma in pregnancy
Comparison: 1 Inhaled magnesium sulphate versus control
Outcome: 7 PEF (%)
Study or subgroup Magnesium sulphate Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Badawy 2012 30 54.2 (11.09) 30 36.17 (10.8) 18.03 [ 12.49, 23.57 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-100 -50 0 50 100
Favours no magnesium Favours magnesium
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Analysis 1.8. Comparison 1 Inhaled magnesium sulphate versus control, Outcome 8 Caesarean birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 1 Inhaled magnesium sulphate versus control
Outcome: 8 Caesarean birth
Study or subgroup Magnesium sulphate Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Badawy 2012 10/30 12/30 0.83 [ 0.43, 1.63 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 10 (Magnesium sulphate), 12 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours magnesium Favours no magnesium
Analysis 2.1. Comparison 2 Intravenous theophylline versus control, Outcome 1 Discontinuation of
intervention due to adverse effects.
Review: Interventions for managing asthma in pregnancy
Comparison: 2 Intravenous theophylline versus control
Outcome: 1 Discontinuation of intervention due to adverse effects
Study or subgroup Favours theophylline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wendel 1996 (1) 3/33 0/32 6.79 [ 0.36, 126.50 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (Favours theophylline), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours theophylline Favours control
(1) Nervousness, vomiting, or insomnia with therapeutic serum levels
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Analysis 2.2. Comparison 2 Intravenous theophylline versus control, Outcome 2 Stillbirth.
Review: Interventions for managing asthma in pregnancy
Comparison: 2 Intravenous theophylline versus control
Outcome: 2 Stillbirth
Study or subgroup Theophylline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wendel 1996 0/33 0/32 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Theophylline), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours theophylline Favours control
Analysis 2.3. Comparison 2 Intravenous theophylline versus control, Outcome 3 Neonatal death.
Review: Interventions for managing asthma in pregnancy
Comparison: 2 Intravenous theophylline versus control
Outcome: 3 Neonatal death
Study or subgroup Theophylline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wendel 1996 0/33 0/32 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Theophylline), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours theophylline Favours control
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Analysis 2.4. Comparison 2 Intravenous theophylline versus control, Outcome 4 Preterm birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 2 Intravenous theophylline versus control
Outcome: 4 Preterm birth
Study or subgroup Theophylline Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Wendel 1996 0/33 0/32 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (Theophylline), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours theophylline Favours control
Analysis 2.5. Comparison 2 Intravenous theophylline versus control, Outcome 5 Length of hospitalisation
for the mother (days).
Length of hospitalisation for the mother (days)
Study Theophylline Control
Wendel 1996 3.2 2.7
69Interventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 Inhaled corticosteroid versus control, Outcome 1 Asthma exacerbations.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 1 Asthma exacerbations
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beclomethasone (four puffs, twice daily)
Wendel 1996 4/33 9/27 100.0 % 0.36 [ 0.13, 1.05 ]
Total (95% CI) 33 27 100.0 % 0.36 [ 0.13, 1.05 ]
Total events: 4 (Inhaled corticosteroid), 9 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.062)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours corticosteroid Favours no corticosteroid
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Analysis 3.2. Comparison 3 Inhaled corticosteroid versus control, Outcome 2 Caesarean birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 2 Caesarean birth
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Beclomethasone (1 mg daily)
Caramez 1998 27/49 23/46 61.4 % 1.10 [ 0.75, 1.62 ]
Subtotal (95% CI) 49 46 61.4 % 1.10 [ 0.75, 1.62 ]
Total events: 27 (Inhaled corticosteroid), 23 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
2 Budesonide (400 g daily)
Silverman 2005 11/102 4/117 38.6 % 3.15 [ 1.04, 9.60 ]
Subtotal (95% CI) 102 117 38.6 % 3.15 [ 1.04, 9.60 ]
Total events: 11 (Inhaled corticosteroid), 4 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
Total (95% CI) 151 163 100.0 % 1.65 [ 0.57, 4.79 ]
Total events: 38 (Inhaled corticosteroid), 27 (No corticosteroid)
Heterogeneity: Tau2 = 0.44; Chi2 = 3.44, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi2 = 3.06, df = 1 (P = 0.08), I2 =67%
0.05 0.2 1 5 20
Favours corticosteroid Favours no corticosteroid
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Analysis 3.3. Comparison 3 Inhaled corticosteroid versus control, Outcome 3 Adherence with intervention.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 3 Adherence with intervention
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beclomethasone (four puffs, twice daily)
Wendel 1996 33/33 27/27 100.0 % 1.00 [ 0.94, 1.07 ]
Subtotal (95% CI) 33 27 100.0 % 1.00 [ 0.94, 1.07 ]
Total events: 33 (Inhaled corticosteroid), 27 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
0.5 0.7 1 1.5 2
Favours corticosteroid Favours no corticosteroid
Analysis 3.4. Comparison 3 Inhaled corticosteroid versus control, Outcome 4 Induced abortion.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 4 Induced abortion
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide (400 g daily)
Silverman 2005 3/102 6/117 100.0 % 0.57 [ 0.15, 2.24 ]
Subtotal (95% CI) 102 117 100.0 % 0.57 [ 0.15, 2.24 ]
Total events: 3 (Inhaled corticosteroid), 6 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
0.002 0.1 1 10 500
Favours corticosteroid Favours no corticosteroid
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Analysis 3.5. Comparison 3 Inhaled corticosteroid versus control, Outcome 5 Spontaneous abortion.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 5 Spontaneous abortion
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide (400 g daily)
Silverman 2005 15/102 11/117 100.0 % 1.56 [ 0.75, 3.25 ]
Subtotal (95% CI) 102 117 100.0 % 1.56 [ 0.75, 3.25 ]
Total events: 15 (Inhaled corticosteroid), 11 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
Analysis 3.6. Comparison 3 Inhaled corticosteroid versus control, Outcome 6 Stillbirth.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 6 Stillbirth
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beclomethasone (four puffs, twice daily)
Wendel 1996 0/33 0/27 Not estimable
Subtotal (95% CI) 33 27 Not estimable
Total events: 0 (Inhaled corticosteroid), 0 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
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Analysis 3.7. Comparison 3 Inhaled corticosteroid versus control, Outcome 7 Neonatal death.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 7 Neonatal death
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beclomethasone (four puffs, twice daily)
Wendel 1996 0/33 0/27 Not estimable
Subtotal (95% CI) 33 27 Not estimable
Total events: 0 (Inhaled corticosteroid), 0 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
Analysis 3.8. Comparison 3 Inhaled corticosteroid versus control, Outcome 8 Preterm birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 8 Preterm birth
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beclomethasone (1 mg daily)
Caramez 1998 9/49 9/46 55.5 % 0.94 [ 0.41, 2.16 ]
Subtotal (95% CI) 49 46 55.5 % 0.94 [ 0.41, 2.16 ]
Total events: 9 (Inhaled corticosteroid), 9 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Budesonide (400 g daily)
Silverman 2005 5/102 8/117 44.5 % 0.72 [ 0.24, 2.12 ]
Subtotal (95% CI) 102 117 44.5 % 0.72 [ 0.24, 2.12 ]
Total events: 5 (Inhaled corticosteroid), 8 (No corticosteroid)
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
(Continued . . . )
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(. . . Continued)
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI) 151 163 100.0 % 0.84 [ 0.43, 1.63 ]
Total events: 14 (Inhaled corticosteroid), 17 (No corticosteroid)
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
Analysis 3.9. Comparison 3 Inhaled corticosteroid versus control, Outcome 9 Birthweight (g).
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 9 Birthweight (g)
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Beclomethasone (1 mg daily)
Caramez 1998 49 3015 (560) 46 3049 (701) 100.0 % -34.00 [ -290.17, 222.17 ]
Subtotal (95% CI) 49 46 100.0 % -34.00 [ -290.17, 222.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
-1000 -500 0 500 1000
Favours corticosteroid Favours no corticosteroid
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Analysis 3.10. Comparison 3 Inhaled corticosteroid versus control, Outcome 10 Apgar score less than seven.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 10 Apgar score less than seven
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beclomethasone (1 mg/day)
Caramez 1998 1/49 1/46 100.0 % 0.94 [ 0.06, 14.57 ]
Subtotal (95% CI) 49 46 100.0 % 0.94 [ 0.06, 14.57 ]
Total events: 1 (Inhaled corticosteroid), 1 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
Analysis 3.11. Comparison 3 Inhaled corticosteroid versus control, Outcome 11 Congenital malformation.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 11 Congenital malformation
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide (400 g/day)
Silverman 2005 1/102 4/117 100.0 % 0.29 [ 0.03, 2.52 ]
Subtotal (95% CI) 102 117 100.0 % 0.29 [ 0.03, 2.52 ]
Total events: 1 (Inhaled corticosteroid), 4 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
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Analysis 3.12. Comparison 3 Inhaled corticosteroid versus control, Outcome 12 “Obstetric complications”.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 12 ”Obstetric complications”
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beclomethasone (1 mg daily)
Caramez 1998 11/49 13/46 100.0 % 0.79 [ 0.40, 1.59 ]
Subtotal (95% CI) 49 46 100.0 % 0.79 [ 0.40, 1.59 ]
Total events: 11 (Inhaled corticosteroid), 13 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
Analysis 3.13. Comparison 3 Inhaled corticosteroid versus control, Outcome 13 “Perinatal complications”.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 13 ”Perinatal complications”
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Beclomethasone (1 mg daily)
Caramez 1998 15/49 10/46 100.0 % 1.41 [ 0.71, 2.81 ]
Subtotal (95% CI) 49 46 100.0 % 1.41 [ 0.71, 2.81 ]
Total events: 15 (Inhaled corticosteroid), 10 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 3.14. Comparison 3 Inhaled corticosteroid versus control, Outcome 14 “Healthy children
delivered”.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 14 ”Healthy children delivered”
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide (400 g daily)
Silverman 2005 78/102 90/117 100.0 % 0.99 [ 0.86, 1.15 ]
Subtotal (95% CI) 102 117 100.0 % 0.99 [ 0.86, 1.15 ]
Total events: 78 (Inhaled corticosteroid), 90 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
0.5 0.7 1 1.5 2
Favours corticosteroid Favours no corticosteroid
Analysis 3.15. Comparison 3 Inhaled corticosteroid versus control, Outcome 15 “Other adverse outcomes”.
Review: Interventions for managing asthma in pregnancy
Comparison: 3 Inhaled corticosteroid versus control
Outcome: 15 ”Other adverse outcomes”
Study or subgroup
Inhaled
corticos-
teroid No corticosteroid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Budesonide (400 g daily)
Silverman 2005 (1) 2/102 3/117 100.0 % 0.76 [ 0.13, 4.49 ]
Subtotal (95% CI) 102 117 100.0 % 0.76 [ 0.13, 4.49 ]
Total events: 2 (Inhaled corticosteroid), 3 (No corticosteroid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
0.01 0.1 1 10 100
Favours corticosteroid Favours no corticosteroid
(1) ”Other adverse outcomes” in corticosteroid group: 1 molar pregnancy; 1 premature separation of the uterus with intrauterine necrosis. ”Other adverse outcomes”
in control group: 1 molar pregnancy; 1 hepatitis in mother (child died); 1 preterm delivery where child died after 3 months due to intestinal complications in nursery.
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Analysis 4.1. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 1 Asthma
exacerbations.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 1 Asthma exacerbations
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 35/194 39/191 0.88 [ 0.59, 1.33 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 35 (Corticosteroid), 39 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.2 0.5 1 2 5
Favours corticosteroid Favours theophylline
Analysis 4.2. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 2 Asthmatic
symptoms at delivery.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 2 Asthmatic symptoms at delivery
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 36/192 32/186 1.09 [ 0.71, 1.68 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 36 (Corticosteroid), 32 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 4.3. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 3 Asthmatic
symptoms (nocturnal).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 3 Asthmatic symptoms (nocturnal)
Study or subgroup Corticosteroid Theophylline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dombrowski 2004 194 0.138 (0.192) 191 0.16 (0.229) -0.02 [ -0.07, 0.02 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-0.2 -0.1 0 0.1 0.2
Favours corticosteroid Favours theophylline
Analysis 4.4. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 4 Asthma medication
requirements (rescue oral corticosteroids for exacerbation).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 4 Asthma medication requirements (rescue oral corticosteroids for exacerbation)
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 16/194 21/191 0.75 [ 0.40, 1.39 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 16 (Corticosteroid), 21 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroid Favours theophylline
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Analysis 4.5. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 5 Asthma medication
requirements (albuterol puffs per day).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 5 Asthma medication requirements (albuterol puffs per day)
Study or subgroup Corticosteroid Theophylline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dombrowski 2004 194 1.4 (2.1) 191 1.5 (2.3) -0.10 [ -0.54, 0.34 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-2 -1 0 1 2
Favours corticosteroid Favours theophylline
Analysis 4.6. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 6 Lung function
(proportion of study visits with FEV1 < 80% predicted).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 6 Lung function (proportion of study visits with FEV1 < 80% predicted)
Study or subgroup Corticosteroid Theophylline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dombrowski 2004 194 0.231 (0.334) 191 0.28 (0.331) -0.05 [ -0.12, 0.01 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-0.5 -0.25 0 0.25 0.5
Favours corticosteroid Favours theophylline
81Interventions for managing asthma in pregnancy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.7. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 7 Lung function
(proportion of study visits with PEFR < 80% predicted).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 7 Lung function (proportion of study visits with PEFR < 80% predicted)
Study or subgroup Corticosteroid Theophylline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dombrowski 2004 194 0.179 (0.283) 191 0.21 (0.3) -0.04 [ -0.09, 0.02 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-0.2 -0.1 0 0.1 0.2
Favours corticosteroid Favours theophylline
Analysis 4.8. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 8 Pre-eclampsia.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 8 Pre-eclampsia
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 16/194 15/190 1.04 [ 0.53, 2.05 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 16 (Corticosteroid), 15 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 4.9. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 9 Caesarean birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 9 Caesarean birth
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 30/194 29/190 1.01 [ 0.63, 1.62 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 30 (Corticosteroid), 29 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroid Favours theophylline
Analysis 4.10. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 10 Postpartum
haemorrhage (blood loss > 500 mL for vaginal birth and > 1 L for caesarean).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 10 Postpartum haemorrhage (blood loss > 500 mL for vaginal birth and > 1 L for caesarean)
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 12/181 10/177 1.17 [ 0.52, 2.65 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (Corticosteroid), 10 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
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Analysis 4.11. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 11 Chorioamnionitis.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 11 Chorioamnionitis
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 10/194 10/190 0.98 [ 0.42, 2.30 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 10 (Corticosteroid), 10 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroid Favours theophylline
Analysis 4.12. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 12 Adverse effects
attributed to intervention.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 12 Adverse effects attributed to intervention
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Dombrowski 2004 4/194 12/191 100.0 % 0.33 [ 0.11, 1.00 ]
Subtotal (95% CI) 194 191 100.0 % 0.33 [ 0.11, 1.00 ]
Total events: 4 (Corticosteroid), 12 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
2 Nervousness
Dombrowski 2004 2/194 6/191 100.0 % 0.33 [ 0.07, 1.61 ]
Subtotal (95% CI) 194 191 100.0 % 0.33 [ 0.07, 1.61 ]
Total events: 2 (Corticosteroid), 6 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
3 Insomnia
0.001 0.01 0.1 1 10 100 1000
Favours corticosteroid Favours theophylline
(Continued . . . )
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(. . . Continued)
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 0/194 5/191 100.0 % 0.09 [ 0.00, 1.61 ]
Subtotal (95% CI) 194 191 100.0 % 0.09 [ 0.00, 1.61 ]
Total events: 0 (Corticosteroid), 5 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
4 Tremor
Dombrowski 2004 1/194 4/191 100.0 % 0.25 [ 0.03, 2.18 ]
Subtotal (95% CI) 194 191 100.0 % 0.25 [ 0.03, 2.18 ]
Total events: 1 (Corticosteroid), 4 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
5 Palpitations
Dombrowski 2004 2/194 3/191 100.0 % 0.66 [ 0.11, 3.88 ]
Subtotal (95% CI) 194 191 100.0 % 0.66 [ 0.11, 3.88 ]
Total events: 2 (Corticosteroid), 3 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
6 Heartburn
Dombrowski 2004 1/194 0/191 100.0 % 2.95 [ 0.12, 72.06 ]
Subtotal (95% CI) 194 191 100.0 % 2.95 [ 0.12, 72.06 ]
Total events: 1 (Corticosteroid), 0 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 4.13. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 13 Discontinuation
of intervention due to adverse effects.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 13 Discontinuation of intervention due to adverse effects
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 6/194 17/190 0.35 [ 0.14, 0.86 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 6 (Corticosteroid), 17 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroid Favours theophylline
Analysis 4.14. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 14 Adherence with
intervention (self-reported compliance).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 14 Adherence with intervention (self-reported compliance)
Study or subgroup Corticosteroid Theophylline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dombrowski 2004 194 0.691 (0.332) 191 0.68 (0.349) 0.01 [ -0.06, 0.08 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 4.15. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 15 Adherence with
intervention (measured compliance).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 15 Adherence with intervention (measured compliance)
Study or subgroup Corticosteroid Theophylline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dombrowski 2004 190 0.271 (0.281) 132 0.36 (0.348) -0.08 [ -0.16, -0.01 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-0.2 -0.1 0 0.1 0.2
Favours thephylline Favours corticosteroid
Analysis 4.16. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 16 Perinatal death.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 16 Perinatal death
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 3/184 4/190 0.77 [ 0.18, 3.41 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (Corticosteroid), 4 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 4.17. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 17 Gestational age
at birth (weeks).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 17 Gestational age at birth (weeks)
Study or subgroup Corticosteroid Theophylline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dombrowski 2004 194 38.1 (3.5) 190 38.2 (3.8) -0.10 [ -0.83, 0.63 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-2 -1 0 1 2
Favours corticosteroid Favours theophylline
Analysis 4.18. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 18 Preterm birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 18 Preterm birth
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 40/194 31/190 1.26 [ 0.83, 1.93 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 40 (Corticosteroid), 31 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 4.19. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 19 Birthweight (g).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 19 Birthweight (g)
Study or subgroup Corticosteroid Theophylline
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Dombrowski 2004 194 3079 (715) 190 3063 (727) 16.00 [ -128.25, 160.25 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 4.20. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 20 Low birthweight
(< 2500 g).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 20 Low birthweight (< 2500 g)
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 (1) 14/153 14/157 1.03 [ 0.51, 2.08 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 14 (Corticosteroid), 14 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroid Favours theophylline
(1) These data are taken from Schatz et al. 2010 which includes the 310 women who had quality of life assessments.
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Analysis 4.21. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 21 Small-for-
gestational age.
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 21 Small-for-gestational age
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 (1) 10/153 10/157 1.03 [ 0.44, 2.40 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 10 (Corticosteroid), 10 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroid Favours theophylline
(1) These data are taken from Schatz et al. 2010 which includes the 310 women who had quality of life assessments
Analysis 4.22. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 22 Neonatal sepsis
(discharge diagnosis of sepsis).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 22 Neonatal sepsis (discharge diagnosis of sepsis)
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 5/191 7/186 0.70 [ 0.22, 2.15 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (Corticosteroid), 7 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
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Analysis 4.23. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 23 Congenital
malformation (major).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 23 Congenital malformation (major)
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 6/193 5/189 1.18 [ 0.36, 3.79 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 6 (Corticosteroid), 5 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroid Favours theophylline
Analysis 4.24. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 24 Antenatal
admissions to hospital for the mother (associated with exacerbation).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 24 Antenatal admissions to hospital for the mother (associated with exacerbation)
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 10/194 15/191 0.66 [ 0.30, 1.42 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 10 (Corticosteroid), 15 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroid Favours theophylline
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Analysis 4.25. Comparison 4 Inhaled corticosteroid versus oral theophylline, Outcome 25 Emergency
department visits for the mother (associated with exacerbation).
Review: Interventions for managing asthma in pregnancy
Comparison: 4 Inhaled corticosteroid versus oral theophylline
Outcome: 25 Emergency department visits for the mother (associated with exacerbation)
Study or subgroup Corticosteroid Theophylline Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dombrowski 2004 30/194 36/191 0.82 [ 0.53, 1.28 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 30 (Corticosteroid), 36 (Theophylline)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours corticosteroid Favours theophylline
Analysis 5.1. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 1 Asthma exacerbations.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 1 Asthma exacerbations
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 28/111 45/109 0.61 [ 0.41, 0.90 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 28 (FENO algorithm), 45 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 5.2. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 2 Admission to neonatal intensive care unit or special care nursery.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 2 Admission to neonatal intensive care unit or special care nursery
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 8/105 18/109 0.46 [ 0.21, 1.02 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (FENO algorithm), 18 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.005 0.1 1 10 200
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Analysis 5.3. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 3 Asthmatic symptoms (ACQ score).
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 3 Asthmatic symptoms (ACQ score)
Study or subgroup FENO algorithm
Clinical
guideline
algorithm
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Powell 2011 111 0.56 (0.67) 109 0.72 (0.8) -0.16 [ -0.36, 0.04 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-0.5 -0.25 0 0.25 0.5
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 5.4. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 4 Asthmatic symptoms (symptom-free days).
Asthmatic symptoms (symptom-free days)
Study Asthma symptoms at end
of study
FENO group (n = 111) Control group (n = 109) P value
Powell 2011 Symptom-free days (past
week)
Median: 7
IQR: 4 to 7
Median: 6
IQR: 2 to 7
0.058
Analysis 5.5. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 5 Asthma medication requirements (inhaled corticosteroids).
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 5 Asthma medication requirements (inhaled corticosteroids)
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 76/111 46/109 1.62 [ 1.26, 2.09 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 76 (FENO algorithm), 46 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Clinical guideline algorithm FENO algorithm
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Analysis 5.6. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 6 Asthma medication requirements (long-acting β2-agonists).
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 6 Asthma medication requirements (long-acting 2-agonists)
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 45/111 19/109 2.33 [ 1.46, 3.71 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 45 (FENO algorithm), 19 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Clinical guideline algorithm FENO algorithm
Analysis 5.7. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 7 Asthma medication requirements.
Asthma medication requirements
Study Current treatment at end
of study
FENO group (n = 111) Control group (n = 109) P value
Powell 2011 Short-actingβ2-agonist use
in past week (days)
Median: 0
IQR: 0 to 3
Median: 1
IQR: 0 to 5
0.024
Powell 2011 Beclometasone dipro-
pionate equivalent ICSdose
(µg/day)
Median: 200
IQR: 0 to 400
Median: 0
IQR: 0 to 800
0.079
Analysis 5.8. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 8 Lung function.
Lung function
Study Lung function at end of
study
FENO group (n = 111) Control group (n = 109) P value
Powell 2011 FENO (ppb) Median: 10.55
IQR: 5.95 to 19.3
Median: 11.0
IQR: 5.9 to 21.4
0.732
Powell 2011 FEV1 (L) Mean: 3.09
95% CI: 3.0 to 3.17
Mean: 3.01
95% CI: 2.91 to 3.10
0.221
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Lung function (Continued)
Powell 2011 FEV1 (%) Mean: 96.4
95% CI: 94.31 to 98.46
Mean: 94.4
95% CI: 91.84 to 96.96
0.235
Analysis 5.9. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 9 Quality of life.
Quality of life
Study Health-related quality of
life at end of study
FENO group (n = 111) Control group (n = 109) P value
Powell 2011 SF12 physical summary
(low = 0, high = 100)
Median: 47.7
IQR: 40.8 to 52.0
Median: 46.9
IQR: 38.2 to 51.8
0.89
Powell 2011 SF12mental summary (low
= 0, high = 100)
Median: 56.9
IQR: 50.2 to 59.3
Median: 54.2
IQR: 46.1 to 57.6
0.037
Powell 2011 AQLQ-M: total score
(good = 0, poor = 10)
Median: 0.75
IQR: 0.38 to 1.25
Median: 0.81
IQR: 0.38 to 1.63
0.54
Analysis 5.10. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 10 Pregnancy-induced hypertension.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 10 Pregnancy-induced hypertension
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 7/104 11/106 0.65 [ 0.26, 1.61 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 7 (FENO algorithm), 11 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 5.11. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 11 Pre-eclampsia.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 11 Pre-eclampsia
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 3/104 5/106 0.61 [ 0.15, 2.49 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (FENO algorithm), 5 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
Analysis 5.12. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 12 Gestational diabetes.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 12 Gestational diabetes
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 8/104 11/106 0.74 [ 0.31, 1.77 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (FENO algorithm), 11 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 5.13. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 13 Caesarean birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 13 Caesarean birth
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Elective
Powell 2011 13/104 16/106 100.0 % 0.83 [ 0.42, 1.63 ]
Subtotal (95% CI) 104 106 100.0 % 0.83 [ 0.42, 1.63 ]
Total events: 13 (FENO algorithm), 16 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
2 Non-elective
Powell 2011 11/104 15/106 100.0 % 0.75 [ 0.36, 1.55 ]
Subtotal (95% CI) 104 106 100.0 % 0.75 [ 0.36, 1.55 ]
Total events: 11 (FENO algorithm), 15 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 5.14. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 14 Antepartum haemorrhage.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 14 Antepartum haemorrhage
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 1/104 1/106 1.02 [ 0.06, 16.08 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (FENO algorithm), 1 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
Analysis 5.15. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 15 Postpartum haemorrhage.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 15 Postpartum haemorrhage
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 5/104 4/106 1.27 [ 0.35, 4.61 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (FENO algorithm), 4 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 5.16. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 16 Ruptured membranes.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 16 Ruptured membranes
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 12/104 9/106 1.36 [ 0.60, 3.09 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (FENO algorithm), 9 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
Analysis 5.17. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 17 Hyperemesis.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 17 Hyperemesis
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 0/104 0/106 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (FENO algorithm), 0 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 5.18. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 18 Termination of pregnancy.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 18 Termination of pregnancy
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 1/105 0/109 3.11 [ 0.13, 75.57 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (FENO algorithm), 0 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours FENO algorithm Favours clinical guideline algorithm
Analysis 5.19. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 19 Stillbirth.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 19 Stillbirth
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 1/105 1/109 1.04 [ 0.07, 16.38 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (FENO algorithm), 1 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 5.20. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 20 Gestational age at birth (weeks).
Gestational age at birth (weeks)
Study FENO group (n = 104) Control group (n = 106) P value
Powell 2011 Median: 39.9
IQR: 38.7 to 40.7
Median: 39.6
IQR: 38.4 to 40.6
0.224
Analysis 5.21. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 21 Preterm birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 21 Preterm birth
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 6/105 9/109 0.69 [ 0.26, 1.88 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 6 (FENO algorithm), 9 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
Analysis 5.22. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 22 Birthweight (g).
Birthweight (g)
Study FENO group (n = 105) Control group (n = 109) P value
Powell 2011 Median: 3520
IQR: 3060 to 3920
Median: 3460
IQR: 3040 to 3730
0.233
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Analysis 5.23. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 23 Low birthweight (< 2500 g).
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 23 Low birthweight (< 2500 g)
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 5/105 5/109 1.04 [ 0.31, 3.48 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 5 (FENO algorithm), 5 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
Analysis 5.24. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 24 Small-for-gestational age.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 24 Small-for-gestational age
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 14/105 16/109 0.91 [ 0.47, 1.77 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 14 (FENO algorithm), 16 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 5.25. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 25 Jaundice.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 25 Jaundice
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 3/105 3/109 1.04 [ 0.21, 5.03 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (FENO algorithm), 3 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
Analysis 5.26. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 26 Congenital malformation.
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 26 Congenital malformation
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 1/105 0/109 3.11 [ 0.13, 75.57 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (FENO algorithm), 0 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 5.27. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 27 Bronchiolitis (multiple versus one or no episodes).
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 27 Bronchiolitis (multiple versus one or no episodes)
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 1/67 10/61 0.09 [ 0.01, 0.69 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (FENO algorithm), 10 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours FENO algorithm Favours clinical guideline algorithm
Analysis 5.28. Comparison 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy,
Outcome 28 Croup (multiple versus one or no episodes).
Review: Interventions for managing asthma in pregnancy
Comparison: 5 FENO algorithm versus clinical guideline algorithm to adjust asthma therapy
Outcome: 28 Croup (multiple versus one or no episodes)
Study or subgroup FENO algorithm
Clinical
guideline
algorithm Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Powell 2011 1/67 7/62 0.13 [ 0.02, 1.04 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (FENO algorithm), 7 (Clinical guideline algorithm)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.005 0.1 1 10 200
Favours FENO algorithm Favours clinical guideline algorithm
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Analysis 6.1. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 1 Asthma exacerbations.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 1 Asthma exacerbations
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 0/29 0/29 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (MAMMA), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
Analysis 6.2. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma
(MAMMA) versus standard care, Outcome 2 Admission to neonatal intensive care unit or special care nursery.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 2 Admission to neonatal intensive care unit or special care nursery
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 3/29 2/29 1.50 [ 0.27, 8.32 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (MAMMA), 2 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
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Analysis 6.3. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 3 Asthmatic symptoms (ACQ score).
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 3 Asthmatic symptoms (ACQ score)
Study or subgroup MAMMA Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Lim 2012 29 0.96 (0.56) 29 1.13 (0.86) 100.0 % -0.17 [ -0.54, 0.20 ]
Subtotal (95% CI) 29 29 100.0 % -0.17 [ -0.54, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
2 6 months
Lim 2012 29 0.54 (0.32) 29 1.1 (0.67) 100.0 % -0.56 [ -0.83, -0.29 ]
Subtotal (95% CI) 29 29 100.0 % -0.56 [ -0.83, -0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.06 (P = 0.000049)
3 3 months - baseline
Lim 2012 29 -0.46 (1.05) 29 -0.15 (0.63) 100.0 % -0.31 [ -0.76, 0.14 ]
Subtotal (95% CI) 29 29 100.0 % -0.31 [ -0.76, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
4 6 months - baseline
Lim 2012 29 -0.89 (0.98) 29 -0.18 (0.73) 100.0 % -0.71 [ -1.15, -0.27 ]
Subtotal (95% CI) 29 29 100.0 % -0.71 [ -1.15, -0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
-2 -1 0 1 2
Favours MAMMA Favours standard care
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Analysis 6.4. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 4 Asthmatic symptoms (ACQ score).
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 4 Asthmatic symptoms (ACQ score)
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 ACQ score < 1.5 (adequately controlled asthma)
Lim 2012 29/29 20/29 100.0 % 1.44 [ 1.12, 1.84 ]
Subtotal (95% CI) 29 29 100.0 % 1.44 [ 1.12, 1.84 ]
Total events: 29 (MAMMA), 20 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.88 (P = 0.0040)
0.5 0.7 1 1.5 2
Favours standard care Favours MAMMA
Analysis 6.5. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 5 Asthma medication requirements (oral corticosteroids).
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 5 Asthma medication requirements (oral corticosteroids)
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 0/29 0/29 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (MAMMA), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
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Analysis 6.6. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 6 Asthma-related days off work.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 6 Asthma-related days off work
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 0/29 0/29 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (MAMMA), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
Analysis 6.7. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 7 Hypertension during pregnancy.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 7 Hypertension during pregnancy
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 2/29 0/29 5.00 [ 0.25, 99.82 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (MAMMA), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.001 0.01 0.1 1 10 100 1000
Favours MAMMA Favours standard care
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Analysis 6.8. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 8 Gestational diabetes.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 8 Gestational diabetes
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 2/29 0/29 5.00 [ 0.25, 99.82 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 2 (MAMMA), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.002 0.1 1 10 500
Favours MAMMA Favours standard care
Analysis 6.9. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 9 Caesarean birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 9 Caesarean birth
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 8/29 9/29 0.89 [ 0.40, 1.98 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 8 (MAMMA), 9 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
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Analysis 6.10. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 10 Gestational age at birth (weeks).
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 10 Gestational age at birth (weeks)
Study or subgroup MAMMA Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lim 2012 29 38.9 (1.6) 29 38.9 (2.9) 0.0 [ -1.21, 1.21 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-4 -2 0 2 4
Favours MAMMA Favours standard care
Analysis 6.11. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 11 Preterm birth.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 11 Preterm birth
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 3/29 2/29 1.50 [ 0.27, 8.32 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 3 (MAMMA), 2 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
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Analysis 6.12. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 12 Birthweight (g).
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 12 Birthweight (g)
Study or subgroup MAMMA Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lim 2012 29 3456.2 (664.6) 29 3448.4 (627.8) 7.80 [ -324.94, 340.54 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-1000 -500 0 500 1000
Favours MAMMA Favours standard care
Analysis 6.13. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 13 Small-for-gestational age.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 13 Small-for-gestational age
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 1/29 1/29 1.00 [ 0.07, 15.24 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (MAMMA), 1 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
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Analysis 6.14. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 14 Apgar score.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 14 Apgar score
Study or subgroup MAMMA Standard care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 1 minute
Lim 2012 29 8.5 (1.1) 29 7.8 (1.7) 100.0 % 0.70 [ -0.04, 1.44 ]
Subtotal (95% CI) 29 29 100.0 % 0.70 [ -0.04, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
2 5 minute
Lim 2012 29 9.1 (0.5) 29 8.8 (0.9) 100.0 % 0.30 [ -0.07, 0.67 ]
Subtotal (95% CI) 29 29 100.0 % 0.30 [ -0.07, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
-2 -1 0 1 2
Favours standard care Favours MAMMA
Analysis 6.15. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 15 Congenital malformation.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 15 Congenital malformation
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 0/29 0/29 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (MAMMA), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
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Analysis 6.16. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 16 Asthma-related hospital admissions.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 16 Asthma-related hospital admissions
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 0/29 0/29 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (MAMMA), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
Analysis 6.17. Comparison 6 Pharmacist-led multi-disciplinary approach to management of maternal
asthma (MAMMA) versus standard care, Outcome 17 Asthma-related emergency visits.
Review: Interventions for managing asthma in pregnancy
Comparison: 6 Pharmacist-led multi-disciplinary approach to management of maternal asthma (MAMMA) versus standard care
Outcome: 17 Asthma-related emergency visits
Study or subgroup MAMMA Standard care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Lim 2012 0/29 0/29 Not estimable
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 0 (MAMMA), 0 (Standard care)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours MAMMA Favours standard care
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Analysis 7.1. Comparison 7 Progressive muscle relaxation (PMR) versus sham training, Outcome 1 Lung
function (FEV1 (L)).
Review: Interventions for managing asthma in pregnancy
Comparison: 7 Progressive muscle relaxation (PMR) versus sham training
Outcome: 1 Lung function (FEV1 (L))
Study or subgroup PMR Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nickel 2006 32 2.22 (0.5) 32 1.75 (0.5) 0.47 [ 0.23, 0.71 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-2 -1 0 1 2
Favours sham Favours PMR
Analysis 7.2. Comparison 7 Progressive muscle relaxation (PMR) versus sham training, Outcome 2 Lung
function (PEFR (L/minute)).
Review: Interventions for managing asthma in pregnancy
Comparison: 7 Progressive muscle relaxation (PMR) versus sham training
Outcome: 2 Lung function (PEFR (L/minute))
Study or subgroup PMR Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nickel 2006 32 395.7 (10.9) 32 345.1 (12.7) 50.60 [ 44.80, 56.40 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
-100 -50 0 50 100
Favours sham Favours PMR
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Analysis 7.3. Comparison 7 Progressive muscle relaxation (PMR) versus sham training, Outcome 3 Quality
of life (STAXI scores).
Review: Interventions for managing asthma in pregnancy
Comparison: 7 Progressive muscle relaxation (PMR) versus sham training
Outcome: 3 Quality of life (STAXI scores)
Study or subgroup PMR Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 State-Anger
Nickel 2006 32 19.6 (3.3) 32 23.5 (3.8) 100.0 % -3.90 [ -5.64, -2.16 ]
Subtotal (95% CI) 32 32 100.0 % -3.90 [ -5.64, -2.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.38 (P = 0.000012)
2 Trait-Anger
Nickel 2006 32 18.6 (3.9) 32 24.2 (3.5) 100.0 % -5.60 [ -7.42, -3.78 ]
Subtotal (95% CI) 32 32 100.0 % -5.60 [ -7.42, -3.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.05 (P < 0.00001)
3 Anger-In
Nickel 2006 32 18.2 (3.4) 32 19.3 (3.6) 100.0 % -1.10 [ -2.82, 0.62 ]
Subtotal (95% CI) 32 32 100.0 % -1.10 [ -2.82, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
4 Anger-Out
Nickel 2006 32 13.6 (5) 32 15.6 (5.4) 100.0 % -2.00 [ -4.55, 0.55 ]
Subtotal (95% CI) 32 32 100.0 % -2.00 [ -4.55, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
5 Anger-Control
Nickel 2006 32 22.3 (4) 32 21.8 (5.1) 100.0 % 0.50 [ -1.75, 2.75 ]
Subtotal (95% CI) 32 32 100.0 % 0.50 [ -1.75, 2.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.44 (P = 0.66)
-10 -5 0 5 10
Favours PMR Favours sham
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Analysis 7.4. Comparison 7 Progressive muscle relaxation (PMR) versus sham training, Outcome 4 Quality
of life (SF-36 health survey scores).
Review: Interventions for managing asthma in pregnancy
Comparison: 7 Progressive muscle relaxation (PMR) versus sham training
Outcome: 4 Quality of life (SF-36 health survey scores)
Study or subgroup PMR Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Physical functioning
Nickel 2006 32 90.1 (5.1) 32 88.6 (6) 100.0 % 1.50 [ -1.23, 4.23 ]
Subtotal (95% CI) 32 32 100.0 % 1.50 [ -1.23, 4.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Role physical
Nickel 2006 32 95.2 (5.8) 32 88.2 (6.9) 100.0 % 7.00 [ 3.88, 10.12 ]
Subtotal (95% CI) 32 32 100.0 % 7.00 [ 3.88, 10.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.39 (P = 0.000011)
3 Bodily pain
Nickel 2006 32 90.2 (9) 32 87.1 (9.6) 100.0 % 3.10 [ -1.46, 7.66 ]
Subtotal (95% CI) 32 32 100.0 % 3.10 [ -1.46, 7.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
4 General health perceptions
Nickel 2006 32 78.8 (9.8) 32 74.5 (8.7) 100.0 % 4.30 [ -0.24, 8.84 ]
Subtotal (95% CI) 32 32 100.0 % 4.30 [ -0.24, 8.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
5 Vitality
Nickel 2006 32 70.2 (7.1) 32 62.5 (9.2) 100.0 % 7.70 [ 3.67, 11.73 ]
Subtotal (95% CI) 32 32 100.0 % 7.70 [ 3.67, 11.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.75 (P = 0.00018)
6 Social functioning
Nickel 2006 32 83.9 (8.1) 32 71.1 (9.4) 100.0 % 12.80 [ 8.50, 17.10 ]
Subtotal (95% CI) 32 32 100.0 % 12.80 [ 8.50, 17.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.84 (P < 0.00001)
7 Role emotional
Nickel 2006 32 83.7 (7.6) 32 71.5 (9.1) 100.0 % 12.20 [ 8.09, 16.31 ]
-20 -10 0 10 20
Favours sham Favours PMR
(Continued . . . )
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(. . . Continued)
Study or subgroup PMR Sham
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 32 32 100.0 % 12.20 [ 8.09, 16.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.82 (P < 0.00001)
8 Mental health
Nickel 2006 32 72.4 (7.8) 32 66.3 (9.5) 100.0 % 6.10 [ 1.84, 10.36 ]
Subtotal (95% CI) 32 32 100.0 % 6.10 [ 1.84, 10.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
-20 -10 0 10 20
Favours sham Favours PMR
A D D I T I O N A L T A B L E S
Table 1. Dose changes based on FENO and ACQ results for the FENO intervention algorithm (Powell 2011)
FENO concentration (ppb) Symptoms (ACQ score) ICS dose change β2-agonist dose change
Level 1 > 29 NA ICS x 1 step No change
Level 2 16 - 29 ≤ 1.5 No change No change
Level 3 16 - 29 > 1.5 No change LABA x 1 step
Level 4 < 16 ≤ 1.5 ICS x 1 step No change
Level 5 < 16 > 1.5 ICS x 1 step LABA x 1 step
ACQ: asthma control questionnaire
FENO: fraction of exhaled nitric oxide
ICS: inhaled corticosteroid
LABA: long-acting β2 agonist
NA: not part of the assessment at this FENO level
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Table 2. FENO algorithm treatment steps (Powell 2011)
ICS step β2 step
Step 1 0 Salbutamol as required
Step 2 Budesonide 100 µg twice per day Formoterol 6 µg twice per day
Step 3 Budesonide 200 µg twice per day Formoterol 12 µg twice per day
Step 4 Budesonide 400 µg twice per day Formoterol 2 × 12 µg twice per day
Step 5 Budesonide 800 µg twice per day Formoterol 2 × 12 µg twice per day
FENO: fraction of exhaled nitric oxide
ICS: inhaled corticosteroid
Table 3. Dose changes based on clinical assessment for the clinical algorithm (control) (Powell 2011)
ACQ score Treatment adjustment
Level 1 > 1.5 1 step
Level 2 0.75 - 1.5 No change
Level 3 < 0.75 1 step
ACQ: asthma control questionnaire
Table 4. Clinical algorithm treatment steps (Powell 2011)
Treatment
Step 1 Salbutamol as required
Step 2 Budesonide 200 µg twice per day
Step 3 Budesonide 400 µg twice per day
Step 4 Budesonide 400 µg and formoterol 12 µg twice per day
Step 5 Budesonide 800 µg and formoterol 24 µg twice per day
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A P P E N D I C E S
Appendix 1. Search strategy for Cochrane Airways Group Trials Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Pregnancy Explode All
#6 MeSH DESCRIPTOR Pregnancy Complications Explode All
#7 pregnan*
#8 #5 or #6 or #7
#9 #4 and #8
#10 (#9) AND (INREGISTER)
(In search line #1, MISC1 is the field in the Register where the reference is assigned to condition, in this case, asthma)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have added a number of additional secondary outcomes for the fetus/neonate (respiratory distress syndrome, intraventricular
haemorrhage, periventricular haemorrhage, chronic lung disease, necrotising enterocolitis, retinopathy of prematurity, patent ductus
arteriosus, hypothalamo-pituitary-adrenal (HPA) axis function (however defined by authors) and hyperbilirubinaemia), as they were
considered important, relating to possible consequences of maternal asthma and/or the pharmacological management of maternal
asthma.
In recognition of the importance of long-term follow-up of the infant into childhood and adulthood, we have also added a number
of secondary review outcomes for the infant as a child and adult (death, any neurodevelopmental disability, growth assessments,
lung function, respiratory morbidity, blood pressure, glucose intolerance/insulin sensitivity, dyslipidaemia, HPA axis function, age at
puberty, bone density, visual impairment, hearing impairment, developmental delay, intellectual impairment, cerebral palsy, motor
delay or impairment, educational achievement, behavioural/learning difficulties), relating to possible health consequences associated
with maternal asthma, including the pharmacological management of asthma during pregnancy.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [administration & dosage]; Algorithms; Anti-Asthmatic Agents [therapeutic use]; Asthma [∗therapy];
Beclomethasone [therapeutic use]; Magnesium Sulfate [administration & dosage]; Muscle Relaxation; Nitric Oxide [administration &
dosage]; Pregnancy Complications [∗therapy]; Randomized Controlled Trials as Topic; Theophylline [therapeutic use]
MeSH check words
Female; Humans; Pregnancy
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